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SUMMARY 
 Viruses are self-organized, symmetrical and rather simple structures, which can cause 
devastating diseases in humans and animals. They are able to readily react to cellular 
cues by changing gene expressions and conformations, which in turn enables dynamic 
interactions with their hosts. A large body of research has shown that the full 
complexity of viruses is unfolded as soon as they interact with host cells. Although 
studies of virus-host interactions have emerged as a key driving force in the research 
of infectious diseases, our understanding of the systems properties of viral infections 
has remained incomplete. Human adenoviruses (HAdVs) are most commonly 
associated with respiratory and gastrointestinal tract infections. In addition, HAdVs are 
the most common viral vectors in clinical gene transfer trials. Although HAdVs have 
been well characterized, there are many unresolved aspects, such as receptor usage 
by species B viruses (HAdV-B), dynamic expression profiles of viral and cellular 
proteins in the infected cells, and how this can be influenced by signal transduction, or 
virally encoded miRNAs. 
To address some of these issues, we employed comprehensive functional genomics 
and biochemistry approaches to obtain a global picture of the infection dynamics of 
HAdVs in cultured cells, from entry to gene regulations. In the stage of HAdV entry, we 
studied the interaction of HAdV-B3/HAdV-B7 fiber knob (FK) to cellular receptor CD46 
by using Biacore and quantitative microscopy. In the progress of dynamic interactions 
and regulations, we targeted three molecular levels including miRNA, mRNA and 
proteins by using quantitative transcriptomics and proteomics of both viruses and host 
infected human epithelial cells. The transcriptomics analysis was carried out by using 
the Agilent microarray and deep sequencing while proteomics was performed by using 
iTRAQ-8plex labeling of peptides or label-free method, followed by LC-MS/MS 
analyses at different time points of infection with different HAdV types. Subsequently, 
the networks were analyzed by using Metacore. For identifying novel miRNAs, we 
applied both in silico predictions and multi-detection methods including RT-PCR, 
miRNA microarray, deep sequencing and Northern blot analysis.  
Our results show that direct binding of HAdV-B3/HAdV-B7-FK to CD46 occurs by an 
avidity mechanism and resolves the controversy about CD46 being a receptor for 
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HAdV-B. Based on quantitative transcriptomics, proteomics and miRNAs, we defined 
some common networks of HAdV serotypes of 3, 5, 11p and 35, such as cytoskeleton 
and cell cycle. We found new components such as galectin-1 (gal-1) and galectin-3 
(gal-3), which were triggered to be secreted into the cell culture supernate. Preliminary 
data suggested that gal-1 and gal-3 interacted with CD46 as well as viral capsids 
including hexon and penton. Concerning the miRNAs, we found four small viral 
miRNAs (vmiRNAs) derived from VA-RNAI and one small vmiRNA derived from a non-
coding viral sequence. Based on in silico analyses of potential targets for these 
vmiRNAs and transcriptomics analysis we found that there are many potential cellular 
and viral gene targets. In summary, this study addressed several systems aspects of 
HAdV infections, including post-translational modifications, potential anti-viral factors of 
innate immunity, small vmiRNAs, and it clarified the role of CD46 for HAdV-B 
infections.   
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ZUSAMMENFASSUNG 
Viren sind autark organisiert, besitzen symmetrische und eher einfache Strukturen, 
können aber bei Mensch und Tier verheerende Krankheiten auslösen. Mittels 
Änderungen ihrer Genexpression und Strukturen passen sie sich problemlos an 
spezifische Eigenschaften der Zellen an, was ihnen eine dynamische Interaktion mit 
ihren Wirtszellen ermöglicht. Umfangreiche Untersuchungen zeigten, dass sich die 
volle Komplexität der Viren bereits beim ersten Kontakt mit der Wirtszelle manifestiert. 
Obwohl sich Untersuchungen der Virus-Wirtszellinteraktionen als Schlüssel zur 
Erforschung von Infektionskrankheiten erwiesen haben, bleibt unser Verständnis der 
Systemeigenschaften von Virusinfektionen immer noch lückenhaft. Humane 
Adenoviren (HAdVs) sind häufig mit Erkrankungen der Atemwege und des 
Verdautrakts assoziiert. Darüber hinaus sind HAdVs die am häufigsten verwendeten 
Vektoren für klinische Gentransfer-Versuche. Obwohl HAdVs gut erforscht sind, gibt es 
immer noch ungelöste Aspekte, wie zum Beispiel die Rezeptorverwendung der 
Vertreter der Spezies-B HAdV-Untergruppe (HAdV-B), Dynamik der Genexpressions- 
und Zellproteinprofile infizierter Zellen, und wie diese durch Signalübermittlungen und 
miRNAs beeinflusst werden. 
Um einige dieser Fragen anzugehen haben wir umfangreiche „functional gemomics“ 
und biochemische Methoden verwendet, mit dem Ziel, einen Überblick über die 
Infektionsdynamik von HAdVs zu erhalten. Bezüglich des Zell-Eintritts der Spezies-B-
Viren haben wir mittels Biacore-Messungen und quantitativer Mikroskopie die 
Interaktion von HAdV-B3/HAdV-B7 fiber knob (FK)-Proteinen mit zellulärem CD46-
Rezeptor untersucht. Zur Erforschung der dynamischen Interaktionen und deren 
Regulierungen haben wir Untersuchungen auf drei molekularen Stufen ausgeführt. 
Diese beinhalteten quantitative Transkriptom- und Proteomanaylse von miRNAs, 
mRNAs und Proteinen sowohl von Viren als auch von infizierten Epithelzellen. Die 
Transkriptomanalyse wurde mittels Verwendung der Agilent microarray- und deep 
sequencing-Methode ausgeführt, während für die Proteomanalyse die iTRAQ-8plex 
Peptid-Markierungsmethode oder die Markier-freie Analysemethode in Kombination mit 
LC-MS/MS angewandt wurden, beides mit unterschiedlichen Adenovirus Serotypen 
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und Zellmaterial von unterschiedlichen Zeitpunkten. Mit Hilfe von Metacore wurden 
anschliessend Netzwerkinteraktionen analysiert. Zur Identifizierung neuer miRNAs 
verwendeten wir einerseits in silico Vorhersagen, und andererseits mehrere 
Detektierungsmethoden, wie RT-PCR, miRNA microarray, deep sequencing and 
Northern blot-Analyse.  
Unsere Resultate zeigten, dass mittels eines Aviditätsmechanismus direkte Bindung 
von HAdV-B3/HAdV-B7-FK an CD46 erfolgt, was die Kontroverse um CD46 als 
Rezeptor für HAdV-B klärt. Basierend auf quantitativen Transkriptom-, Proteom-, und 
miRNA-Analysen haben wir gemeinsame Netzwerkinteraktionen für die HAdV 3, 5, 11p 
and 35 Serotypen definiert, die zum Beispiel Zytoskelett, und Zellzyklus beinhalteten. 
Wir entdeckten neue Komponenten wie Galectin-1 (Gal-1) und Galectin-3 (Gal-3), 
welche zur Sekretion in den Zellkulturüberstand angeregt wurden. Vorläufige Daten 
lassen darauf schliessen, dass Gal-1 und Gal-3 mit CD46 und mit viralen Capsiden 
inklusive Hexon und Penton interagieren. Bezüglich miRNAs haben wir vier kleine 
miRNAs (vmirRNAs) gefunden, die von VA-RNAI hergeleitet sind, und eine kleine 
vmiRNA, die von nicht-kodierender Virus-Sequenz hergeleitet ist. Basierend auf in 
silico-Analysen von möglichen Targets dieser vmiRNAs, wie auch auf 
Transkriptomanalysen, haben wir zahlreiche zelluläre und virale Targets gefunden. 
Zusammengefasst, die hier beschriebenen Untersuchungen hatten mehrere Aspekte 
von HAdV-Infektionen im Fokus, inklusive postranslationelle Modifizierungen, 
potenzielle antivirale Faktoren des angeborenen Immunsystems, sowie kleine 
vmiRNAs, und sie klärte den Rolle von CD46 bei HAdV-B Infektionen. 
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PROJECT OUTLINE 
 
PROJECT 1: Avidity effect of interaction between CD46 in human adenovirus 
species B fiber knobs 
Objectives: to determine the affinities between HAdV-B3/HAdV-B7-FK to CD46. 
 
Methods: competition assays (flow cytometry), microscopic kinetics (Fluorescence 
Recovery After Photobleaching (FRAP), kinetics/affinity (Biacore). 
 
Results: all experimental data including competition assay, microscopic kinetics and 
Biacore strongly supports direct binding of HAdV-B3/HAdV-B7-FK to CD46. High 
density of CD46 on cell surface is required for binding to HAdV-B3/B7-FK.   
 
References: Hung V. Trinh*, Guillaume Lesage*, Venus Chennamparampil, Christoph 
Burckhardt, Stefan Schauer, Menzo Havenga, Urs F. Greber, and Silvio Hemmi. 
Avidity-based mechanism allows human adenovirus 3 and 7 to use CD46 as receptor 
(submitted to J. Virol). 
Notice (*): equal contribution
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PROJECT 2: Functional genomics approaches to study molecular system 
dynamics of human adenovirus infection 
Objectives: to gain insights into the molecular dynamics governed by HAdV-B3, HAdV-
C5, HAdV-B11 and HAdV-B35 infections.  
 
Methods: quantitative analysis for cellular miRNAs, transcriptomics for gene expression 
and quantitative proteomics for protein expression using iTRAQ-label and label free 
methods and network interaction by Metacore.  
 
Results: complete web-lab and statistical analysis for the quantitative transcriptomics 
gene expression and miRNA expression and quantitative proteomics for 3, 12, 24 and 
48 h time courses of HAdV-B3, HAdV-C5, HAdV-B11 and HAdV-B35 infections 
 
References:  
Hung V. Trinh, Jonas Grossmann, Peter Gehrig, Bernd Roschitzki, Urs Greber, Silvio 
Hemmi. Comparison of iTRAQ-8plex and label-free quantitation in human 
adenoviruses (manuscript is included in this thesis). 
Hung V. Trinh, Peter Gehrig, Hansruedi Baetschmann, Hubert Rehrauer, Andrea 
Patrignani, Jonas Grossmann, Michael O Hengartner, Urs Greber, Silvio Hemmi. 
Functional genomics approaches to study molecular system dynamics of human 
adenovirus type 3 infection (manuscript in preparation). 
Hung V. Trinh, Peter Gehrig, Hansruedi Baetschmann, Hubert Rehrauer, Andrea 
Patrignani, Jonas Grossmann, Ralph Schlapbach, Urs Greber, Silvio Hemmi. 
Comparison of system cellular networks regulated by human adenoviruses type 3, 5, 
11 and 35 infections (manuscript in preparation). 
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Hung V. Trinh, Peter Gehrig, Bernd Roschitzki, Walter Nickel, Urs Greber, Silvio 
Hemmi. Infection of human adenovirus type 3 induces secretion of galectin-1 
(manuscript in preparation). 
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PROJECT 3: Computational and experimental analysis of potential miRNAs 
encoded by human adenoviruses 
Objectives: to identify novel miRNAs encoded by HAdV-B3 (HAdV-B3-miRNAs). 
 
Methods: in silico miRNA predictions, experimental validations (RT-PCR, Northern blot 
analysis, miRNA microarray, Ago2 immunoprecipitation), mass parallel sequencing, 
target prediction in comparison with quantitative transcriptomcis and proteomics.  
 
Results: 25 vmiRNAs were detected by stem-loop RT-PCR out of 75 predicted 
miRNAs. Mass parallel sequencing of small RNAs derived from HAdV-B3-infected cells 
revealed 32 sequences reads with more than 10 reads. We observed a potential 
cluster of vmiRNAs located in an intronic region, encoding 3-5 vmiRNAs. In addition, 
the 5’ and 3’ ends of both VA-RNAI and VA-RNAII regions gave rise to high small RNA 
expression levels when analyzed by miRNA microarray and deep sequencing. Five 
vmiRNAs were further confirmed by both Northern blot analysis using total RNA and by 
stem-loop RT-PCR following immunoprecipitation by Ago2 antibody. To determine the 
potential targets of these vmiRNAs, we compared obtained transriptomics data to in 
silico target predictions. 
 
References: Hung V. Trinh, Silvia Gutnik, Remy Bruggmann, Malik Yousef, Weihong 
Qi, Sirisha Aluri, Gunter Meister, Markus Stoffel, Urs Greber, Silvio Hemmi. 
Computational and experimental analysis of potential miRNAs encoded by human 
adenoviruses type 3 (manuscript is included in this thesis) 
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INTRODUCTION 
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Chapter 1: General introduction in virology 
What are viruses, and how do they evolve? 
Viruses are the smallest biological entities carrying genomes and proteins. They have 
coevolved tightly with their hosts, and hence they should be considered to be classified 
in the tree of live 1-4. They do not have organelles and cannot replicate themselves. 
They need functioning cells for their replications. They only come to life when they 
have invaded a host cell. They infect most of organisms including animals, plants, 
eubacteria or archaea 5. Since the first discovery of the tobacco mosaic virus by 
Martinus Beijerinck in 1898 6, many different types of viruses have been described 7.  
Virus particles (known as virions) consist of the genetic material made from either 
double strand (ds) DNA or single strand (ss) DNA, dsRNA, ssRNA(+), ssRNA(-), 
ssRNA reverse or dsDNA reverse transcribed, based on the Baltimore classification 
(http://expasy.org/viralzone/). Capsid proteins protect genetic material and they shape 
the virions. The shapes of viruses range from simple helical and icosahedral forms to 
more complex structures. In most cases, genetic materials are released from capsids 
inside the host cells and enter into nuclei using host machineries followed by 
transcription and replication of the viral genes.  
Viruses are found wherever there is life in almost all living organisms 8; however our 
understanding of how they evolved remains unsolved. There are several hypotheses 
how viruses could have emerged. The “escape hypothesis” suggests that viruses 
evolved by escape from the host as DNA like plasmids or transposons containing 
mobile genetic elements (see experimentation in maize by McClintock 9). The 
“coevolution hypothesis” by Mahy and Van Regenmortel 10 suggests that viruses 
evolved from complex molecules of protein and nucleic acid at the same time as cells 
first appeared on earth and hence evolved dependently from cellular machinery for 
billions of year. Both of these hypotheses cannot explain the complexities of virus 
formation, capsid structures and replication mechanisms. Recently, viruses have been 
recognized as ancient with origins that pre-date the divergence of life into the three 
domains 10.   
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Replication cycles 
In order to enter a cell, viruses typically interact with a receptor on the plasma 
membrane of the host cell. Different viruses use different receptors for entry. For 
instance, World haemorrhagic fever arenaviruses uses transferrin receptor 1 as 
primary receptor 11, human immunodeficiency virus (HIV) uses CD4 as attachment 
receptor 12 and human cytomegalovirus enters to the cells through epidermal growth 
factor receptor (EGFR) 13. Following the attachment step, viruses enter into the host 
cells by receptor-mediated endocytosis or membrane fusion or pore-mediated 
penetration or possibly by a piggy-back process on cellular cargo (Fig. 1). Viruses 
undergo major conformational changes leading to internalization and subsequent 
penetration of an endosomal membrane or the plasma membrane 14,15. Virus 
internalization into the host cell via receptor-mediated endocytosis can occur via 
clathrin-mediated endocytosis, caveolin-mediated endocytosis or clathrin- and 
caveolin-independent endocytosis 16,17. In case of some non-enveloped picornaviruses 
18, they can release their genome into the host cytoplasm through creation of a pore in 
the host membrane. In plant and bacteria containing a thick cell wall, viruses evolved a 
genome injection mechanism and left the capsids outside. The membrane fusion or 
capsid penetration can be triggered by low pH or particular ionic cues in endosomes. 
The viral genomes often reach the nuclei and import their genome into the 
nucleoplasm.  The virus then replicates independently from the host replications in 
case of episomal genomes or together with the host DNA if the viral DNA is integrated 
into the host chromosomes, e.g., in case of retroviruses. Upon transcription and 
translation of viral proteins, the viral components assemble into new virions, which are 
then released from the host cells by lysis or non-lytic secretion processes, and start a 
new replication cycle. 
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Fig. 1. Virus entry. Adapted from ViralZone (http://expasy.org/viralzone/).  
 
Viruses in human diseases and prevention  
Viruses cause many serious human diseases such as hemorrhagic fevers, AIDS, or 
respiratory disease. Some viruses like hepatitis B and C viruses can cause life-long or 
chronic infections and continuously replicate in the body despite the host defense 19. 
The influenza H1N1 virus spread all over the world in 1918 and killed nearly 100 million 
people 20. HIV originated from Africa and infected over 38 million people. It is estimated 
that 2.7 million new cases infections occurred and 2 million people died in 2007 21 
(http://data.unaids.org/).  
Once viruses infect the host cells, it is difficult to eliminate them. Therefore, the 
prevention of virus infections is the most effective way. Thus, vaccines are used to 
prevent viral infections by creating a robust, specific and long lasting immune 
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response. The use of vaccines has resulted in a dramatic decline in morbidity and 
mortality associated with various life-threatening viruses such as polio, measles, 
mumps and rubella and eradicated smallpox infections 22. Vaccines are combined to 
prevent over thirteen viral human infections of humans 23.  
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Chapter 2: Molecular analyses of viruses 
MicroRNAs: an emerging class of post-transcriptional regulators of gene 
expression 
MicroRNAs (miRNAs) are small non-coding RNAs of 18–24 nucleotides in length. 
miRNA lin-4 and its target mRNA, lin-14 were discovered by Ambros, Ruvkun and 
colleagues in Caenorhabiditis elegans 24,25. Subsequently, an increasing number of 
miRNAs were identified in the major metazoan species including plants 26, human 27,28, 
and viruses 29. Up to now, 1,048 experimentally characterized human miRNAs are 
registered in the miRNA database miRbase 16 (http://microrna.sanger.ac.uk/).  
More recently, it has become evident that miRNAs are involved in many biological 
processes such as developmental timing, differentiation and cell death 30, cancer 31,32, 
diabetes 33, cardiovascular diseases 34,35, and virus infections 36,37. An exciting 
development in the miRNA field has been the rapidly accumulating evidence that 
dysregulation of miRNAs may contribute to many additional diseases. A promising 
result in miRNA related therapeutics against chronic hepatitis C virus infection was 
recently provided by miR-122 in primates 38. 
Given the important function of miRNAs in biological systems, this raises the question 
of how miRNAs work? miRNAs bind to the 3’ untranslated regions (3’ UTRs) of the 
target mRNAs, which results in their sequence-specific cleavage, translational 
repression or deadenylation, resulting in post-transcriptional gene silencing 39. miRNAs 
are transcribed by RNA Polymerase II or III in the nucleus to form large pri-miRNA 
transcripts (Fig. 2). Next, they are processed by the microprocessor Drosha-DGCR8 
(Pasha) into pre-miRNAs of 70-110 nucleotides, which are translocated into the 
cytoplasm by Exportin 5. Subsequently, the pre-miRNAs are recruited by Dicer to 
generate single-strand mature miRNAs of 18-24 nucleotides, which are incorporated 
into the miRNA-associated multiprotein RNA-induced silencing complex (miRISC). The 
mature miRNA then binds to complementary sites in the mRNA target and affects gene 
expression. The degree of complementarity can determine whether silencing occurs at 
the level of protein translation (imperfect) or by target-mRNA cleavage (perfect) 39-41. 
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Fig. 2. The biogenesis of miRNAs 41. miRNAs are first transcribed from coding or non-coding 
sequences. In most cases, they are derived from non-coding sequences and give rise to pri-
miRNAs. The pri-miRNAs are further processed by Drosha and DGCR8 into pre-miRNAs (70-
110 nucleotides). The pre-miRNAs are then exported to the cytoplasm where they are finally 
processed to mature miRNAs (18-25 nucleotides). The mature miRNAs are guided by the RISC 
complex to target 3’UTRs or 5’UTRs of target mRNAs causing their degradation or translational 
repression 39.  
 
miRNAs encoded by viruses and their functions 
It is not surprising that miRNAs play roles in viral infections, given their omnipresence 
in multicellular organisms. Currently, there are 235 vmiRNAs deposited in miRBase 
version 16 (http://www.mirbase.org/cgi-bin/browse.pl).  
In 2004, Pfeffer et al. identified the first virus-encoded miRNAs expressed in B cells 
latently infected with EBV 29. Since then, twenty-five EBV pre-miRNAs have been 
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reported in B cells and nasopharyngeal carcinomas 42-44. In influenza A, each 5’-end of 
the eight viral RNA genomic segments was found to encode a vmiRNA 45. Synthesis of 
vRNA requires the RNA-dependent RNA polymerase RdRp, nucleoprotein and the 
nuclear export protein NS2. Moreover, vmiRNAs are detectable during replication of 
various influenza A virus subtypes across multiple host species and associate 
physically with the RdRp. The depletion of these vmiRNAs resulted in a dramatic loss 
of vmiRNA in a segment-specific manner 45, suggesting that vmiRNAs regulate the 
switch from transcription to replication. 
Efficient productive replication of viruses relies on the ability to exploit the biosynthetic 
machinery of the infected cells. Processes regulated by vmiRNAs include, in addition to 
autoregulation of viral genes, inactivation of apoptosis as well as innate host cell 
defense mechanisms, such as the IFN pathway, establishment and/or maintenance of 
latent infection, stimulation of cellular growth, oncogenesis and pathogenesis 46. 
Current evidence indicates that viruses use their own vmiRNAs to manipulate both 
cellular and viral gene expression 47.  Viral genes controlled by endogenous miRNA 
include, i.e. the early SV40 T antigen, which is down-regulated by the miRNA miR-S1 
expressed late in infection. This is advantageous for the virus since it limits the 
susceptibility of infected cells to cytotoxic T cells 48. Another example for vmiRNAs 
targeting viral gene expression is EBV miR-BART2. It targets viral DNA polymerase 
(BALF5). During productive EBV replication, the BALF5 mRNA is cleaved 49. The miR-
BART2 is expressed during latent infection; however, DNA polymerase catalytic 
subunit (BALF5) is a lytic gene. Induction of lytic replication is controlled by miR-
BART2 expression, suggesting miR-BART2 may regulate the latent-lytic switch by 
preventing premature BALF5 expression. In EBV, latent membrane protein 1 (LMP-1), 
inducing cell proliferation during latency, is targeted by three EBV miRNAs, miR-
BART1-5p, miRBART16, and miR-BART17-5p 50. Overexpression of these vmiRNAs 
causes inhibition of growth and stimulation of apoptosis 50. 
Besides viral genes, vmiRNAs also target cellular genes involved in cell proliferation, 
survival and antiviral defense pathways 47. HCMV expresses another immunoevasion 
miRNA that targets the mRNA encoding major histocompatibility complex class I 
polypeptide-related sequence B (MICB) 51. MICB is a ligand for a cell-surface receptor 
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of natural killer (NK) cells, which are innate immune cells that provide one of the early 
lines of defense against viral infection. The MICB–receptor interaction is a key 
regulator of NK-cell activity and hence of NK-cell killing of virus-infected cells. BCLAF1, 
a protein involved in apoptosis, was identified as a target of KSHV miR-K5 in both B 
cells and endothelial cells 52. Small interfering RNA inhibition of BCLAF1 resulted in an 
increase in lytic KSHV replication, suggesting that modulation of BCLAF1 by KSHV 
miRNAs might promote the reversion of latent infection 52. 
In contrast, cellular miRNAs also target viral genes in different actions. In HIV-1, a 
cluster of cellular miRNAs including miR-28, miR-125b, miR-150, miR-223 and miR-
382 target the 3’ end of mRNAs, promoting HIV-1 latency in resting primary CD4+ T 
lymphocytes 53. In another aspect, vmiRNAs disrupt the global cellular miRNA 
expression by overexpression of vmiRNAs during infection, resulting in a global down-
regulation of cellular miRNAs 54. In turn, down-regulation of cellular miRNAs may be 
involved in virus infection. For instance, down-regulation of cellular miR-27 enhances 
MCMV infection 55. The question then arises whether cellular miRNAs can be used as 
therapeutic targets to inhibit or enhance virus infectivity or immunity.   
More recently, vmiRNAs or noncoding RNAs were shown to be involved in regulation 
of cellular miRNAs. The human cytomegalovirus miRNA miR-UL112 acts 
synergistically with a cellular miR-376a to promote the escape from immune elimination 
56. The 3’UTR binding site in MHCB overlaps with both viral and cellular miRNAs, which 
suggests that human viruses may have coevolved with their natural human host to 
develop unique mechanisms to escape recognition and elimination by cells of the 
immune system. In another recent finding in Herpesvirus saimiri, viral U-rich noncoding 
RNAs of unknown function called HSUR1 and HSUR2 constitute the binding sites for 
cellular miR-27 57. Transient knockdown and ectopic expression of HSUR 1 
demonstrated that it directs degradation of mature miR-27 in a sequence-specific and 
binding-dependent manner. This result suggests that viral noncoding RNAs can 
modulate host-cell gene expression via the miRNA pathway 57. 
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Virus infections modulate cellular miRNA expression  
Virus infections have been shown to regulate cellular gene expression in multiple ways 
including via signaling cascades. Commonly, Toll-like receptors (TLR) are a major anti-
viral signaling pathway activated upon virus infection. For instance, dendritic cell (DC) 
activation requires phagocytosis of infected material, followed by signaling through the 
dsRNA receptor TLR3 58. Following activation of TLR signaling, the transcriptional 
modulators such as NF kappa B are triggered which eventually regulates the 
expression of oncogenic miRNAs 59.  
To determine the different expression levels of cellular miRNAs after virus infections, 
many recent studies have performed miRNA expression profiling with different viruses. 
This included HIV-1 60, EBV 61 and HAdV-B3 62. The infection of HIV-1 causes down-
regulation of most of the cellular miRNAs including anti-vmiRNAs and up-regulation of 
few cellular miRNAs including the miR-17-92 cluster 60. It has been known that HIV-1 
actively suppresses the expression of this polycistronic miRNA cluster miR-17/92, 
which is required for efficient viral replication 63. Later, Houzet et al. performed miRNA 
profiling in the peripheral blood mononuclear cells of HIV-infected patients and 
revealed 59 down-regulated and 3 up-regulated cellular miRNAs indicating significant 
regulation of cellular miRNAs by virus infection 64. In case of EBV, an oncogenic human 
Herpes virus, 9 cellular miRNAs were up-regulated while 7 cellular miRNAs were 
down-regulated by more than a 2-fold change 61. The proto-oncogene protein (c-MYB) 
is targeted by miR-155, and a tumor suppressor gene SIAH1 is targeted by miR-424. 
Both miR-115 and miR-424 are upregulated, which suggests that EBV virus modulates 
tumorigenesis 61. In Influenza, a group of miRNAs including miR-200a and miR-223 are 
differentially expressed in mouse cells where their predicted cellular targets are 
inversely correlated with the expression of these miRNAs 65. More recently, Qi et al. 
applied deep sequencing to quantify the relative expression changes of cellular 
miRNAs in HAdV-B3-infected laryngeal epithelial cells 62, which resulted in 44 up-
regulated and 36 down-regulated miRNAs of 492 quantified cellular precursor miRNAs.  
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Approaches to identify the factors involved in virus-host interaction  
Identification of host factors involved in virus-host interactions has been established for 
some human viruses including HIV 66, West Nile virus (WNV) 67, dengue virus 68, 
Hepatitis C virus (HCV) 69 and influenza virus 70 by using interfering siRNA screens and 
computational network databases. Brass and Konig et al. identified a number of factors 
including cellular and viral encoded factors that regulate multiple processes of HIV 
infection, and life-threatening opportunistic infections 66,67,71. 305 host factors affecting 
WNV infection were identified by a similar genome-wide RNAi screen approach 67. 
Among these, ubiquitin ligase CBLL1 was found and it is required for WNV infection 
and endoplasmic reticulum lead to reduction of viral infection. 42 conserved factors 
were found to be required for Dengue virus infection of both fly and human cells 68. 
Phosphatidylinositol 4-kinase (PI4KA) and !-subunit of the coat protein I (COPI) were 
identified as factors involved in HCV infection 69. Inhibitors of COPI and PI4KA blocked 
HCV replication 69. Furthermore, Li et al. addressed comprehensive factors which act in 
the signaling network interaction in HCV 72. Cellular factors regulating viral replication, 
kinase signaling, ubiquitination and so on were revealed in influenza 70,73.   
Although interference siRNA is a powerful method to identify cellular factors involved in 
the regulation network, the interaction of virus-host occurs in multiple dimensions in a 
highly dynamic manner. Thus, a proper quantitative approach for multi molecular levels 
such as mRNA, proteins and small regulator miRNAs together with computing network 
can be helpful to define significantly regulated components in complex biological 
systems. On one hand, Damm et al. discussed such approaches by using single-
particle tracking (SPT) combined with computational analysis and modeling, and 
genome-wide RNA interference to reveal the host components required for virus entry 
74. This approach can potentially reveal the virus dynamics in real-time. On the other 
hand, global quantitative analysis of multi molecular levels in these systems is 
proposed. For example, the global mRNA and miRNA expressions have been 
analyzed 75,76. Lim et al. showed that inversely correlated predicted target genes for 
miR-1 and miR-124 regulate gene expression 77. Similarly, certain levels of inversed 
correlation between miRNA expression and their target predictions were shown in 
several biological models in human liver development 76 and melanoma 78. In addition, 
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Baek et al. compared the miRNA and protein expression in parallel by introducing miR-
223 in mouse neutrophils. Hundreds of genes, which are the targets of miR-223, were 
repressed 75. The repression of some targets was revealed at the protein level and not 
at mRNA level, which indicated that the impact of miRNA on protein output can be 
readily determined.  
The complex quantitative approaches (mRNAs, proteins and miRNAs) and network-
based methods have not been used so far to identify the factors involved in virus-host 
interactions. Therefore, we aimed to utilize such a comprehensive approach for human 
HAdV-B3, HAdV-C5, HAdV-B11 and HAdV-B35 infections of human lung 
adenocarcinoma epithelial cells.  
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Chapter 3: Human adenoviruses and their use in gene 
therapy 
General background of human adenoviruses  
Human adenoviruses (HAdVs) were initially isolated in 1953 from cultured human 
adenoid tissue samples 79. Since then, HAdVs have on one side served as model 
systems to study various aspects of molecular and cellular biology, including DNA 
replication, gene and cell cycle regulation, RNA splicing, and viral entry and 
transformation 80. On the other side HAdVs have become the most widely used and 
most extensively studied viruses for gene delivery/therapy purposes such as targeting 
genetic diseases, for cancer treatment and vaccination 81,82. A total of 55 different 
human HAdV serotypes have been identified, which are classified into species A-G 
83,84. The HAdV species B is further divided into subgroup B1 (HAdV-B3, HAdV-B7, 
HAdV-B16, HAdV-B21 and HAdV-B50) and B2 (HAdV-B11, HAdV-B14, HAdV-B34 and 
HAdV-B35).  
 
HAdV as a vector tool to deliver target genes for gene therapy 
Gene therapy is still a highly experimental and immature field of biomedicine that, after 
about two decades of clinical applications, has finally begun to demonstrate 
incontrovertible clinical therapeutic efficacy in several serious diseases, including 
cancer and childhood immunodeficiency. The most widely used HAdV vectors in the 
clinics are derived from serotypes HAdV-C2 and HAdV-C5. However, limited 
expression of the receptor for HAdV-C2/HAdV-C5 has been reported for cell types and 
tissues, for instance, polarized airway epithelial cells 85-88 and brain tissue 89. In order to 
overcome low transduction efficiency of species C-based vectors for cellular targets 
with low virus receptor, alternative HAdV species B such as HAdV-B3 or HAdV-B35 
have been evaluated. Species B vectors revealed an extended tropism compared to 
species C vectors and were able to efficiently infect, e.g., hematopoietic cells and DCs, 
but also numerous cancer cells 90-94. Therefore, an emerging issue that remains to be 
solved for improvement of gene therapy includes detailed characterization of HAdV 
species B-host interactions.  
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Anti-viral drugs for HAdVs 
In general, HAdVs cause mild infection of the upper respiratory tract, gastrointestinal 
tract, and the eye 95,96, but can lead to more serious complications in 
immunocompromised patients and very young children 97. Infections with HAdV-B3 are 
a major cause of acute febrile and severe respiratory illness, and most symptomatic 
HAdV infections affect children or military recruits 98. Infections of HAdVs induced the 
innate immune responses involving regulation of cytokines and activation of effector 
leukocytes 99. Therefore, the treatment for HAdV infections would be an important task 
in case of highly immunocompromised patients. However, at the moment, a cure for 
HAdV infections is not available, and no specific drug has been approved by the Food 
and Drug Administration for treating HAdV infections.  
Two broad spectrum anti-viral drugs, cidofovir and ribavirin are currently used to treat 
HAdV-infected patients 100. Cidofovir is a cyclic nucleoside phosphonate, which 
interferes with DNA replication 101. It acts as deoxynucleotide triphosphate (dNTP) 
analogue, which binds to viral DNA polymerase and inhibits the viral replication 
process 102. Ribavirin also acts as a nucleoside analogue, but was found to be efficient 
in species C HAdV only 103. Other potential anti-viral drugs such as 
dehydroepiandrosterone, epiandrosterone analogue 104 and stavudine 105 are being 
tested. More recently, small miRNA approaches have been applied in tests of HAdV-
C5 replication in mouse by introducing the miRNAs binding sites to decrease 
expression of viral genes 106. Introducing three liver-specific miRNA binding sites into 
E1A, Ylosmaki et al. have recently evaluated attenuation of HAdV replication in liver 
Huh7 cells 107. Further studies in mice with injection of a variant with four miRNA 
binding sites showed 50- and 80-fold decrease at 6 and 96 h post infection (p.i.), 
respectively, accompanied by a strong abrogation of liver toxicity 106.  
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Chapter 4: The HAdV particle, genome organization and 
gene expression 
HAdV structure 
HAdVs are non-enveloped icosahedral (20 facets and 12 vertices) particles with a 
diameter of 70 to 100 nm 108,109. The particles are composed of an outer protein capsid 
and an inner, linear dsDNA-associated core (Fig. 3A). The genome consists of about 
36 kbp encoding 40 to 50 early and late genes. The capsid is composed mainly of 
geometrically arranged hexon proteins further stabilized by the “cementing” proteins IX, 
VIII and IIIa and 12 penton bases at each vertex 110. The major coat proteins include 
hexon (polypeptide II), penton base (polypeptide III) and fiber (polypeptide IV). The 
penton complex at the vertex is formed from penton base, a pentamer of polypeptide III 
and fiber forming a trimer. Thus, an intriguing symmetry mismatch occurs within the 
penton complex. The complexes of the capsid were recently resolved by atomic 
structure at 3.6 Å resolution by electron microscopy (cryo-EM) 111 and at 3.5 Å 
resolution by x-ray crystallography 112. These findings provided substantial advance in 
understanding of how major and minor capsid proteins interact within the virion (Fig. 
3B) 113. 
Other minor coat proteins including polypeptides IIIa, VI, VIII and IX act as capsid 
cement (Fig. 3B). Protein IIIa exposes the outer surface of the virion where it contacts 
four different hexons 114. Its role appears to be that of a rivet whose function is to hold 
the capsid facets together. Protein VI (27.2 kDa full length, ~22 kDa cleaved) has been 
assigned to a position on the inner capsid surface. It anchors the rings of peripentonal 
hexons and connects the highly ordered capsid to the less ordered core region and 
connects the bases of two adjacent peripentonal hexons 114. Protein VIII is very small 
(~25 kDa full length, ~14 kDa cleaved) which is located on the inner surface 
underneath the inner boundaries of penton base and hexons 111. Polypeptide IX (14-15 
kDa) is the best characterized of the minor proteins. Protein IX stabilizes the virion, but 
is not required for assembly. Mutants lacking protein IX are more thermolablile than 
wild type 115,116. The protein IX is inlaid into the outer surface of the capsid-not on the 
outer surface itself but halfway down the hexon 111. These detailed understandings will 
provide new opportunities to improve rationale design of new virions for gene therapy. 
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Fig. 3. HAdV virion. (A) Section of HAdV structure, revealing viral protein components and viral 
DNA 108. The HAdV virion contains seven capsid proteins with major coat proteins (hexon, 
penton and fiber), double-strand DNA, and four DNA-associated proteins or core proteins. (B) 
Superposed on a medium-resolution image of the virion surface are triangles 111,113. One 
network structure is mediated by protein IIIa at the vertices, within group-of-six (GOS) tiles, a 
penton base and its five surrounding hexons. Another is mediated by ropes (protein IX) that lash 
hexons together to form group-of-nine (GON) tiles and bind GONs to GONs. A third is mediated 
by IIIa and VIII, and binds each GOS to five surrounding GONs. The triangles represent four 
GONs in the center, in white, and three GONs surrounding it, in black 111,113. 
 
The HAdV genome organization and its gene expression 
The HAdV genome is organized into six transcription units. Transcription of E1, E3, 
VA-RNA and late proteins occurs from the plus-strand and thus from left to right. 
Transcription of E2 and E4 occurs from the minus-strand and thus from right to left. 
The immediate early E1A transcription unit is the first to be expressed. E1A yields 
multiple polypeptides due to alternate mRNA splicing. In HAdV-B3, it yields a 13S 
28 kDa, 12S 25 kDa and 9S 7 kDa mRNA and polypeptide, respectively (Fig. 4). The 
13S and 12S mRNAs encode nuclear targeting sequence at the carboxy terminus, 
while 9S mRNA does not. One of the multiple functions of E1A is to act as 
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transcriptional co-activator of the other early genes including E1B, E2, E3, E4 and the 
major late promoter (MLP) and to stimulate DNA synthesis (Fig. 4) 117.  
Similar to E1A, E1B also produces multiple alternatively spliced mRNAs including 21 
kDa and 55 kDa polypeptides in HAdV-B3. A primary function of both the 21 kDa and 
55 kDa E1B polypeptides is to protect infected cells from apoptosis induced by E1A 
proteins and other processes associated with infection, thus keeping them alive long 
enough to manufacture large quantities of progeny virus 118.  
The E2 region consists of two alternatively splicing regions, termed E2A and E2B, 
which encode three proteins necessary for synthesis of viral DNA. Of major importance 
is the terminal binding protein (TP), which is essential to prime viral DNA synthesis. 
The pTP also mediates attachment of the HAdV genome to specific sites on the 
nuclear matrix 119. Covalent attachment of pTP/TP has been suggested to protect viral 
DNA from exonucleases and facilitate unwinding of DNA duplex at the origin of 
replication. The pTP exists as a stable heterodimer with E2B DNA polymerase (Pol) 
and participates in initiation of DNA replication 120. The Pol catalyzes both the initiation 
and elongation steps of HAdV DNA replication 121. Similar to other DNA polymerases, 
Pol also exhibits an intrinsic 3´"5´ proofreading exonuclease activity 122. E2A DNA 
binding protein (DBP) is synthesized in both early and late phase in the infectious cycle 
and is involved in DNA replication, as well as early and late gene expression 123. DBP 
binds to single-stranded DNA with cooperativity and high affinity, thus protecting single-
stranded DNA from nuclease attack 124,125.  
The increased concentration of viral DNA templates appears to be sufficient to induce 
transcription of the intermediate pIX and IVa2 genes encoded within the E2 
transcription unit. The IVa2 protein is the second adenoviral transcriptional activator: Its 
specific binding to two adjacent sequences within the first intron of the MLP 
transcription unit activates the late phase of viral DNA replication 126.  
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Fig. 4. Genome organization and transcription units of HAdV-B3. The green bars represent 
transcription units, whereas the red bars represent encoding proteins or ORFs. The length of 
the bar indicates the relative length of transcription unit or encoding sequences. The genome 
annotation is adapted from NCBI.  
 
The early region 3 (E3) encodes several mRNAs through alternative splicing. E3 
consists of E3A and E3B regions with multisplicing products (Fig. 4). Among the E3 
products is the gp19K glycoprotein. It is present largely in the endoplasmic reticulum, 
where it binds to certain class I histocompatibility antigens, preventing transport to the 
cell surface. Such inhibition allows infected cells to suppress lysis by class I-restricted, 
HAdV specific cytotoxic T lymphocytes, an obvious advantage to production and 
spread of viral progeny 127. E3 RID-beta, an HAdV-encoded receptor internalization 
and degradation (RID) protein (previously named E3-10.4K/14.5K), is composed of 
RIDalpha and RIDbeta subunits and is implicated in tumor necrosis factor (TNF) 
receptor family and epidermal growth factor receptor (EGFR) down-regulation 128. In 
addition, it was suggested to have lipid homeostasis functions 129.   
The E4 transcription unit is located at the extreme right end of the HAdV genome and 
encodes six ORFs in HAdV-B3. E4 products possess a wide range of activities crucial 
to successful viral replication 130. E4 products contribute a major source of inflammation 
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in recipients of gene therapy vectors with E1A deletion. E4orf4 is a death factor, and 
works in part by inducing a Src-mediated cytoplasmic apoptotic signal leading to 
caspase-independent membrane blebbing and cell death.  
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Chapter 5: Virus receptors and entry of HAdVs 
The entry of HAdVs first occurs at the plasma membrane of epithelial cells, which are 
protected by the extracellular matrix containing multiple glycosylated proteins. The 
different HAdV species bind to different receptors. For species C HAdV-C2 and HAdV-
C5, the initial interactions occur through binding of the fiber knob domain to the 
Coxsackie B virus-Adenovirus attachment receptor (CAR) (Fig. 5) 131, a widely 
distributed immunoglobulin gene family member. CAR is involved in cell-cell contacts 
at tight and adherence junctions 132 and knockout of CAR in the mouse results in 
severe defects in embryonic heart development and death at embryonic day 12 133. 
After binding to CAR, the species C HAdVs engage a secondary receptor, !v 
containing heterodimeric integrins for internalization 134,135, which facilitate viral 
endocytosis into clathrin-coated pits and signaling into target cells. Cytosolic virus 
particles are transported along microtubules by directional motion 136,137 towards the 
nucleus and the genome is imported into the nucleus upon docking to the CAN/Nup214 
receptor 138.  
 
 
Fig. 5.  Entry pathway of HAdV-C2/HAdV-C5 in epithelial cells 139. Fiber knob of HAdV-
C2/HAdV-C5 binds to the primary CAR receptor followed by binding of penton base to !v 
integrins. The binding triggers clathrin-mediated viral endocytosis. The large GTPase dynamin, 
PI3K, the small GTPases Rac1, and Cdc42 are required for the endocytosis. Coated vesicles 
are delivered into endosomes where pH is lower than cytosol environment. Ad particles escape 
from endosomes and travel by microtubule-dependent and dynein/dynactin-dependent viral 
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transport to reach the nuclear pore complex where it recognizes nuclear receptor CAN/Nup214 
and it disassembles upon recruiting the nuclear histone H1 and the H1 import factors importin # 
and importin 7. 
 
In case of species B HAdVs, CD46 has been shown as a primary receptor for HAdV-
B3 140,141, HAdV-B7 141, HAdV-B11 141,142 and HAdV-B35 141,143. Receptor utilization of 
CD46 is not restricted to species B viruses. Additional HAdVs that bind to CD46 
include species D HAdV-D37 and HAdV-D49 144,145. The widely expressed CD46 
belongs to a family of regulators, which prevent complement activation on autologous 
tissue 146. CD46 also links innate and adaptive immunity in macrophages and 
lymphocytes 147. The extracellular domain of CD46 consists of four amino-terminal 
copies of an approximately 60-amino-acid structural motif, termed short consensus 
repeat (SCR), followed by one to three Ser-Thr-Pro (STP) rich domain(s), a short 
region of unknown function proximal to the cell membrane, a transmembrane spanning 
domain, and a carboxy-terminal cytoplasmic tail. Antibody blocking assays, together 
with infectivity and mutagenesis studies revealed that binding of human HAdV-B35 to 
CD46 occurs through the N-terminal two SCR I-II domains 148-150. 
As already mentioned, data by Sirena et al. and Fleischli et al. where they used rodent 
cells ectopically expressing CD46 indicated that HAdV-B3/HAdV-B7 utilizes CD46 as a 
primary receptor 140,141. In contrast, other groups suggested alternative receptors rather 
than CD46. For instance, the Curiel group suggested that HAdV-B3 and other 
members of HAdV species B utilize CD80 and CD86 as attachment receptors 151,152. 
The group of Arnberg suggested that all species B Ads except Ad3 and Ad7 would 
utilize CD46, and all serotypes including HAdV-B3 and HAdV-B7 would bind to a 
second, so far elusive common receptor (sBAR) 142,153. However, the Lieber group 
suggested an additional unknown receptor X, neither CD46 nor CD80/86, for HAdV-
B3/HAdV-B7 154, which they recently showed to be desmoglein 2 (DSG2). In Hela cells, 
DSG2 also served as a receptor for HAdV-B11 and HAdV-B14 155. These results do not 
resolve the issue of how a junction protein such as DSG2 is accessed by a virus from 
the apical side, nor do they show whether DSG2 or CD46 or both together are used as 
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attachment receptors. Wang et al. also suggested that upon HAdV-B3 binding, DSG2 
triggers events reminiscent of epithelial-to-mesenchymal transition, leading to transient 
opening of intercellular junctions 155. The underlying mechanisms remain however 
unknown.  
Here we aimed to characterize how HAdV-B3/HAdV-B7 binds to CD46 in cells and in 
vitro. We discovered that these species B2 HAdV use the CD46 receptor by an avidity 
mechanism.  
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Chapter 6: Molecular analyses of HAdV infections 
Transcriptomics in HAdVs  
Transcriptomics has been applied with various HAdV serotypes using infection time 
courses to define up- and down-regulated genes. Following HAdV-A12 infection of 
Hela cells, Dort et al. documented the up-regulation of cellular immune response genes 
including G1P2, IFIT1, and IFIT2 within 12 h p.i.. 156. At 48 h p.i., expression of most 
cellular genes turned down 156. HAdV-C2 infection resulted in 382 significantly up- or 
down-regulated genes with more than 1.5-fold change during 10 to 20 h p.i., compared 
to 79 genes in HAdV-A12 157. Among these, 55% of the regulated genes were 
commonly detected in both HAdV-A12 and HAdV-C2, suggesting some shared 
network in both these infections 157. Microarray analysis of early infections of HAdV-C2 
in primary lung fibroblast cells revealed significant changes in a number of genes 
encoding transcription factors including ATF3, ATF4, KLF4, KLF6 and ELK3, and 
immune response factors (NR4A1 and CEBPB) 158. Zhao et al. further analyzed 
extensively the transcriptomics in HAdV-C2, which resulted in 988 genes with more 
than 2-fold expression changes 159. In HAdV-C5, 2,000 significant genes, which 
account for 10% of analyzed transcripts, were changed more than 2-fold 160.   
In addition to wild-type HAdVs, the gene expression profiles for HAdV vectors with 
E1/E3 deletions were investigated. Infection of HAdV-C5-E1/E3 deletion in HB2 cells 
resulted in 24 and 95 significantly regulated genes at 24 h and 72 h p.i. 161. Again, a 
large number of genes involved in innate and inflammatory immune responses were 
observed. Similar to this study, Rao et al. showed 345 genes with expression changes 
over 2-fold compared to wild-type HAdV-C5 162, suggesting that E1B is one of the 
major factors altering gene expression changes during HAdV-C5 infections. HAdV-C2 
with E1/E3 or E1/E2b/E3 deletions revealed significant dysregulation of 15% measured 
transcripts with the majority of genes involved in innate responses and proinflammatory 
responses 163 164. Particularly, the signaling adapter protein MyD88 acted as a 
significant HAdV immunity amplifier and regulator in vivo 163.  
Although many studies have addressed the transcriptomics of HAdV-C2/C5 infected 
cells, no study has conducted transcriptomics with HAdV species B. Vectors derived 
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from HAdV species B represent promising tools for future gene therapy approaches. 
Therefore, finding common and unique regulation patterns among the different types of 
species B will contribute to a better understanding of tropism and infectivity of these 
vectors.     
 
Viral miRNAs encoded by HAdVs and their actions 
HAdVs express extremely abundant VA-RNAI and VA-RNAI, which are composed of 
160-176 nt and form dsRNAs with hairpin structures. The major structural features of 
these RNAs including terminal stem, apical stem-loop and central domain are 
conserved in all HAdVs, except the location of the loop 165. Recently, these VA-RNAs 
were found to be transported by Exportin 5 to the cytoplasm, where they accumulate in 
the late phase of virus infection 166. Both VA-RNAs seem to inhibit RNA interference by 
possibly saturating Exportin 5, Dicer and RISC due to high expression during the late 
phase of HAdV replication 167. VA-RNAI was found to be processed into about 22 nt 
RNAs, but seems to be a poor Dicer substrate, as only about 1% of VA-RNAI 
molecules was processed 168. Removal of both VA-RNAI and VA-RNAII was reported 
to result in a dramatic decrease in viral replication capacity 169, but could be 
compensated by two small-structured RNAs (EBER 1 and EBER 2) encoded by EBV 
170. A recent study revealed that late in HAdV-infected cells, 80% of the RISC 
complexes were loaded with VA-RNAII, although VA-RNAI is the more abundantly 
expressed RNA 171. As the authors were able to isolate processed VA-RNA species 
from polyribosomes, they speculated that these represent true miRNAs. Nevertheless, 
these studies pointed to the possibility that VA-RNAI may serve two functions during 
HAdV propagation. It appears to antagonize the cellular defense pathways against 
both long and short dsRNA by binding the two key enzymes in the respective 
pathways, dsRNA-activated protein synthesis inhibitor (PKR) of the IFN pathway and 
Dicer of the RNA silencing pathway. PKR is a kinase, which is activated by viral 
replication. The activated PKR phosphorylates eukaryotic initiation factor 2 (eIF-2), 
which prevents initiation of translation 172. VA-RNA binds PKR, inhibiting its activation 
and permitting protein synthesis 173. HAdV mutants without VA-RNAs revealed a defect 
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in the viral replication process due to PKR-mediated translational arrest in IFN-treated 
cells 174. Similarly, EBRR1 RNA can bind to PKR 175 and partially reduce the inhibition 
of protein synthesis by PKR in reticulocyte lysates 176. However, the EBERs do not 
counteract IFN effects on vesicular stomatitis virus replication or B-lymphocyte 
transformation by EBV 177.  
More recently, targets of miRNA (mivaRNAI-138) derived from 3’end of HAdV-C5 VA-
RNAI were found to include the splicing and translation regulator TIA-1, which was 
down-regulated in infected cells or in transfected cells expressing mivaRNAI-138 178. In 
addition, transfection of a plasmid expressing both VA-RNAs caused down-regulation 
of another 33 genes, while transfection of VA-RNAI alone resulted in down-regulation 
of 30 genes, and transfection of mivaRNAI-138 in down-regulation of 26 genes. These 
findings strongly suggest that endogenous miRNAs play important roles in the 
infectious life cycle in HAdV. 
To summarize, miRNAs are small and highly flexible to target multiple mRNAs without 
triggering dsRNA response pathways. They represent attractive candidates for the 
regulation of both viral and host cell gene expression.  
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Abstract 
The species B human adenoviruses (short Ad) debatably infect epithelial and 
hematopoietic cells upon attaching to the CD46 or desmoglein 2 receptor by one or 
several of their twelve fiber knob trimers (FK).  The B1 viruses Ad3/7/16/21/50 acutely 
infect eyes and respiratory organs, and the B2 viruses Ad11/14/34/35 kidney and 
urinary tracts.  Receptors commonly capture multivalent ligands by avidity, as 
measured for example by increased ligand binding with increased receptor density.  To 
test if avidity explains the controversy of CD46 receptor function in species B1 
infections, we measured the dissociation constants (KD) of Ad3/7-FK on immobilized 
CD46 using biosensors.  At high CD46 densities, Ad3/7-FK had KD values 15-fold 
higher than Ad11/35-FK, and poorly bound to low density CD46, unlike Ad11/35-FK.  
The cell surface levels of ectopically expressed CD46 in CHO or human M010119 
melanoma cells lacking desmoglein 2 positively correlated with Ad3/7 infections, while 
Ad11/35 infections of CD46-positive cells were independent of CD46 levels.  Soluble 
CD46 crosslinked with anti-CD46 antibodies strongly blocked Ad3/7/11/35 infections, 
while soluble CD46 alone blocked Ad11/35 only.  Soluble Ad3/7-FKs poorly inhibited 
Ad3/7 infection of CHO-CD46 cells, unlike Ad11/35-FKs, which efficiently blocked 
Ad3/7/11/35 illustrating that Ad3/7-FKs bind with lower affinity to CD46 than Ad11/35-
FKs.  Ad3/7-FKs, nonetheless, reduced the time of fluorescence recovery after photo-
bleaching of eGFP-CD46, and inhibited Ad3/7 infection of A549 cells expressing high 
levels of CD46.  Together, these data show that avidity binding of Ad3/7 to CD46 leads 
to infection of CD46-positive cells, and provides a paradigm for receptor recruitment by 
a multivalent ligand. 
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Introduction 
Human Adenoviridae are comprised of 55 types, classified into seven species, A to G 
(http://www.vmri.hu/~harrach/AdVtaxlong.htm), based on genome sequence 
comparison, hemagglutination and additional features.  The B1 viruses Ad3, Ad7, 
Ad16, Ad21, Ad50 (short Ad3/7/16/21/50) predominantly infect the upper respiratory 
tract, whereas the B2 viruses Ad11/14/34/35 are associated with kidney and urinary 
tract infections with fatal outcome in immunocompromised patients (27, 50, 60).  
Recent epidemiological reports described the reemergence of several of these virus 
types associated with outbreaks of respiratory disease (5, 29, 35, 68).  The tropism of 
species B viruses is broader than that of the C species, and includes cancer cells, 
dendritic cells and hematopoietic stem cells.  This feature makes the B species 
interesting vectors for gene therapy and vaccination approaches (48).  
Ads attach to their host cells by binding of the trimeric fiber protein to a cellular surface 
receptor.  The fiber protein consists of a tail for anchorage to the penton base, a shaft 
of variable length, and a globular fiber knob (FK).  The latter is responsible for the 
binding of the virus particle to a primary attachment receptor (38).  Species B Ads bind 
a different cell surface receptor than most of the other species members (67).  CD46 
has been identified as a cellular attachment receptor for species B serotypes, including 
Ad11 (53), Ad35 (14) and Ad3 (55), and species D Ad37 and Ad49 (28, 65).  The 
widely expressed CD46 belongs to a family of regulators, which prevent complement 
activation on autologous tissue (30).  CD46 also links innate and adaptive immunity in 
macrophages and lymphocytes (47).  The extracellular domain of CD46 consists of 
four amino-terminal copies of an approximately 60-amino-acid structural motif, termed 
short consensus repeat (SCR), followed by one to three Ser-Thr-Pro (STP) rich 
domain(s), a short region of unknown function proximal to the cell membrane, a 
transmembrane spanning domain, and a carboxy-terminal cytoplasmic tail.  Antibody 
blocking assays, together with infectivity and mutagenesis studies revealed that 
binding of human Ad35 to CD46 occurs through the N-terminal two SCR I-II domains 
(12, 15, 49). 
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Whether CD46 functions as an attachment receptor for all species B types has been 
controversial.  Virus competition, CD46 antibody blocking, and siRNA knock down of 
CD46 suggested that more than one receptor exists for species B Ads (14, 18, 34, 52, 
53, 55, 59).  It was suggested that all species B Ads except Ad3 and Ad7 would utilize 
CD46, and all serotypes including Ad3 and Ad7 would bind to a second, so far elusive 
common receptor (sBAR) (34, 52).  Another group proposed an alternative 
classification, where group I members (Ad16/21/35/50) would almost exclusively use 
CD46, while group II members (Ad3/7/14) would not use CD46 but receptor X, more 
recently suggested to be desmoglein 2, and the only member of group III (Ad11p) 
would be able to use both receptors (59, 61).  Both classifications contrast, however, 
with findings by others, who reported functional utilization of CD46 by Ad3 and Ad7 in 
rodent cells ectopically expressing CD46 (11, 12, 19, 55, 56).    
Affinity analysis of monovalent interactions of different species B FKs to CD46 SCR I-II 
revealed a broad range of affinities, with similar dissociation constants (KD) for Ad11 
and Ad35-FK (Ad11/35-FK) in the range of 5 to 19 nM, but strongly increased KD 
values of 284 nM for Ad21-FK and 437 nM for Ad16-FK, and an about 2,000-fold 
reduced affinity for both, Ad7-FK and Ad14-FK to CD46 SCR I-II, compared to Ad11-
FK (8, 42, 43).  The crystal structures of FKs for Ad3 (9), Ad35 (41, 62), Ad16 (42), and 
Ad7 and Ad14 (43) have revealed a generally conserved overall fold and trimeric 
organization.  Interestingly, the different FKs have low sequence identity, especially at 
the surface loops, which mediate binding to CD46, as indicated by co-crystal structures 
of CD46 SCR I-II with Ad11-FK (44), or Ad21-FK (8).  These crystal structures also 
suggested interactions of the trimeric fiber molecule with three CD46 molecules, albeit 
involving substantial differences in the number and types of contacts.  The binding 
surface on CD46 SCR I-II for Ad11-FK comprises a large continuous area of 1,681 Å2, 
with three main contact points composed of fiber knob DG, HI and the IJ loop residues.  
A more recent co-crystal structure of Ad11-FK complexed to an extended CD46 SCR I-
IV confirmed the involvement of the DG and HI loops, but not of the IJ loop (45).  
Together, this wealth of structural evidence indicates that there are no central binding 
motifs among species B Ads, which would explain the macroscopic observations that 
there is a wide range of affinities for CD46 between the different FKs (8, 42, 62). 
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Here we tested the hypothesis that avidity effects determine if the low affinity CD46-
binders Ad3/7-FK attach to CD46, and thereby allow these viruses to use CD46 as an 
entry receptor.  We used biosensor measurements to demonstrate that affinities of 
Ad3/7-FKs to immobilized CD46 are enhanced at increased receptor densities, and 
Ad3/7 infection of CD46-negative CHO or human melanoma cells increased with 
increasing levels of ectopic CD46.  We further show that multimerized soluble CD46 
blocked Ad3/7 infection, and that Ad3/7-FK reduced fluorescence recovery after photo-
bleaching of eGFP-CD46 and reduced Ad3/7 infection in A549 cells expressing high 
levels of CD46.  These data argue that CD46 is a receptor for all species B 
adenoviruses on cells provided that it is present at sufficient levels.  Ad3/7/14 can 
hence use CD46 or possibly desmoglein 2 as functional receptors. 
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Materials and Methods 
Viruses and cells.   
Ad3CMV-eGFP, Ad7CMV-eGFP Ad11CMV-eGFP and Ad35CMV-eGPF containing the 
CMV-eGFP expression cassette in the deleted E1 region were prepared at 
concentrations of 7.1x1011, 1.6x1011, 6.6x1011 1.3x1012 virus particles (vp)/ml and have 
been described previously (11, 12).  Ad3 (prototype strain GB), Ad7 (prototype strain 
Gomen), Ad11p and Ad35 (Holden strain) were radio labeled as described earlier (12).  
Specific activities were in the range of 2.6 x 10-5 to 4.9 x 10-5 cpm/vp.   
Chinese hamster cell lines CHO-K1 and CHO-15B6 (containing a mutation in the N-
acetylglucosamininyl-transferase 1), the human 293T and 911 embryonic kidney cells, 
and the A549 lung carcinoma cells were grown in Dulbecco’s modified Eagle’s medium 
(DMEM) plus 8% fetal bovine serum (FBS).  The primary human melanoma cell 
cultures M010119 were grown in RPMI 1640 plus 8% FBS as described earlier (51).  
CHO-CD46 cell lines stably expressing the BC1 splice isoform were generated as 
described for the BHK-CD46 cells (55).  For stable transfection of CHO-15B6 and 
M010119 cells with the N-terminal eGFP-tagged CD46-encoding cDNA (eGFP-CD46), 
a PCR-amplified CD46 sequence was cloned into pcDNA3.1-CARSP-eGFP-CAR 
(Burckhardt et al, in preparation), replacing the mature CAR cDNA.  In the resulting 
construct, the 19 amino acid residues of the human CAR signal peptide sequence were 
followed by two spacer residues, 239 residues of eGFP, ten additional spacer residues, 
and 344 residues of the mature CD46 BC1 isoform.  To avoid eGFP-induced 
dimerization of the tagged CD46, an A206K mutant of eGFP was utilized (66).  
Following selection in DMEM plus 8% FBS and 0.8 mg/ml G418, individual clones were 
picked and screened giving rise to the limiting dilution clone CHO-eGFP-CD46#33.5.  
To generate human melanoma M010119 and lung carcinoma A549 cells expressing 
eGFP-CD46, a lentiviral expression system was used.  For this, the eGFP-CD46 cDNA 
was subcloned into the lentiviral pBlasti vector (25), and lentiviral vectors were 
generated by transient transfection in 293T cells.  M010119 and A549 cells transduced 
with lentiviral vector pBlasti-eGFP-CD46 were selected in blasticidin-containing 
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medium at 4 $g / ml.  Resulting bulk cultures M010119-eGFP-CD46#8 and A549-
eGFP-CD46#2 revealed homogenous CD46 expression.   
 
Immunoreagents.   
Cytofluorometric analysis, CD46-specific antibodies and secondary fluorochrome 
conjugates have been described previously (12, 55).  The hybridoma cell line secreting 
the MCI20.6 anti-CD46 antibody was a generous gift from Denis Gerlier (37).  
Monoclonal 8E5-anti desmoglein 2 was purchased from Santa Cruz Inc., and goat anti-
human IgG-Fc from BETHYL Lab. Inc.. 
 
Virus binding and transduction assays.   
Binding experiments including radio-labeled Ads were performed as described 
previously (12).  For eGFP expression analysis, triplicates of 105 cells were seeded in 
12-well plates.  After incubation for 3 h at 37°C, 5% CO2, the cells were infected with 
recombinant eGFP-expressing Ads at virus concentrations of 10, 100, or 1,000 vp/cell.  
Medium was replaced 5 h p.i., and cells were analyzed two days p.i. by flow cytometric 
analysis (Cytomics FC 500; Beckman Coulter).   
For FK competition experiments, cells were seeded in triplicate 12-well plates and were 
allowed to adhere as above.  After 3 h, the medium was removed and the cells were 
washed with cold PBS.  For blocking with FK proteins, serial 5-fold dilutions of the 
different FKs were prepared in PBS, resulting in concentrations of 5,000, 1,000, 200, 
40, and 8 ng/ml.  500 $l of FK dilutions were added to the cells and incubated for 1 h 
on ice under constant shaking.  Subsequently, eGFP-encoding Ad vectors were added 
and incubated for 1 h.  The amount of virus added was optimized in preceding 
experiments and was adjusted such that for all five eGFP-expressing vectors, similar 
reporter expression levels in the range of 100 to 500 were obtained by FACS 
measurement.  Thus, for A549 cell transduction, Ad3-, 5-, 7-, 11-, and 35-eGFP 
vectors were used at 14,800, 2,825, 8,200, 1,314 and 2,540 vp/cell, respectively.  For 
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CHO-CD46#2, the virus input was adjusted to 29,600, 2,825, 8,200, 657 and 1,088 
vp/cell, respectively.  The cells were washed twice with cold PBS and were returned to 
standard cell culture conditions.  Analysis of cells was performed two days p.i., as 
described above.  For competition experiments including recombinant CD46ex-huFc, 
FK proteins were replaced with the indicated concentrations of CD46ex-huFc or 
CARex-huFc.  In case of including cross-linking of CD46ex-huFc and CARex-huFc, the 
adapter proteins were pre-incubated on ice with goat anti-human IgG antibody for 
30 min before adding to the cells.  Statistical evaluation was performed using Student’s 
t test. 
 
Generation of recombinant soluble Ad receptor and fiber knob proteins.  
Production of the soluble CD46ex-huFc and CARex-huFc has been described earlier 
(10, 55).  CD46ex-huFc comprises 295 amino acids of the mature extracellular domain 
including all SCR I-IV domains, the STP of BC1, plus the short region of unknown 
function, fused to the 232 amino acids of the human IgG1-Fc domain including hinge, 
CH2 and CH3 regions.  Production of CD46-SCR I-II consisting of 145 amino acids, 
including a N-terminal his-tag and spacer, has been described in (12).  CARex-huFc 
protein comprises the extracellular domain of the Coxsackie virus B and Ad receptor 
fused to the human IgG1-Fc domain.  The five recombinant FKs derived from Ad3, 5, 
7, 11, and 35 were produced using the Bac-to-Bac baculovirus expression system 
(pFastBac, Stratagene).  All FKs contained a N-terminal 6xhis-tag used for single step 
Ni-NTA-agarose affinity chromatography, followed by the recognition site for TEV 
protease.  FK comprised the fiber sequence residues 114 to 319 for Ad3 (NCBI gene 
bank ID (GI) 78059423), 384 to 581 for Ad5 (GI: 56160559), 126 to 325 for Ad7 (GI: 
51173336), 126 to 325 for Ad11 (GI: 56160807), and 126 to 323 for Ad35 (GI: 
56160945).  Calculated weights of the FK monomer/trimers were 26.28/78.85, 
24.98/74.95, 25.63/76.89, 25.90/77.71, and 25.50/76.50 kDa for FK of Ad3, 5, 7, 11, 
and 35, respectively. 
 
Fluorescence recovery after photo-bleaching (FRAP).   
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For FRAP experiments, CHO-eGFP-CD46#33.5 or A549-eGFP-CD46#8 cells were 
seeded in 6 channel $-slide IV ibiTreat (ibidi®) at 10,000 cells/well one day prior to 
analysis.  Soluble FKs were then added to the wells at various concentrations ranging 
from 0.1 to 64 ng/$l and incubated at 37°C for 15 min before recording with confocal 
microscopy.  We noticed that at the concentration of 64 ng/$l, Ad11/35-FKs had a 
slight toxic effect on the cells, illustrated by blebbing of the membrane rendering 
experimentation at higher concentration non-physiological.  FRAP was performed on a 
Leica SP5 confocal laser scanning microscope (Leica Microsystems) with the following 
setup.  eGFP was excited using the 476 and 488 nm lines of an Ar laser and emission 
was recorded in the range of 496 to 560 nm at a pinhole size of one airy disc and a 
pixel size of 0.13 $m.  Bleaching was performed with the built in “FRAP wizard” at a 
laser power of 80%, while imaging was performed at 6-8%.  The imaging procedure 
was as follows: first 10 images at a speed of 1.314 s/frame to determine the initial 
fluorescence level, then a square region of interest (ROI) of 3x3 micrometer was 
bleached twice with a speed of 1.314 s/frame.  The initial recovery phase was then 
monitored by 10 images at the same fast speed followed by a set of 20 images 
recorded with a 5 s interval to monitor the slow recovery.  Finally the series were 
concluded by 10 images recorded at the speed of 1.314 s/frame to establish the 
plateau value reached at the end of the recovery.  Exposing the ROI twice to 80-100% 
intensity of the laser was sufficient to generate photo-bleaching of the fluorescent 
signal in the ROI.  The background signal was first measured in an unbleached region 
outside the cell and subtracted, and second, the signal was normalized with an 
unbleached control area on the same cell.  The intensity values were displayed relative 
to pre-bleach values obtained from the first 10 frames. The fluorescence recovery 
curves were fitted using a least squares method applying a hyperbole function: Signal 
normalized (t) = a+b*t/(t %+t), where a is the offset of the curve after bleaching and b is the 
amplitude of recovery at the end of the experiment and t1/2 is the half maximum 
recovery time.  Mean and standard error of the mean were obtained from fits to single 
recovery curves. 
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Surface plasmon resonance (SPR) analysis for kinetics/affinity between CD46 
and Ad-FKs   
SPR experiments were performed on a Biacore T100 system (GE Healthcare) at 25°C 
equipped with a CM5 sensor chip.  All reagents including amine-coupling kit, HBS-P+ 
and CM5 chips were purchased from Biacore (GE Healthcare).  Buffer HBS-P+ pH 7.4 
(10 mM HEPES, pH 7.4, 150 mM NaCl, 0.05% (v/v) Surfactant P20) was used as 
running buffer for the entire measurement.  Each CM5 chip contained four flow cells, 
designated Fc1-Fc4.  The Fc2/Fc4 were used to immobilize the CD46ex-huFc ligand, 
while Fc1/Fc3 were used to immobilize the CARex-huFc ligand.  The immobilization 
procedure included three steps; surface activation by using a 1:1 mix of 0.4 M 1-ethyl-
3-(3-dimethylaminopropyl)-carbodiimide in water (EDC) and 0.1 M N-
hydroxysuccinimide in water (NHS) for 420 s with a flow rate of 5 $l/min, immobilization 
of 0.12 $M ligands in 10 mM sodium acetate pH 4.0 buffer, and deactivation of excess 
reactive groups by using 1 M ethanolamine-HCl pH 8.0 for 420 s with a flow rate of 
5 $l/min.  Following completion of immobilization, the sensor chip was conditioned 
three times with 50 mM NaOH to stabilize the surface.  For initial binding assays, Ad3-, 
11- and 35-FK analytes were injected at 18.75 and 150 nM, and Ad7-FK at 11.07 and 
88.59 nM in HBS-P+ buffer at either 30 or 50 µl/min using a contact time of 240 or 
280 s.  For kinetic studies, Ad3, 7, 11 and 35 FK analytes were injected at 0.27, 0.82, 
2.47, 7.41, 22.22 and 66.67 nM in HBS-P+ buffer at either 30 or 50 µl/min using a 
contact time of 300 or 360 s and a dissociation time of 3,600 s.  After each binding 
cycle, the CM5 surface chip was regenerated by injection of 3 M MgCl2 for 30 to 45 s, 
followed NaOH in a range of 4–50 mM for 20 s.  All analyte concentrations were 
repeated twice and the obtained sensograms were corrected by subtracting the data 
from the reference flow cell and from blank buffer injections (double referencing).  
Kinetic/affinity analysis of FK binding to immobilized CD46 was performed using three 
models in combination with the Biacore T100 evaluation software version 2.0.3.  A first 
included a 1:1 fitting model provided by the Biacore T100 evaluation software itself, 
which failed to describe the obtained binding data satisfyingly.  Second, two trivalent 
models were tested and included the equations described by Lortat-Jacob et al. (31) 
and a variation of the equations described by Fournel et al. (13) (Johan Hoebeke, 
   
 
55   
personal communication).  Both trivalent models resulted in reasonable good fitting for 
Ad11- and 35-FK to immobilized CD46 judged by !2 values, but they showed relatively 
large errors for Ad3- and Ad7-FK binding kinetics.  Third, a two-stage reaction model 
was applied to globally fit the binding data, which provided the lowest !2 values for all 
four FK binding reactions.  In this model, analyte (A) binds to ligand (B) to form the 
complex AB, then complex AB changes to ABx, which cannot dissociate directly to 
A+B.  The net reactions are described by equations 1–6, where "kd1, "kd2, "ka1, and "ka2 
are standard deviation for individual kd1, kd2, ka1, and ka2, respectively.  "KD is the 
standard deviation for overall KD.   
! 
A + B"
kd1
ka1
AB"
kd 2
ka2
ABx (Eq.1)
A = conc
B 0[ ] = Rmax, dBdt = #(ka1 * A*B # kd1 * AB) (Eq.2)
AB 0[ ] = 0, dABdt = (ka1 * A*B # kd1 * AB) # (ka2 * AB # kd2 * ABx) (Eq.3)
ABx 0[ ] = 0, dABxdt = (ka2 * AB # kd2 * ABx) (Eq.4)
Total response :  AB + ABx + RI 
KD = kd1ka1
kd2
kd2 + ka2
 (Eq.5)
$KD = ( kd2ka1(kd2 + ka2)
%kd1 )2 + (
kd1(kd2 + ka2) # kd1kd2
ka1(kd2 + ka2)2
$ kd2 )2
+( kd1kd2ka12(kd2 + ka2)
$ ka1 )2 + (
kd1kd2
ka1(kd2 + ka2)
$ ka2 )2  (Eq.6)
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Results  
 
Binding and affinity determinations of CD46 to Ad3/7/11/35-FK by surface 
plasmon resonance.   
To characterize species B Ad interactions with CD46 we applied biosensor technology 
using soluble CD46 and the FKs of Ad3/7/11/35, which were predominantly present in 
trimeric form as concluded from SDS-PAGE analyses (SFig. 1A, B).  Initial Biacore 
experiments using sensor chips had previously been described for immobilized FKs 
and monovalent CD46-SCR I-II as soluble analyte thereby avoiding avidity effects of 
CD46 (8, 42, 43, 62, 63).  The SCR I-II domain comprised the binding sites for the FKs 
(12, 44, 49, 62).  Under these conditions, we determined the affinities of Ad11/35-FK to 
CD46-SCR I-II, and found that they were consistent with a 1:1 (monophasic) binding 
model, where one surface FK monomer interacted with one soluble CD46-SCR I-II 
(data not shown).  Ad3/7-FK, however, did not bind to immobilized CD46-SCR I-II, 
most likely due to low affinity of their monomers to CD46-SCRI-II, in agreement with 
earlier data for Ad7-FK (43).  
In a reversed set-up of the SPR measurements we immobilized the extracellular 
domain of CD46 fused to human Fc (CD46ex-huFc, see 55) to the flexible dextran 
matrix of the sensor chip and used FKs as analytes.  CD46ex-huFc is a disulfide-linked 
dimer, as suggested by native gel electrophoresis (SFig. 1C), in comparison with SDS-
PAGE analyses of the reduced protein of 85 kDa apparent molecular weight (not 
shown).  We first tested if different concentrations of immobilized CD46ex-huFc would 
give different binding responses for the FKs.  
Hereto, flow cell 2 (Fc2) of the CM5 sensor chip was coated with high density of 
CD46ex-huFc (2,630 resonance units, RU), and the control Fc1 with high density of 
CARex-huFc (3,431 RU).  In a parallel set up, Fc4 was coated with low surface density 
of CD46ex-huFc (345 RU), and Fc3 with low density of CARex-huFc (278 RU).  We 
then determined the sensograms for Ad3/7/11/35-FK binding to CD46ex-huFc using 
differential analyses of Fc2-1 and Fc4-3 pairs, respectively.  We noticed that higher 
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concentrations of soluble Ad3/7-FK (150 and 89 nM, respectively) were required than 
Ad11/35-FK (18.75 nM) to reach equilibrium binding at high CD46ex-huFc density 
levels (Fig. 1A-D).  At equilibrium binding, both Ad3/7-FK and Ad11/35-FK slowly 
dissociated, indicative for stable complexes.  At low CD46ex-huFc density, the 
Ad11/35-FKs and to a very low extent also Ad7-FK but not Ad3-FK showed detectable 
binding.  The absolute binding values Rmax varied by factors of 2-3 between Ad3 and 
Ad7-FK, and Ad11 and Ad35-FK, as well as different technical replicas of the 
experiments, possibly reflecting different degrees of FK purities and chip conditions. 
Combined binding kinetics and affinity measurements were carried out for each of the 
four FKs.  For this, we used three independent measurements in the range of 0.27, 
0.82, 2.47, 7.41, 22.22 and 66.67 nM, and two different high-density CD46 biosensor 
chips of 2,630 RU and 1,121 RU.  Both biosensor chips gave similar results (Fig. 1E-H, 
STable 1).  In addition, Ad3-FK binding was found to be independent of the flow rate at 
the standard flow rate of 30 $l/min and an increased flow rate of 55 $l/min (STable 1), 
excluding the possibility that the binding reactions were influenced by mass transfer 
effects (36).  The values for the kinetic rate constants were highly reproducible for the 
individual FKs, with low standard errors for the association and dissociation constants 
(see Fig. 1E-H, STable 1).  The kinetics and binding data could be best fitted to a two-
stage reaction model rather than monophasic, or trivalent binding models (see 
equations in Materials and Methods).  Modeling of the measured association and 
dissociation rate constants and R values was carried out based on global fittings for 
ka1, ka2, kd1 and kd2, and local calculations of Rmax, and % !2/Rmax.  All % !2/Rmax values 
were below 5%.  The average apparent KD values (Table 1) were not significantly 
different for Ad3-FK (2.48 x10-10 M) and Ad7-FK (3.70 x10-10 M), whereas the apparent 
KD for Ad11-FK and Ad35-FK were 10-15-fold lower (P=0.002/0.0669 for Ad3/7 
compared to Ad11, and P=0.0014/0.063 for Ad3/7 versus Ad35) and amounted to 2.46 
x10-11 and 1.78 x10-11 M, respectively.  Thus, the 10-15-fold difference between the 
apparent KD values for Ad3/7 and Ad11/35 at high CD46 densities deviated 
considerably from the 2,000-fold differences of KD reported for the monovalent CD46 
binding to Ad7-FK and Ad11-FK (43).  Since the measurements were performed using 
similar set ups, this suggests that at high surface densities of CD46, trimeric FK 
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interacts with two or even three CD46 binding sites and the resulting avidity effects 
overcome low affinity restrictions of single FK–CD46 interactions. 
 
Increasing ectopic expression of CD46 leads to enhanced transduction of 
adenovirus species B Ad3, 7, 11, and 35 in rodent and human cells.   
To test if avidity effects are manifested on cells, we analyzed the influence of CD46 
expression levels on species B serotype binding and infectivity.  We and others had 
shown earlier that rodent cells such as hamster BHK and CHO cells, or mouse Ltk- and 
B16 cells stably expressing CD46 become sensitive to infection with various human 
species B Ads, including Ad3, 7, 11, and 35 (11, 12, 19, 55, 56).  Yet, binding of Ad3/7 
to such cells has not been found by others (14, 18, 34, 52, 53, 59), suggesting that 
threshold levels of CD46 expression could be important for binding of these serotypes 
to CD46.   
To address this question, we generated clonal CHO cells stably expressing variable 
levels of the CD46 BC1 isoform and compared their species B serotype binding and 
transduction properties.  The highest levels of CD46 were measured in CHO-CD46#2 
cells with an arbitrary mean fluorescence intensity (MFI) of 161, followed by CHO-
CD46#1 (MFI of 45), and CHO-CD46#6 (MFI of 33) (Fig. 2A).  All three CHO clones 
were derived from CHO-15B6 cells.  Additional CHO-CD46#RC cells, which were 
derived from CHO-K1 cells (3) and expressed similar CD46 levels as CHO-CD46#1 
were included as controls in the transduction study.  These cells gave similar data to 
CHO-CD46#1 and are not shown here.  We noticed, however, that the CD46 stably 
transfected cells had broader expression ranges than for example human lung 
carcinoma A549 cells, which had an MFI of 74. We therefore used the stably CD46 
expressing CHO cells exclusively at low passage numbers to ensure comparable 
expression levels.  
For initial comparative binding assays, cells were incubated with 1,000 vp of [3H]-
thymidine-labeled wild type Ad3/7/11/35 followed by determination of cell-associated 
viruses by liquid scintillation counting (Fig. 2B).  CHO-CD46#2 cells expressing the 
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highest levels of CD46 revealed highest virus binding for all four viruses, followed by 
CHO-CD46#1 and CHO-CD46#6 cells, which bound 2-4-fold more virus compared to 
parental CHO cells.  Binding of Ad3/7/11 to A549 cells was intermediate when 
compared to CHO-CD46#2 and CHO-CD46#1 cells, whereas binding of Ad35 was 
higher to A549 than CHO-CD46#2 cells. 
Since binding experiments have a relatively low dynamic range, we performed 
transduction experiments using eGFP-expressing vectors as a read out for infectivity.  
We first compared the virus-blocking activity of the anti-CD46 antibody MEM-258 for 
Ad3 infection in A549 and CHO-CD46#2 cells.  Pre-incubation with this antibody 
resulted in 49% reduction in A549 cells and 86% reduction in CHO-CD46#2 cells at the 
highest concentration of 20 $g/ml tested (Fig. 2C).  This is in good agreement with our 
earlier results reporting more than 90% blocking of Ad3 binding to rodent BHK-CD46 
cells, and 40% blocking to human K562 cells (55).  The data are also compatible with 
other studies reporting variable inhibition of Ad3 binding to human cells, with an upper 
48% inhibition in human Huh7 hepatoblastoma cells (59). 
When eGFP transgene expression was analyzed following inoculation with increasing 
amounts of recombinant Ad3/7/11/35 expressing eGFP, a robust increase of transgene 
expression was found in all four CHO-CD46 cells (including CHO-CD46#RC cells), 
when compared to the parental cells (Fig. 2D and Table 2).  At a virus concentration of 
1,000 vp/cell, e.g., Ad3-mediated eGFP expression increased 18-fold in CHO-CD46#6 
cells, 55-fold in CHO-CD46#1 cells, and 192-fold in CHO-CD46#2 cells, when 
compared to parental CHO cells.  When standardized to A549 cells, Ad3-eGFP-
mediated transgene expression levels amounted to 0.24% in parental CHO cells, 19% 
in CHO-CD46#6 cells (with 2.2-fold lower CD46 than A549), 60% in CHO-CD46#1 
cells (with about 1.5-fold lower CD46 than A549), and 211% in CHO-CD46#2 cells 
(2.2-fold higher CD46 than A549).  For better comparison of transduction efficiency, 
vp/cell concentrations necessary to reach the arbitrary MFI value of 100 were 
calculated (Table 2).  These values followed the same pattern, as highest input of 
8,207 Ad3 vp/cell was needed for CHO-CD46#6 cells, 2,597 vp/cell for CHO-CD46#1 
cells, and 717 vp/cell for CHO-CD46#2 cells to reach comparable transduction levels.  
Transduction with Ad7 was about 2-fold more efficient than Ad3 when comparing vp/ml 
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values necessary to reach MFI of 100.  Ad11/35 consistently transduced all tested cells 
more efficiently than Ad3/7, including control A549 cells and parental CHO cells.  When 
standardized to Ad35, Ad3 infection of CHO-CD46#6, #1, #2 and A549 needed 27-, 
16-, 4.2- and 2.7-fold higher vp input to obtain the MFI value of 100, respectively.  For 
Ad7, these numbers amounted to 9.5-, 7.3-, 1.57 and 1.1-fold.  In contrast, Ad11 had in 
this assay a similar transduction efficacy as Ad35. Of note, when using Ad5-eGF in 
these cells, resulting eGFP reporter levels do not change more than a factor of 2 within 
the different CD46-expressing clones compared to parental CHO cells. 
We also tested whether human melanoma M010119 cells with low CD46 expression 
(MFI of 17.8) were increasingly transduced with Ad-eGFP vectors by increasing CD46 
levels.  Stable transfection of these cells (M010119-eGFP-CD46#8) resulted in about 
nine-fold higher CD46 expression levels (MFI of 155, Fig. 2E left panel), compared to 
the parental cells.  In this case, an N-terminal eGFP-tagged CD46 BC1 isoform was 
used, in which the endogenous signal peptide was replaced by the CAR signal peptide, 
followed by the eGFP sequence and the sequence of the mature CD46 BC1 isoform.  
Of note, the receptor function of the eGFP-tagged CD46 form was retained for all four 
species B serotypes tested in M010119-eGFP-CD46#8 cells (Fig. 2F), as well as in the 
additionally established CHO-eGFP-CD46#33.5 and A549-eGFP-CD46#2 cells 
(SFig. 2B, D). The eGFP-CD46 fusion protein retained the binding capacity of those 
monoclonal antibodies that interfere with virus binding, that is, M177, 13/42, GB24, 
MEM258 (SFig. 2E,  11), whereas an almost complete loss of binding was observed for 
CD46 antibodies weakly or not interfering with virus binding (Tra-2, E4.3, MCI20.6).  In 
A549-eGFP-CD46#2 cells, this allowed discriminating between endogenous CD46 
level and the sum of endogenous and additionally expressed eGFP-tagged CD46, 
which amounted to a two-fold difference (SFig. 2C). 
When using 1,000 vp/cell, M010119-eGFP-CD46#8 cells with the nine-fold higher 
CD46 level revealed 86-, 26-, 2.1- and 2.3-fold enhancement of reporter eGFP for 
Ad3/7/11/35 mediated transduction, respectively, when compared to parental M010119 
cells (Fig. 2F, Table 3).  Determination of vp/cell ratios necessary to reach MFI value of 
100, revealed 127-, 52-, 3.1-, and 2-fold enhancement of Ad3/7/11/35-mediated 
transduction, respectively.  Of note, both, the parental M010119 low-CD46 cells as well 
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as the M010119-eGFP-CD46#8 high-CD46 cells expressed no desmoglein 2, when 
analyzed by cytofluorometric means (Fig. 2E, middle and right panel), in contrast to 
A549 cells which expressed high levels of desmoglein 2.  Transduction analysis was 
also performed for CHO-eGFP-CD46#33.5 cells (SFig. 2A, B), which expressed 2.3-
fold higher levels of CD46 when compared to A549 cells (and thus similar levels as the 
CHO-CD46#2 cells).  MFI 100 virus concentrations determined for these cells 
(Table 4), were in the same range as those determined for CHO-CD46#2 cells 
(Table 2).  Further, the A549-eGFP-CD46#2 cells with about 2-fold higher CD46 
expression than parental cells (SFig. 2C), revealed a tendency of maximal 2-fold 
increase of sensitivity to the species B vectors (Table 4).  
In summary, ectopic expression of CD46 in rodent cells, or enhanced expression of 
CD46 in human CD46 low cells negative for desmoglein 2 resulted in increased 
infection of Ad3/7/11/35 species B serotypes.  Infection efficacy of Ad3/7 correlated 
with CD46 density levels in these cells, whereas Ad11 reached a plateau with the 
medium CHO-CD46#1 cells and Ad35 already with the lowest CHO-CD46#6 cells.  
This is compatible with the notion that Ad3/7 exert a lower affinity for CD46 than 
Ad11/35, but suggests that avidity effects help to overcome the low affinity. 
 
Cross-linking of soluble CD46 leads to enhanced blocking of Ad3 and Ad7 
infection in CHO-CD46 and A549 cells.   
We earlier documented that soluble CD46ex-huFc was at least 100-fold more potent at 
blocking Ad11/35 binding to rodent cells expressing CD46, when compared to Ad3 and 
7 (11).  To further test the hypothesis that avidity allows Ad3/7 to use CD46 as a 
functional receptor, we repeated the virus blocking assays with CD46ex-huFc, but 
included this time complexed or cross-linked adapter protein.  We reasoned that 
antibody-mediated complexes of CD46ex-huFc could provide locally more binding sites 
per molecule, mimicking more closely the situation on the cell membrane where CD46 
can diffuse freely and forms clusters following multivalent binding (7).   
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When using 50, 500, and 5,000 ng/ml of CD46ex-huFc protein alone, only Ad11-eGFP 
and Ad35-eGFP mediated transgene expressions were significantly reduced in CHO-
CD46#2 and A549 cells (Fig. 3A-D).  At the intermediate concentration of 500 ng/ml 
CD46ex-huFc, transgene expression levels were reduced by 85 to 92% for both cell 
types.  In contrast, even at the highest concentration of 5,000 ng/ml, CD46ex-huFc did 
not result in any significant reduction of Ad3/7 mediated transgene expression, when 
compared to negative controls including the CARex-huFc protein (Fig.3B, D).  
However, when combining CD46ex-huFc protein at a concentration of 500 ng/ml with 
two-fold increasing amounts of cross-linking goat-anti human Fc antibody, significant 
blocking was also achieved for both Ad3 and Ad7-mediated transgene expression.  
Inhibition followed a precipitin-type curve reaching a plateau in the range of 500, 1,000 
or 2,000 ng/ml of goat anti-human Fc.  Highest blocking for Ad3-eGFP amounted to 
65% in CHO-CD46#2 cells and 83% in A549 cells, and for Ad7-eGFP, highest blocking 
achieved was 77% in both cell types.  Thus, by multimerizing CD46ex-huFc, the 
complexed protein became a potent blocker of Ad3/7.  A similarly multimerized 
complex consisting of CARex-huFc had no significant effects on Ad3/7 infection.  
 
Fiber knob-mediated species B Ad cross competition assays in CHO-CD46 A549 
and cells.   
To further characterize affinity differences and receptor usage by species B Ads, we 
performed blocking studies with species B Ads and soluble FKs in CHO-CD46#2 and 
A549 cells.  CHO-CD46#2 cells were included since they do not express desmoglein 2 
(61), whereas in human A549 cells, both types of receptors are present (18, 19, 34, 52, 
53).   
Virus inhibition assays were performed using five different eGFP-expressing vectors as 
readout for binding and infectivity.  For CHO-CD46#2 cells, Ad3/7/11/35-eGFP inputs 
of 29,600, 8,200, 657, and 1,088 vp/cell, respectively, were used.  For A549 cells, the 
virus inputs amounted to 14,800, 8,200, 1,314 and 2,540 vp/cell, and in addition, for 
Ad5-eGFP an input of 2,825 was applied.  The virus input concentrations were 
determined in preceding experiments and were chosen such that the unblocked 
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transgene expression values amounted to fluorescence intensity values in the range of 
about 200, thereby allowing an optimal dynamic range (not shown).  All five Ad FK 
proteins were tested in a dose-dependent manner with the highest concentration of 
5,000 ng/ml diluted in a 5-fold dilution series to the lowest concentration of 8 ng/ml 
(Fig 4A, B and Table 5).   Specificity of this assay was confirmed by the finding that the 
species C Ad5-FK only gave rise to inhibition of its corresponding virus, but not for any 
of the species B serotypes.  The same was found for the individual species B FKs, 
which only inhibited species B serotypes, but not the species C Ad5-eGFP. 
 
The cross-competition assays revealed differences in the capacity of the individual FKs 
to compete with species B viruses.  The Ad3/7-FKs on one side, and Ad11/35-FKs on 
the other side showed similar behavior, which, however, was different in the two cell 
types tested.  In CHO-CD46#2 cells, Ad3/7-FKs elicited at best weak competition for 
corresponding and non-corresponding Ad3 and Ad7, and no effect at all on non-
corresponding Ad11 and Ad35.  This is illustrated by the 40% inhibition of Ad3-eGFP 
transduction at the highest applied Ad3-FK concentration of 5,000 ng/ml, and a non-
significant 7% inhibition for Ad7-eGFP transduction.  Ad3-FK concentrations necessary 
for 50% inhibition (FK-50%) were larger than the highest concentration used and could 
thus not be calculated.  Ad7-FK was more efficient than Ad3-FK, and using 
5,000 ng/ml, 86 and 81% of Ad3/7 mediated eGFP expression was inhibited, 
respectively.  FK-50% inhibition values for Ad7-FK were determined to be 169 and 
2,690 ng/ml for Ad3/7-mediated transgene expression, respectively.   
In contrast, Ad11/35-FKs led to efficient blocking of corresponding as well as all non-
corresponding viruses in these cells.  Thus, applying 5,000 ng/ml of Ad11-FK, 
inhibitions between 97 to 99% were obtained for of Ad3-, Ad7-, Ad11-, and Ad35-
mediated transgene expression, respectively, and the corresponding FK-50% inhibition 
values amounted to 14, 79, 22, and 37 ng/ml, respectively.  Likewise, Ad35-FK 
blocking efficiency was in the range of 85 to 97% at 5,000 ng/ml, and the 
corresponding FK-50% values were 5, 63, 14, and 26 ng/ml.  
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The binding inhibition pattern found for A549 cells was different than for CHO-CD46#2 
cells.  In A549 cells, Ad3/7-FKs very efficiently competed for corresponding and non-
corresponding Ad3 and 7 in A549 cells (Fig. 4B, Table 5).  This resulted for Ad3-FK at 
highest concentration of 5,000 ng/ml in 93 and 78% blocking efficiency of Ad3- and 7-
mediated eGFP expression, respectively, with FK-50% Ad3/7 inhibition values of 25 
and 23 ng/ml, respectively.  With highest concentrations of Ad7-FK, blocking efficiency 
of 95 and 87% was achieved for Ad3/7-mediated eGFP expression, respectively, with 
FK-50% values of 17 and 31 ng/ml, respectively.  However, as for CHO-CD46#2 cells, 
Ad3/7-FKs revealed no effect on non-corresponding Ad11 and Ad35 in A549 cells.  
Ad11-FK efficiently blocked all four species B serotypes, with FK-50% inhibition values 
of 31, 87, 13, 13 ng/ml, whereas Ad35-FK was less efficient at inhibiting Ad3 and 7, 
with FK-50% values of 470, and 4’459 ng/ml, respectively, but very efficient at inhibiting 
Ad11 and 35, with FK-50% values of 33 and 5 ng/ml, respectively. 
In summary, blocking studies with Ad3/7-FKs revealed different effects for 
corresponding viruses in CHO-CD46 cells or human A549 cells.  In CHO-CD46 cells, 
the observed low blocking efficiency confirms the low affinity of the Ad3/7 soluble FK 
molecules to CD46.  In contrast, the efficient blocking activity of Ad3/7-FK in A549 
suggests lower dependency of Ad3/7 on avidity effects in A549 than CHO-CD46 cells. 
 
eGFP-CD46 photo-bleaching recovery analysis in presence of Ad3-, 7-, 11-, and 
35-FK in CHO-eGFP-CD46 and A549-eGFP-CD46 cells.   
In order to further address the observed difference in blocking potency of the serotype 
B1 FKs in CHO-CD46#2 cells compared to human A549 cells, we performed FRAP 
studies in CHO-eGFP-CD46#33.5 and A549-eGFP-CD46#2 cells.  These cells express 
defined levels of eGFP-tagged CD46 (SFig. 2A, C), with CHO-eGFP-CD46#33.5 
expressing tagged CD46 only, and A549-eGFP-CD46#2 expressing an about equal 
mix of eGFP-tagged and untagged CD46.  To test whether the individual species B 
FKs had any effects on the fluorescence recovery following photo-bleaching, recovery 
of the fluorescent signal of the eGFP-tagged CD46 was monitored in absence or 
presence of the different trimeric FKs (Fig. 5A-F, SFig. 4A-F).   
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We first compared the effect of the individual FKs in CHO-eGFP-CD46#33.5 cells by 
applying a single concentration of 2.5 ng / $l (Fig. 5A).  At this concentration, neither 
Ad3 nor Ad7-FK induced any significant change in recovery of the fluorescence signal, 
as Ad3/7-t1/2 amounted to 2.3 ±0.5 s and 1.2 ±0.3 s, respectively, compared to the 
control and Ad5-FK!t1/2 values of 1.6 ±0.3 s and 2.7 ±0.5 s.  In contrast, the cells 
incubated with the Ad35/11-FKs revealed a delayed rate of recovery of similar 
magnitude, with Ad11-FK and Ad35FK-t1/2 of 7.8 ±1.5 s and 5.9 ±1.0 s, respectively.  
The mobile fraction (Mf) was replenished for all samples to the control level after less 
than two minutes (SFig 4A).  To further refine these observations, we performed FRAP 
experiments with increasing concentrations of the individual FKs in the same cells.  
When using four-fold increasing Ad3-FK concentrations ranging from 4 ng/$l to 
64 ng/$l, again no effect on fluorescence recovery was noticed (Fig. 5B, SFig. 4B).  
Titration of the Ad7-FK led to similar results (data not shown).  When using 0.1, 1, and 
4 ng/$l of either Ad11-FK (Fig. 5C, SFig. 4C) or Ad35-FK (Fig. 5D, SFig. 4D), already 
the lowest concentration of 0.1 ng/$l had a significant effect on the fluorescence 
recovery.  The corresponding Ad11- and Ad35-FK-t1/2 values amounted to 9.3 ±1.7 s, 
and 8.1 ±1.4 s, respectively.  Applying the highest concentration of 4 ng/$l of these FKs 
resulted in an about four-fold increase of t1/2 values characteristic for the eGFP-CD46 
fluorescence recovery.  To confirm the specificity of the system used here, Ad5-FK was 
included in the FRAP study, but revealed no effect on CD46 recovery (Fig. 5E, 
SFig. 4E). 
Finally, we tested the same set-up in A549-eGFP-CD46#8 cells (Fig. 5F, SFig. 4F).  
Applying 4 ng/$l of Ad11/35-FKs elicited a strong reduction of the CD46 dynamic, 
resulting in Ad11- and Ad35-FK-t1/2 values of 21.0 ±2.2 s and 13.7 ±3.3 s compared to 
Ad5-FK t1/2 value of 6.7 ±0.9 s at 64 ng/$l.  The highest Ad3/7-FK concentrations of 
64 ng/$l revealed a slower recovery (Ad3FK-t1/2=10.5 +/-1.2s and Ad7-t1/2=9.3+/-1.4s).  
In summary, the FRAP assays with an inherently low sensitivity dynamic scale are in 
agreement with a complete dependency on avidity for Ad3/7 infection of CHO-CD46 
cells, and a lesser dependency on avidity for A549 cells.  
 
   
 
66   
Discussion 
To initiate infection of susceptible cells, enveloped and non-enveloped viruses use 
multiple binding strategies, characterized by a broad range of affinity interactions when 
analyzed for single binding interaction sites (21, 64).  Viruses with low affinities include, 
e.g., influenza virus with an affinity in the millimolar range for sialic acid, and other 
viruses with affinities in the micromolar range for their protein receptors as determined 
by biacore, such as rhinovirus for intercellular adhesion molecule-1, echovirus for 
decay-accelerating factor, and reovirus for junction adhesion molecule (2, 4, 26, 57).   
 
Avidity captures low affinity interactions 
Biologically meaningful binding of viruses to low affinity receptors occurs, when virus 
particles expose multiple binding sites.  This allows for avidity effects and increases 
overall affinity.  Avidity is characterized by a synergistic (and not additive) combination 
of individual bond affinities, which depends sensitively on the structure and geometry of 
the involved molecules (33).  For example, in the case of an IgG with a valency of two, 
avidity can lead to a strong increase of overall affinity, when compared to 
corresponding monovalent Fab fragments (see e.g., an early study from 16).  
Particularly strong avidity effects were also reported for low affinity ErbB2-specific 
single chain variable fragment antibodies, where the antibody fragment with the lowest 
affinity showed highest avidity increase upon dimerization (39).  Interestingly, avidity 
mechanisms have been suggested to allow the species B Ad16 to use CD46 for 
productive infection by increasing the affinity to CD46 by 70-fold compared to Ad11 
(42).  In addition, viruses containing trimeric attachment receptors, such as the reovirus 
sigma 1 protein or the long and short fibers of bacteriophage T4, have been suggested 
to employ avidity mechanisms for infection (31). 
The Ad3/7 and also Ad14 were claimed to be CD46 non-binders due to their low affinity 
interactions with CD46 (14, 18, 34, 52, 53, 59).  Several lines of evidence from our 
study here support avidity-based mechanisms for Ad3/7 infection of CD46 positive 
cells.  First, the binding of species B Ad3/7-FK to immobilized CD46 on a biosensor 
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chip was more dependent on the receptor density than binding of Ad11/35-FK, and the 
Ad3/7-FK binding had only 10-15 fold lower apparent affinity than Ad11/35-FK.  This 
result deviates significantly from a previous report of 2,000-fold difference for 
monovalent affinities for Ad7/11-FK (43).  Second, Ad3/7 infection correlated with the 
levels of ectopically expressed CD46, while Ad11/35 infection was saturated at low 
CD46 expression levels.  Third, crosslinking of soluble CD46 increased its blocking 
effect on Ad3/7 infection in human A549 cells and CHO-CD46 cells.  Fourth, soluble 
Ad3/7-FKs inefficiently blocked Ad3/7 infection of CHO-CD46 cells, unlike Ad11/35-
FKs, which efficiently blocked all four tested B serotypes, confirming that Ad3/7 FKs 
bind with lower affinity to CD46 than Ad11/35 FKs.  These data support and extend our 
earlier binding site mapping studies, which showed that Ad3/7 engage CD46 through 
similar surfaces as species B2 Ad11/35 (11).  In support of this, the recent SPR studies 
by Persson et al. revealed a broad variation of CD46 binding affinities, and the authors 
concluded that Ad7/11/14/35 are capable to bind to the same epitopes on CD46 (43).  
All these data are in accordance with the observations that both the low affinity CD46 
binder Ad3 and the high affinity binder Ad35 use virtually identical pathways to infect 
human cells that are CD46-positive (1, 23).   
Similar to the species B serotypes, also the CAR-tropic species C Ad serotypes have a 
broad spectrum of CAR affinities over nearly 3 orders of magnitude, ranging from the 
low affinity binder Ad9 to the high affinity binder Ad5 (24).  In addition, avidity effects 
could be measured by an increase of FK affinity from about 25 nM for monomeric 
immobilized Ad2 FK to 1 nM for multivalent immobilized CAR in SPR assays employing 
minimal-sized proteins produced in E.coli (31).  The avidity-driven multivalent binding 
reaction to immobilized high density CAR (200 RU equivalent to our CD46 high density 
chips) could be fitted to a trivalent binding model.  We thus consider it likely that many 
different Ads use avidity effects.  Avidity effects for Ad–receptor interactions can occur 
at two levels.  The trivalent FK protein can increase the overall affinity compared to a 
monovalent protein, and the virus particle with 12 fiber trimers can possibly 
simultaneously form multiple contact points with the cell surface.  Both of these 
mechanisms can contribute to increase the overall affinities of the virus particle to its 
receptor.   
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Apparent KD values for species B Ads differ from monovalent KD values of 
previous studies 
The apparent KD values determined here for Ad3/7 are about 5 logs lower, and 3 logs 
lower for Ad11/35 compared to the KD values for the monovalent CD46 interactions (8, 
42, 43, 62, 63).  There are several reasons for these differences.  For example, the 
CD46-SCR I-II protein used in other studies was produced in mutant CHO cells and 
contained homogenous, high mannose N-linked carbohydrates (43).  In addition, and 
perhaps more importantly, our CD46 protein was produced in normal CHO cells, and 
consisted of an antibody-like dimer comprising the complete extracellular domain, and 
presumably also O- and N-linked glycosylations (55).  The extended CD46 SCR I-IV 
domain has recently found to reveal a somewhat different binding to Ad11-FK, as the 
contact site did not include the IJ loop previously described for CD46 SCR I-II 
interaction (45).  The dimeric nature of our CD46ex-huFc could explain why our kinetic 
data for the binding of the four species B Ads fit better to two-stage reaction models 
than to trivalent binding models, described earlier for Ad2-FK interaction with CAR (31).  
Importantly, we could internally compare the different affinities, since we performed all 
species B FK affinity measurements with the same set-up of bound CD46 ligand.  We 
suggest, thus, that the observed KD differences between the monovalent and trivalent 
affinities of the Ad3/7/11/35-FKs truly reflect avidity effects.  Of note, 4 log avidity 
effects have been observed in binding of dimeric ephrin-A5 ligand to dimerized EphA3 
receptor (40). 
 
Virus–receptor affinity versus receptor density  
A recent systematic study with retargeted MV vectors has shown that viruses 
displaying HER2/neu-specific single-chain variable fragment antibodies had high 
avidity and cell killing ability due to dozens of single chain molecules in the viral 
envelope, even if their single affinities were in the micromolar range (20).  This study 
also noticed a receptor threshold level for productive infection, together with an inverse 
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correlation of attachment receptor affinity and receptor density requirements for 
infection.  In particular, suprathreshold affinities did not further enhance the efficiency 
of MV infection, which corresponds well with our results for high affinity CD46 binders 
Ad11/35.  It also fits well with another observation showing that Ad35 FK mutants with 
either 4-fold or 60-fold higher affinity at the monovalent interaction level did not 
translate into corresponding higher transduction efficiencies, regardless of the CD46 
receptor density present on cells (63).   
With the FK neutralization experiments in CHO-CD46#2 expressing cells, we noticed 
that Ad3/7-FKs did not efficiently compete against the binding of corresponding virus 
particles, in contrast to Ad11/35-FKs, which efficiently blocked all four viruses.  This is 
due to low affinity of Ad3/7-FK for CD46, since binding of the different species B Ads is 
restricted to CD46 in these cells (11, 55).  This conclusion was corroborated by the 
findings that soluble CD46ex-huFc inefficiently inhibited binding of Ad3/7 to the cells, in 
agreement with weak blocking efficiency of Ad3/7 by soluble CD46 (11, 59), and also 
by soluble monovalent CD46 for MV infection (54).  Ad3/7 inhibition was, however, 
strongly enhanced by crosslinking the CD46ex-huFc protein (Fig. 3), suggesting that 
crosslinked CD46ex-huFc mimics the multiple interaction situation when the virus 
contacts the cell surface.  Similarly, CD46 crosslinking by genetically fusing the CD46 
ectodomain to the octamer oligomerization domain of C4b binding protein resulted in a 
2 log enhanced MV neutralizing activity in vitro and in vivo due to enhanced virus 
binding (6).   
These data suggest that the receptor density is of key importance not only for 
interaction of CD46 with trimeric FK, but also the multivalent virus particle.  Together or 
alone, this gives rise to avidity effects, which allow Ad3/7 to infect cells expressing 
sufficient levels of CD46 (11, 19, 55).  The lack of Ad3/7 infection in CHO-CD46 cells 
reported by other groups is most likely due to low CD46 expression levels, and also 
assay systems of low sensitivity or limited dynamic range (14, 17, 34, 53, 59).   
 
Desmoglein 2 versus CD46 as receptor for Ad3/7  
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Down regulation of CD46 by RNA interference in human cells did not reduce Ad3/7 
infection unlike Ad35 infection (19, 59), and blocking studies with CD46 antibodies 
showed only partial inhibition of Ad3/7 infection up to 50% depending on the cell type 
(55, 59).  This lead to the suggestion that human cells express an alternative receptor 
X for Ad3/7/14, which recently was identified to be desmoglein 2 (61).  Based on 
biochemical experiments, it was suggested that receptor X is a trypsin and cation-
dependent factor (53, 59), features that were both confirmed for desmoglein 2.   
Our data here show that in human M010119 melanoma cells that lack desmoglein 2, 
Ad3/7 uses CD46 as functional receptor.  We have unpublished data indicating that in 
a total of sixteen primary human melanoma cultures, half were negative for 
desmogelin 2, but were all positive for CD46 (not shown).  To further evaluate the role 
of the two receptors for Ad3/7 infection, it remains to be determined how widespread 
desmoglein 2 expression levels are among human cells and tissues, and to what 
extent the individual receptors contribute to virus infection in cells co-expressing both 
receptors.  The observation that none of the receptor antibodies alone achieved more 
than 50 to 60% virus blocking in human cells (55, 59, 61) suggests that both receptors 
simultaneously serve as attachment receptors.  Depending on the affinities of Ad3/7 for 
the individual receptors, one receptor might be predominantly used if the other receptor 
falls below a critical threshold level.  
Alternatively, desmoglein 2 or yet another factor Y could associate with CD46 and 
modulate the oligomeric state of CD46.  This could explain our observation that Ad3/7-
FKs reduced the time of fluorescence recovery after photo-bleaching of eGFP-CD46 in 
A549 cells, but not in CHO-CD46#2 cells (Fig. 5).  It is also possible that desmoglein 2 
or factor Y is a tethering factor for CD46, which prolongs the half-life of CD46, and 
thereby enhances the CD46 levels at the plasma membrane.  In support of this 
scenario, the CD46 surface levels are known to be regulated by endocytosis.  In the 
absence of ligand, CD46 undergoes constitutive clathrin-mediated internalization and 
recycling back to the plasma membrane in human and rodent cells (7).  When 
crosslinked by an antibody, CD46 is taken up by macropinocytosis and degraded.  If 
the CD46 ligand is Ad3 or Ad35, macropinosomes are lysed and virus particles escape 
from endosomal degradation by entering to the cytosol (1, 23).  Any conditions that 
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lead to clustering or enhanced cell surface levels of CD46 could enhance the avidity 
effects for the low affinity binding B serotypes.  Such conditions could include 
recruitment of CD46 into lipid domains (58) or association with  integrins or 
tetraspanins (32).  In this sense, receptor Y would be a modulator for CD46 function, 
and would not be required for Ad3 infection if the CD46 levels were sufficiently high.  
In summary, our study shows that species B1 adenoviruses use low affinity interactions 
and avidity to bind to the CD46 receptor.  This has important consequences for tropism 
and possibly evolution of the species B1 viruses, where viral receptor-binding proteins 
are under selective pressure and undergo constant variation to evade neutralization by 
antibodies (22, 42).  High affinity binding could, for example, represent a dead-end in 
evolutionary terms, as such viruses are constrained to a single receptor.  Weak affinity 
to a receptor could be the first step in gaining access to a new attachment receptor.  
Conspicuously, several Ad serotypes have been reported to utilize more than one 
attachment receptor (67).  For example, the species D Ad9 with a very short fiber was 
found to allow fiber-independent binding of the penton base directly to integrins, if 
integrins were present in sufficient amounts (46).  In integrin-low cells, the virus instead 
used CAR for productive infection.  Avidity effects of the Ad3/7 serotypes for CD46 
could hence provide a large affinity window for attachment, and expand the repertoire 
of the viruses for other receptors.   
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Legends to figures 
Fig. 1. Subtracted SPR sensograms for Ad3-, Ad7-, Ad11- and Ad35-FK interacting 
with CD46.  Soluble receptor CD46ex-huFc was immobilized on a CM5 chip at high 
density in Fc2 (2,630 RU, 1, 3) and low density in Fc4 (345 RU, 2, 4).  Control CARex-
huFc was immobilized at high density in Fc1 (3,431 RU, 1, 3) and low density in Fc3 
(278 RU, 2, 4).  (A) to (D), FK analytes were injected over the sensor surface at 18.75 
and 150 nM concentrations for Ad3-FK (A), Ad11-FK (C) and Ad35-FK (D), and at 
11.07 and 88.59 nM for Ad7-FK (B), respectively.  Association times were either 240 or 
280 s.  (E) to (H), overlay of analyte responses for Ad3-, Ad7-, Ad11- and Ad35-FK at 
different concentrations.  Measurements were performed using the CD46 high-density 
2,630 RU CM5 chip.  Serial concentrations of 0.27, 0.82, 2.47, 7.41, 22.22 and 
66.67 nM of Ad3-FK (E), Ad7-FK (F), Ad11-FK (G), and Ad35-FK (H) were injected in 
HBS-P+ buffer at 30 µl/min under contact time of 300 s and dissociation time of 3,600 s 
(for better visibility only four of the six binding curves are shown).  Data evaluation was 
fitted globally by two-stage reaction model with Biacore T100 evaluation software, and 
resulting kinetics/affinity results are listed in STable 1 and summarized in Table 1. 
Fig. 2.  Binding and transduction of adenovirus species B viruses to cells with 
increasing CD46 levels.  (A) Flow cytometry profiles of CD46 expression in A549 
human lung cells, parental rodent CHO and four different stable and clonal CHO-CD46 
transfectants.  Numbers after slash indicate mean fluorescence intensity values (MFI) 
resulting from utilizing the MCI20.6 anti-CD46 antibody, controls using isotype control 
were in the range from 0.8 to 1 (not shown).  (B) For Ad binding assays, 5 x 105 of 
human A549 cells, and the different rodent CHO-CD46 cells were incubated on ice with 
1,000 vp of the indicated [3H]-labeled species B serotypes.  After incubation for 2 h, the 
cells were washed and cell-associated radioactivity was determined.  Mean values and 
standard deviations of triplicates from one representative experiment are shown.  
Asterisks indicate here and in the experiments below the level of significance (*P<0.05; 
**P<0.005; ***P<0.0005 for comparisons of corresponding Ad binding (infection) in 
parental CHO versus CD46-transfected cells).  (C) CD46 antibody-mediated inhibition 
of Ad3-eGFP transduction.  A549 and CHO-CD46#2 cells were pre-incubated in 
absence or presence of MEM258 anti-CD46 or control E1-1 anti-CAR antibody for 1 h, 
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followed by addition of Ad3-eGFP for another 1 h, and eGFP analysis 48 h p.i..  GFP 
expression levels were normalized to values obtained with the E1-1 antibody, and p-
values were calculated for corresponding values.  (D) Transduction assays of human 
A549, parental CHO and CHO-CD46 expressing cells.  105 cells were incubated with 
eGFP expressing Ad3, Ad7, Ad11, and Ad35 vectors at increasing virus concentrations 
of 10, 100, and 1,000 vp/cell.  eGFP expression was analyzed two days p.i. by flow 
cytometry and are expressed as MFI.  (E) Flow cytometry profiles of CD46 (left panel) 
and desmoglein 2 (middle and right panel).  Parental M010119 and stable transfected 
M010119-eGFP-CD46#8 cells were stained with GB24 anti-CD46 (stains both, 
endogenous and eGFP-tagged CD46) or with 8E5 anti-desmoglein 2 antibody.  
Staining of A549 was included for comparison.  (F) Transduction assays of human 
parental and stable CD46-transfected M010119 melanoma cells.  Cells were 
transduced and tested as described above.  Background fluorescence intensity for 
uninfected M010191-eGFP-CD46 cells was higher due to the eGFP-tagged CD46 in 
these cells. 
Fig. 3.  Cross-linking of CD46ex-huFc strongly increases blocking of Ad3/7 infection in 
CHO-CD46#2 and A549 cells.  (A) CHO-CD46#2 cells or (C) A549 cells were pre-
incubated for 1 h in the cold using the indicated concentrations of adapter CD46ex-
huFc alone or in combination with a 2-fold increase series of goat-anti human Fc 
antibody.  Following addition of the different eGFP-expressing vectors for another 1 h, 
cells were washed and analyzed 48 h p.i.  Controls included replacement of CD46ex-
huFc with CARex-huFc for CHO-CD46#2 cells (B) and A549 cells (D). Asterisks 
indicate the level of significance (*P<0.05; **P<0.005; ***P<0.0005 for comparisons of 
corresponding Ad infection using CD46ex-huFc versus CARex-huFc). 
Fig. 4.  Inhibition of Ad3-, Ad7-, Ad11-, and Ad35-eGFP transduction in CHO-CD46#2 
and A549 cells by recombinant Ad fiber knobs.  Cells were pre-incubated for 1 h in the 
cold using a 5-fold dilution series of the individual FK proteins, followed by addition of 
the different eGFP-expressing vectors for another 1 h. (A) For CHO-CD46#2 cells, the 
viral inputs amounted to 29,600, 8,200, 657, and 1,088 vp / cell for Ad3-, Ad7-, Ad11-, 
and Ad35-eGFP, respectively.  The virus input concentrations had been determined in 
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expression values amounted to fluorescence intensity values of about 200.  eGFP 
analysis was performed 48 h p.i..  FKs are color-coded as follows: Ad5-FK in green, 
Ad3-FK in red, Ad7-FK in purple, Ad11-FK in cyan and Ad35-FK in dark blue.  (B) For 
A549 cells virus inputs amounted to 14,800, 8,200, 1,314, 2,540 and 2,825 vp/cell for 
Ad3-, Ad7-, Ad11-, Ad35-, and Ad5-eGFP, respectively.  Otherwise, the procedure was 
the same as above. 
Fig. 5.  Analysis of FK binding interaction to fluorescence-tagged CD46 by confocal 
FRAP.  104 CHO-eGFP-CD46#33.5 cells (A-E), or A549-eGFP-CD46#2 cells (F) were 
seeded in each of the six $-slide channels one day prior imaging.  (A) Fluorescence 
recovery kinetics of FRAP experiments performed in presence of 2.5 ng/$l of Ad5-, 3-, 
7-, 11- and 35-FK.  The data are depicted as 1/2 values, the time required to reach 
50% of complete recovery.  (B) to (E) Titration of the effect of Ad3-FK (B), Ad11-FK 
(C), Ad35-FK (D), and Ad5-FK (E), using the indicated range of FKs.  (F) Comparison 
of the effect of 64 ng/$l of Ad5-, 3-, 7-FK, and 4 ng/$l of Ad11- and 35-FK in A549-
GPF-CD46#2 cells.  The control sample (no FK) is depicted in black and the FKs are 
color-coded as in Fig. 4.  Error bars represent standard errors of the means.  Statistical 
significance was assessed by t-tests with a threshold p-value set at 0.01. 
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Table 1. Summary kinetics/affinity analyses of Ad-FKs binding to immobilized CD46ex-
huFc 
 
 ka1 (M-1s-1)  kd1 (s-1) ka2 (s-1) kd2 (s-1) KD ± SEM (M) 
Ad3-FK 2.30 x105 6.88 x10-4 2.01 x10-3 1.76 x10-4 2.48 ± 0.27 x10-10 
Ad7-FK 1.44 x105 4.19 x10-4 1.94 x10-3 1.99 x10-4 3.70 ± 1.38 x10-10 
Ad11-FK 9.27 x105 3.27 x10-4 5.41 x10-3 1.60 x10-4 2.46 ± 1.50 x10-11 
Ad35-FK 3.08 x106 4.66 x10-4 1.25 x10-3 1.29 x10-4 1.78 ± 1.04 x10-11 
 
Values are averages of three individual measurements  
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Table 2.  Species B serotype-mediated eGFP transgene expression in different CHO-
CD46-expressing cells compared to parental CHO and human A549 cells 
 
 eGFP expression levels: Fold change compared to CHO
a 
 CHO-CD46#6 CHO-CD46#1 CHO-CD46#2 
Ad3-eGFP 18 55 192 
Ad7-eGFP 37 85 354 
Ad11-eGFP 40 88 79 
Ad35-eGFP 60 106 96 
eGFP expression levels: % of A549 expressionb 
 
CHO CHO-CD46#6 CHO-CD46#1 CHO-CD46#2 
Ad3-eGFP 0.24 19 60 211 
Ad7-eGFP 0.23 21 50 202 
Ad11-eGFP 1.03 49 105 95 
Ad35-eGFP 2.66 177 305 284 
 eGFP expression levels: vp/cell needed to reach MFI 100c 
 CHO-CD46#6 CHO-CD46#1 CHO-CD46#2 A549 
Ad3-eGFP 8,207 (27) 2,597 (16) 717 (4.2) 1,513 (2.7) 
Ad7-eGFP 2,919 (9.5) 1,210 (7.3) 267 (1.57) 602 (1.1) 
Ad11-eGFP 634 (2.1) 291 (1.8) 314 (1.8) 329 (0.6) 
Ad35-eGFP 307 165 170 562 
 
a Ratio of eGFP mean fluorescence intensity levels from CD46-expressing cell line to parental 
CHO were determined for 1,000 vp/cell input.  
b Percentage of eGFP mean fluorescence intensity levels of CD46-expressing cells relative to 
A549 cells were determined for 1,000 vp/cell input.  
c Regression lines were calculated for the eGFP expression levels; numbers in parentheses 
correspond to fold-higher virus concentration input compared to Ad35-eGFP.  
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Table 3.  eGFP transgene expression analysis in M010119 and M010119-eGFP-
CD46#8 cells 
eGFP expression levels: vp/cell needed to reach 
MFI 100b 
 
eGFP expression levels: Fold 
change compared to 
M010119a M010119 
M010119-eGFP-
CD46#8 
Ad3-eGFP 86 34,513 271 (127) 
Ad7-eGFP 26 4,695 91 (52) 
Ad11-eGFP 2.1 344 110 (3.1) 
Ad35-eGFP 2.3 258 130 (2.0) 
 
a Ratio of eGFP mean fluorescence intensity levels from M010119-eGFP-CD46#8 cells to 
parental M010119 cells were determined for 1,000 vp/cell input.  
b Regression lines were calculated for the eGFP expression levels.  Numbers in parenthesis 
correspond to fold-enhancement of transduction efficiency in M010119-eGFP-CD46#8 cells 
compared to M010119 cells, based on MFI 100 values. 
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Table 4.  eGFP transgene expression analysis in CHO-eGFP-CD46#33.5 and A549-
eGFP-CD46#2 cells 
eGFP expression levels: vp/cell needed to reach MFI 100a 
 CHO-eGFP-
CD46#33.5 
A549-eGFP-
CD46#2b 
A549 
Ad3-eGFP 823 497 (1.1) 559  
Ad7-eGFP 270 258 (1.6) 412  
Ad11-eGFP 397 247 (1.4) 354  
Ad35-eGFP 110 171 (2.1) 358  
 
a Regression lines were calculated for the eGFP expression levels.  
b Numbers in parenthesis correspond to fold-enhancement of transduction efficiency in A549-
eGFP-CD46#2 cells compared to parental A549 cells, based on MFI 100 values. 
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Table 5.  Inhibition of Ad3/7/11/35-eGFP and Ad5-eGFP-mediated reporter expression 
by fiber knob cross competition.  
% Inhibition of eGFP expression a 
Competitor Cells Ad3-eGFP Ad7-eGFP Ad11-eGFP Ad35-eGFP Ad5-eGFP 
CHO-CD46 40 7 18 -3 nd 
Ad3-FK 
A549 93 78 28 18 17/-9 
CHO-CD46 86 81 21 -10 nd 
Ad7-FK 
A549 95 87 4 -18 2/12 
CHO-CD46 99 98 99 97 nd 
Ad11-FK 
A549 93 95 99 100 -10/-6 
CHO-CD46 98 85 97 96 nd 
Ad35-FK 
A549 74 56 99 99 -1/-7 
CHO-CD46 1 -35 16 0 nd 
Ad5-FK 
A549 24 9 -21 29 26/97 
FK concentration for 50% inhibition (ng/ml) b 
 
 
Ad3-eGFP Ad7-eGFP Ad11-eGFP Ad35-eGFP Ad5-eGFP 
CHO-CD46 nd nd nd nd nd 
Ad3-FK 
A549 25 23 nd nd nd 
CHO-CD46 169 2’690 nd nd nd 
Ad7-FK 
A549 17 31 nd nd nd 
CHO-CD46 14 21 22 37 nd 
Ad11-FK 
A549 31 87 13 14 nd 
CHO-CD46 5 63 14 26 nd 
Ad35-FK 
A549 470 4,459 33 5 105 
 
aData correspond to inhibitions obtained using 5,000 ng/ml FK concentration in Fig. 2C, D.   
bData were calculated by applying regression lines to values in Fig. 2C, D.  nd: not determined.
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STable 1. Overview kinetics/affinity analysis of Ad-FKs binding to immobilized CD46ex-huFc 
Annalyte / RU chip / 
binding experiment 
Flow rate 
(ul / min) ka1 (M
-1s-1)
 a
 kd1 (s
-1) ka2 (s-1) kd2 (s-1) % !!/Rmax KD (M) 
Ad3-FK / 1121 / 1 55 2.04 x105 (0.0014) 7.11 x10-4 (0.019) 1.97 x10-3 (0.0037) 1.64 x10-4 (0.0022) 0.64 - 1.31 2.68 x10-10 (0.0093) 
Ad3-FK / 1121 / 2 30 1.92 x105 (0.0013) 7.18 x10-4 (0.020) 2.03 x10-3 (0.0037) 1.65 x10-4 (0.0022) 0.66 - 1.28 2.81 x10-10 (0.0101) 
Ad3-FK / 2630 / 3 30 2.93 x105 (0.0035) 6.36 x10-4 (0.019) 2.02 x10-3 (0.0046) 1.98 x10-4 (0.0029) 1.36 - 2.78 1.94 x10-10 (0.0079) 
Ad7-FK / 1121 / 4 30 4.20 x104 (0.012) 3.39 x10-4 (0.059) 3.77 x10-3 (0.036) 5.08 x10-5 (0.061) 0.03 - 0.50 1.07 x10-10 (0.0249) 
Ad7-FK / 2630 / 5 30 2.44 x105 (0.0047) 5.88 x10-4 (0.015) 1.18 x10-3 (0.0035) 2.58 x10-4 (0.0064) 0.44 - 0.93 4.32 x10-10 (0.0195) 
Ad7-FK / 2630 / 6 30 1.44 x105 (0.0046) 3.30 x10-4 (0.011) 8.67 x10-4 (0.048) 2.90 x10-4 (0.015) 0.25 - 0.71 5.72 x10-10 (0.0419) 
Ad11-FK / 1121 / 7 30 9.04 x105 (0.021) 9.86 x10-5 (0.091) 6.96 x10-4 (0.11) 7.57 x10-5 (0.39) 2.86 - 5.05 1.07 x10-11 (0.0531) 
Ad11-FK / 2630 / 8 30 7.96 x105 (0.012) 3.93 x10-4 (0.018) 1.03 x10-3 (0.0054) 1.28 x10-4 (0.01) 0.27 - 3.72 5.47 x10-11 (0.0527) 
Ad11-FK / 2630 / 9 30 1.08 x106 (0.00086) 4.90 x10-4 (0.032) 1.45 x10-2 (0.023) 2.77 x10-4 (0.046) 3.52 - 4.19 8.48 x10-12 (0.199) 
Ad35-FK / 1121 / 10 30 3.54 x106 (0.0088) 2.16 x10-4 (0.015) 1.12 x10-3 (0.0081) 1.06 x10-4  (0.0037) 0.12 - 3.03 5.23 x10-12 (0.0751) 
Ad35-FK / 2630 / 11 30 2.12 x106 (0.0034) 7.96 x10-4 (0.030) 1.33 x10-3 (0.0042) 1.51 x10-4 (0.0049) 0.27 - 3.08 3.85 x10-11 (0.0222) 
Ad35-FK / 2630 / 12 30 3.60 x106 (0.0057) 3.85 x10-4 (0.019) 1.30 x10-3 (0.0061) 1.31 x10-4 (0.0076) 0.16 - 4.76 9.76 x10-12 (0.0833) 
 
a values in parentheses are errors of the fitting procedure  
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Legends to supplemental figures 
SFig. 1.  Analysis of recombinant Ad-FK and CD46ex-huFc proteins.  (A, B) Individual FK 
proteins were produced using the Baculovirus expression system.  Purified FK proteins from 
Ad3, Ad5, Ad7, Ad11, and Ad35 were analyzed by either 12.5% reducing PAGE and sypro 
ruby red staining (A), or by 10% native PAGE and Coomassie Blue staining (B).  (C) Analysis 
of recombinant CD46ex-huFc.  Three !g of purified CD46ex-huFc were analyzed by 10% 
native PAGE and Coomassie Blue staining. 
 
SFig. 2.  Characterization of eGFP-tagged CD46 in CHO-eGFP-CD46#33.5 and A549-
eGFP-CD46#2 cells.  (A) Flow cytometry profile of eGFP-tagged CD46 expression in CHO-
eGFP-CD46#33.5 cells.  Cells were stained with GB24 anti-CD46 antibody.  Staining of A549 
was included for comparison.  (B) Test for functionality of eGFP-tagged CD46 in CHO-eGFP-
CD46#33.5 cells.  105 CHO-eGFP/CD46#33.5 cells were transduced with increasing 
concentrations of 10, 100, and 1,000 vp/cell of eGFP expressing Ad3, Ad7, Ad11, and Ad35 
vectors.  eGFP expression levels were analyzed two days p.i. by flow cytometry and are 
expressed as MFI.  Asterisks indicate the level of significance (*P<0.05; **P<0.005; 
***P<0.0005 for comparisons of corresponding Ad infection in parental CHO versus CHO-
eGFP-CD46#33.5 cells).  (C) Flow cytometry profile of CD46 expression in A549-eGFP-
CD46#2 (left panel) and parental A549 cells (right panel).  Cells were stained with MCI20.6 
anti-CD46 antibody (stains endogenous form of CD46 only), and M177 anti-CD46 antibody 
(stains total pool of CD46).  (D) Test for functionality of eGFP-tagged CD46 in A549-eGFP-
CD46#2 cells.  Transduction was performed as described above for CHO-eGFP-CD46#33.5 
cells and included A549-eGFP-CD46#2 cells (left panel) and parental A549 cells (right 
panel).  (E) Binding of CD46-specific antibodies to eGFP-tagged CD46.  Flow cytometry 
analysis of A549 cells expressing normal CD46 and CHO-eGFP/CD46#33 cells expressing 
eGFP-tagged CD46 was performed using the CD46 antibodies known to block species B 
Ads (M177, 13/42, GB24, and MEM258), and antibodies with weak blocking activity (Tra-2, 
E4.3, MCI20.6). 
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SFig. 3.  FRAP and mobility fraction (Mf) analysis of the eGFP-CD46 in presence of human 
Ad-FK 5, 3, 7, 11 and 35.  The mobility of the fluorescence-tagged CD46 receptor was 
monitored by confocal microscopy over time after photo-bleaching.  Each plot comprises the 
average fluorescence recovery curves for the indicated FKs and the corresponding 
histogram illustrating the Mf at the end of the recovery.  The !1/2 values illustrated in Fig. 5 
were obtained from the same set of data.  (A) Fluorescence recovery curve of FRAP 
experiments performed in presence of 2.5 ng/!l of Ad5-, 3-, 7-, 11- and 35-FK.  (B) to (E) 
Titration of the effect of Ad3-FK (B), Ad11-FK (C), Ad35-FK (D), and Ad5-FK (E), using the 
indicated range of FKs.  (F) Comparison of the effect of 64 ng/!l of Ad5-, 3-, 7-FK, and 4 
ng/!l of Ad11- and 35-FK in A549-GPF-CD46#2 cells.  The control sample (no FK) is 
depicted in black and each FK is color-coded as follows: Ad5-FK in green, Ad3-FK in red, 
Ad7-FK in pink, Ad11-FK in cyan and Ad35-FK in dark blue.  Error bars represent standard 
error of the means. 
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Abstract  
Both iTRAQ-label and label-free methods are widely used in quantitative proteome analysis. 
Here, we aimed to compare iTRAQ-label and label-free quantitation using human A549 cells 
infected with adenovirus type 3 (HAdV-B3) and type 5 (HAdV-C5). iTRAQ-labeled protein 
samples were quantified using ProteinPilot (PP) or ScaffoldQ+ (Sc+) software while non-
labeled samples were performed using Progenesis LC-MS (PL) or ProgenesisF-T2PQ (PF2) 
software. As a result, R2 correlation coefficients were archived between 0.48 and 0.78 for 
iTRAQ-label while 0.5 and 0.86 for label-free experiments. Overall, the label-free method 
resulted in higher dynamic range than the iTRAQ-label method and its ratio seemed to be 
more accurate than iTRAQ-labeling, as suggested by Western-blotting of two downregulated 
proteins of galectin-1 and transferrin receptor in HAdV-B3-infected cells to non-infected cells. 
Our results strongly support the notion that iTRAQ-label tends to underestimate the actual 
ratios and label-free can be used as an alternative method to overcome this problem. 
Beyond solving the technical issue, we also uncovered protein regulation patterns upon 
HAdV-B3 or HAdV-C5 infection, which contribute to a better understanding of pathogen-host 
interactions.  
.  
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 Introduction 
Quantitative proteomics based on mass spectrometry (MS) has recently become an 
important component of biological and clinical research, allowing, e.g., the identification of 
new functional modules and pathways, or the detection of disease biomarkers 1, 2. Relative 
quantitation of two or more samples for studies of differential protein expression is of 
particular importance. Such quantitative results can be gained by use of stable isotope labels 
or by label-free approaches 3-5.  
Several labeling methods have been developed relying on the mass differences between 
light and heavy isotopes such as 2H, 13C, 15N, and 18O to allow relative protein quantitation 
using MS. In vivo metabolic labeling methods were introduced, with cell-culture enrichment 
using stable isotope labeled amino acids (SILAC), particularly, arginine 6, lysine 7, tyrosine 8 
and leucine 9. The SILAC labels are of advantage for use in cell culture, but cannot be 
applied for direct labeling of purified protein or peptide samples. For direct labeling, two most 
popular chemical labeling strategies are being used. The first, isotope coded affinity tags 
(ICAT) allows labeling of cysteine-containing peptides followed by enrichment and MS 
analysis 10. However, peptides devoid of cysteine residues can not be measured. The 
isobaric tag for relative and absolute quantitation (iTRAQ) system by Applied Biosystems 
was developed for relative quantitation and also for absolute quantification with internal 
peptide standards 11. Since the iTRAQ reagents react with primary amines of N-termini or 
lysine residues, most peptides can be efficiently labeled. iTRAQ reporter ions are 
subsequently released during collision-induced dissociation (CID) fragmentation, and their 
relative intensities are used for protein quantitation. In contrast to ICAT and SILAC, where 
two or three samples are compared at a time, iTRAQ allows simultaneous labeling and 
quantification of four samples 11, or eight samples 12. By combining multiple samples in one 
run, the instrument running time for analyses and variations between the different runs are 
considerably reduced. Other advantages of iTRAQ include their compatibility with different 
MS platforms, including MALDI-TOF/TOF, Q-TOF, Orbitrap-XL and Orbitrap-Velos 
instruments. High-throughput quantitative proteomics combined with iTRAQ-label produces 
large datasets. To quantify the iTRAQ ratios, for example, an array of bioinformatic tools was 
introduced, including ProQuant (Applied Biosystems), TandTRAQ 13, Multi-Q 14, Mascot 2.2 
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(Matrix Science, London, UK), Sc+ (http://www.proteomesoftware.com/) and PP 15. PP 
utilizes Paragon as a search algorithm. Unlike ProteinPilot (PP), Scaffold does not contain a 
search engine, but it uses Bayesian statistics to estimate peptide and protein identification 
probabilities based on Mascot or other search outputs. The (more) recently up-dated 
ScaffoldQ+ (Sc+) version contains all features for iTRAQ quantitation. Although iTRAQ-
labeling has been widely applied, there is an ongoing dispute concerning the accuracy of the 
deduced protein quantitations when using this method, particularly when dealing with sample 
mixtures of high complexity 16. Whereas microarrays can measure differences in expression 
levels spanning over 3 orders of magnitude, iTRAQ-labels typically reveal fold changes of 
less than 2 orders of magnitude 17. From a technical point of view, this may be perceived as 
a limitation of the iTRAQ-labeling method for quantitative proteomics. 
There are two general approaches for label-free quantitation, measurement of spectral peak 
intensities 18 and spectral counting 19. The label-free approach can be applied for both 
shotgun and targeted proteomics 20. Moreover, it is not only a cost-effective method but also 
more reproducible 21. However, correct interpretation of quantitation levels obtained by label-
free methods necessitates extended processing of raw LC/MS data, facing high demands 
with respects to the bioinformatic tools. Thus, multiple software analyses make the data 
interpretation more reliable. Due to a variety of factors, including peptide compositions, their 
physicochemical properties and local chemical environment and counting of spectrum-
peptide matches are often not an accurate measures of protein abundance 22, 23. To 
overcome the bias of MS/MS spectral counting, Lu et al. developed the Absolute Proteomics 
Expression counting method including correction factors that predict detection rates of 
peptides to obtain a better protein quantitation result 24. More recently, Grossmann et al. 
adapted a method for the label-free quantitation by selecting the top N most intense 
precursor ions per protein, depending on the quality of acquired data (TNPQ) 25. The N can 
be varied from the top two most intense features (T2PQ) to the top three most intense 
features (T3PQ) or more 25. Unlike other label-free quantitation softwares, Progenesis LC-MS 
(PL, Nonlinear Dynamics) uses vectors to match all experiments to one reference sample in 
order to achieve a good reference map for comparison. Next, a global scaling factor for each 
LC-MS run is estimated to normalize all runs. The peptide abundance is the sum of the peak 
areas within the isotope boundaries while the protein abundance is the sum of the 
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abundances of all peptide ions, which have been identified as coming from the same protein. 
Finally, the peak lists are exported in the mgf format and can be used for the Mascot search 
engine, which later on imports Mascot results back into PL. Due to high-throughput and high 
speed of MS instruments and based on improved reproducibility of pre-fractionating complex 
peptide mixtures by LC, label-free quantitative proteomic methods are increasingly 
considered as reliable and they are used to complement labeling methods 26. 
The controversy which quantitative proteomics method is more reliable is still ongoing. 
Several comparative studies have been performed including analysis of different isotope 
labels, and use of isotope label versus (vs) label-free approaches 27, 28. In general, isotope 
labels offer higher reproducibility in quantitation, while label-free methods require highly 
reproducible LC-MS/MS platforms 3. The comparison study for different isotope labels 
including DIGE, ICAT and iTRAQ indicated that iTRAQ is more sensitive than ICAT 27. In 
another study, Patel et al. compared iTRAQ-label and label-free methods, which resulted in 
79 common proteins quantified by both methods 28. However, the issue which quantitation 
method is more reliable for complex samples remains unsolved.  
In this study, we further evaluated whether the iTRAQ-labeling tends to underestimate 
differences in the actual expression level of proteins compared to label-free method. We 
performed a large-scale proteome analysis of complex protein samples derived from human 
lung adenocarcinoma cells infected with human adenovirus type 3 (HAdV-B3) or type 5 
(HAdV-C5). Adenoviruses are significant pathogens causing respiratory disease, 
gastroenteritis, acute hemorrhagic cystitis, meningoencephalitis or conjunctivitis 29-32. We 
compared the correlations of up- or down-regulated proteins of HAdV-B3/HAdV-C5-infected 
cells to non-infected cells when using iTRAQ-label vs label-free approaches. Since HAdVs 
are widely used and the most extensively studied viruses for gene delivery/therapy purposes 
33, 34, the accurate analyses of global protein expression changes in infected cells will hence 
contribute to enhance the understanding of virus–host interactions.  
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Experimental Section 
Cells, virus and sample preparation for quantitative proteome analysis.  
Human A549 lung adenocarcinoma epithelial cells were cultured in Dulbecco's modified 
Eagle's medium (Sigma) supplemented with 8% fetal bovine serum. A549 cells were infected 
with HAdV-B3 or HAdV-C5 using a multiplicity of infection (MOI) of 200 infectious virus 
particles/cell. Control non-infected and HAdV-B3/C5 infected-cells were harvested at 24 
hours (h) post infection (p.i.). The cells were washed twice by centrifugation in phosphate-
buffered saline. The cell pellets were then resuspended by sonication in lysis buffer 
containing 10 mM Hepes pH 7.4, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 
0.1% sodium dodecyl sulfate (SDS), and protease inhibitor cocktail (Roche). Non-solubilized 
material was removed by centrifugation at 16,000 " g for 20 minutes (min). The proteins 
contained in the supernatant were precipitated by addition of trichloroacetic acid (TCA) to 
20% and twice washed with 100% acetone. Finally, the proteins were solubilized in 0.5 M 
triethylammonium bicarbonate pH 8.5 plus 0.2% SDS, 1 M urea and 15% methanol. Protein 
concentrations were measured by the Qubit method (Invitrogen). For downstream analysis 
by LC-MS/MS, 30 µg of individual protein samples were used.  
For the iTRAQ-8plex labeling experiments, 30 µg proteins were reduced in 2 mM of Tris[2-
carboxyethyl] phosphine (TCEP) at 37°C for 1 h and the cysteine residues were blocked in 
10 mM methyl methanethiosulfonate (MMTS) at room temperature for 15 min followed by 
trypsin digestion (modified trypsin, Promega) at a protease:protein ratio of 1:12.5 (w/w) at 
37°C for 8-10 h. iTRAQ-8plex reagents (Applied Biosystems) were added to the peptide 
samples, which were incubated at room temperature for 140 min. The reaction was stopped 
by addition of 10 mM KH2PO4, 25% acetonitrile (ACN), pH 2.6 (solvent A), followed by 
centrifugation at 16,000 x g for 10 min to remove the aggregated proteins.  
 
Chromatography and mass spectrometric analyses. 
The digested protein samples were separated by using multidimensional liquid 
chromatography. In the first dimension, the peptide mixtures were fractionated using a strong 
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cation exchange chromatography (SCX) column (Polysulphoethyl A, 2.1 mm inner diameter, 
200 mm length, 300 Å pore size, 5 µm particle size, PolyLC Inc.)  A linear binary gradient 
from solvent A (10 mM KH2PO4, 25% ACN, pH 2.6) to solvent B (10 mM KH2PO4, 0.35 M 
KCl, 25% ACN, pH 2.6) was applied: 0% to 5% solvent B in 15 min, 5% to 35% B in 35 min, 
and 35% to 100% B in 10 min. The entire run lasted 90 min, and 27 SCX fractions were 
collected. These fractions were vacuum-dried and redissolved in 0.1% trifluoroacetic acid 
(TFA), 5% ACN. Based on the SCX chromatograms, the 27 SCX fractions were combined 
into 8 pools. All pools were further desalted by Sep-Pak C18 columns (Waters), which were 
equilibrated by 100% methanol, 80% ACN, and washed by 0.5% ACN plus 0.1% TFA. 
Peptides were loaded on the pre-treated columns, which then were washed twice with 0.1% 
TFA, 5% ACN. Finally, peptides were eluted with 0.1% TFA, 80% ACN, vacuum-dried and 
redissolved in 0.1% TFA, 5% ACN.  
The pooled SCX fractions were then separated in a second dimension by reversed-phase 
liquid chromatography on an Ultimate chromatography instrument (Dionex) coupled with 
MALDi-MS/MS. LC-MALDI-MS/MS is the off-line separation of peptides on a capillary liquid 
chromatography (LC) system. The cleaned peptide samples were automatically injected by a 
Famos autosampler and separated by an UltiMate capillary LC system (Dionex/LC Packings) 
and load onto a C18 PepMap main column (75 µm ID, 150 mm length, 100 Å pore size, 3 µm 
particle size; Dionex) using a linear binary gradient (solvent A: 0.1% TFA; solvent B: 0.1% 
TFA, 80% ACN). HPLC linear gradients were increased by solvent B from 0% (10 min) to 
50% (100 min) and from 50% to 100% (112 min). The peptides eluting from the LC column 
were then mixed with 3-4 mg/ml of matrix #-Cyano-4-hydroxycinnamic acid (Bruker 
Daltonics) in 0.1% TFA, 70% ACN containing internal neurotensin peptide (Sigma), and were 
automatically deposited onto an Opti-TOF® LC MALDI plate (Applied Biosystems) by using a 
Probot spotting device. Four SCX pools gave rise to 1,664 spots on each LC MALDI plate. 
MS/MS analysis was conducted with a 4800 MALDI-TOF/TOF instrument (Applied 
Biosystems). 
Mass spectrometric analysis was performed on a 4800 MALDI-TOF/TOF instrument 
equipped with a 355 nm Nd:YAG laser. Mass spectra were acquired in positive reflectron 
mode in the mass range from m/z 850 to 4000, with a focus mass of m/z 2100. They were 
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generated by accumulating data from 600 laser pulses, and they were internally recalibrated 
based on the molecular mass of the neurotensin peptide. The ten most intensive peptide ion 
signals showing a S/N ratio > 100 were subjected to MS/MS acquisition. Peptide collision-
induced dissociation was conducted at a collision energy of 1 kV and at a gas pressure of 
approximately 2.5 x 10-6 Torr. During MS/MS acquisition, a method with a stop condition was 
used. In this method, a minimum of 1000 and a maximum of 2000 laser pulses were allowed 
for each spectrum.  
For the label-free approach, 30 µg proteins were reduced in 5 mM of TCEP at 37°C for 1 h 
and blocked in 10 mM iodoacetamide at room temperature for 30 min followed by trypsin 
digestion at 37°C for 8-10 h. The trypsin digestion was stopped by adding 5% TFA and the 
pH value was adjusted by 10 mM KH2PO4, 25% ACN, pH 2.6. The aggregated proteins were 
removed by centrifugation at 16,000 x g for 10 min. The protein digests were purified by 
using Sep-Pak C18 columns (Waters). The desalted peptides were vacuum-dried and 
dissolved in 0.2% formic acid and 3% ACN.  The samples were injected into an Eksigent-
nano-HPLC system (Eksigent Technologies, Dublin CA, USA) by an autosampler and 
separated on a self-made reverse-phase tip column (75 µm " 80 mm) packed with C18 
material (3 !m, 200 Å, AQ, Bischoff GmbH, Leonberg, Germany). The column was 
equilibrated with 97% solvent A (A: 1% ACN; 0.2% formic acid in water) and 3% solvent B 
(B: 80% ACN, 0.2% formic acid in water). Peptides were eluted using the following gradient: 
0-50 min, 3-30% B; 50-58 min, 30-50% B, and 58-60 min, 50-97% B at a flow rate of 0.2 
µL/min. High accuracy mass spectra were acquired on an LTQ-ICR-FT-Ultra mass 
spectrometer (Thermo Scientific, Bremen, Germany) in the mass range of 300-2,000 m/z and 
at a target value of 1x106 ions and a resolution of 100,000 at m/z 400. Up to five data 
dependent MS/MS were recorded in parallel in the linear ion trap from the most intense ions 
with charge states 2+ or 3+ using collision induced dissociation. Target ions already selected 
for MS/MS acquisition were dynamically excluded for 120 seconds.  
 
Database searches and quantitative proteome analysis.  
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Both PP and Mascot search engines were used for protein identification from iTRAQ data 
acquired on a MALDI-TOF/TOF instrument. Only Mascot was utilized to identify proteins from 
data acquired on the LTQ-FT-ICR instrument for label-free quantitation. For the analysis with 
PP v3.0 (Applied Biosystems), the acquired data was directly fetched from the Oracle 
database and searched with the Paragon algorithm.  For the analyses with Mascot, peak lists 
(mgf files) were generated using Mascot Distiller software v2.3 (Matrix Science Ltd., London, 
UK). The same database, which contains a non-redundant protein database for both human 
and HAdVs proteins (www.uniprot.org) and a few of HAdV entries derived from NCBI, was 
applied for both PP and Mascot searches. The combined database contains 41,135 entries 
in total including the concatenated reversed decoy entries, which were added in order to 
estimate the protein false discovery rate (FDR) 35.  
In Mascot searches, tolerances of 25 ppm for peptide masses and 0.25 Da for fragment ions 
were considered for data obtained by using the MALDI-TOF/TOF instrument. In case of data 
obtained by LTQ-FT-ICR analyses, tolerances of 5 ppm for peptides and of 0.6 Da for 
fragment ions were used. In all searches, carbamidomethylation or MMTS modification of 
cysteine residues was selected as fixed modifications and oxidation was considered as 
variable modification. To obtain a protein FDR below 5%, identified proteins were filtered on 
peptide levels of an ion score $ 30.  
Next, PP and Sc+ (Proteome Software) were used for protein quantitation of iTRAQ-labeled 
samples. For PP, background correction was applied and biological modifications were 
allowed. To obtain a protein FDR under 5%, protein identifications were filtered with PP 
score $ 1.3 (equivalent to 95% confidence). PP Analysis resulted in both protein identification 
and quantification. In contrast, we only used the protein identification feature from Mascot 
searches and applied the quantification feature from Sc+. To improve reliability and 
confidence of protein quantitation, all precursors ion signals showing an intensity % 50 were 
discarded before the data were imported into Sc+. The quantitative analyses for the label-
free approaches were performed by using the commercial PL software (Nonlinear Dynamics) 
as recommended by the vendor on the one hand or the Progenesis feature data export was 
combined with the emerging “high flyer” strategy to quantify proteins based on LC-MS 
signals. The idea of this strategy termed ProgenesisF-T2PQ (top 2 protein quantitation, PF2) 
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or ProgenesisF-T3PQ (top 3 protein quantitation, PF3) 25, is that irrespective of how many 
peptides are found for one particular protein, only the most intense (n) precursor signals are 
used to produce a quantitative protein value. We adapted this method referred to as PF2 or 
PF3, respectively, based on the aligned Progenesis feature map by averaging the top N 
normalized volumes of features from the same protein. 
 
Western blot analysis.  
40 !g/lane of A549 cell lysate proteins were separated on 10 or 15% SDS-PAGE, 
respectively. The rabbit-anti human galectin-1 (LGALS1) antibody was a generous gift from 
Walter Nickel (University of Heidelberg, Germany). The monoclonal mouse anti-human 
transferrin receptor 1 (CD71) antibody (clone 3B8 2A1) was purchased from Hycult Biotech, 
and the monoclonal mouse anti-"-tubulin antibody (DM1A) was purchased from Sigma. 
Secondary horseradish peroxidase- conjugated anti-mouse antibodies (cat: NA931V), were 
purchased from GE Healthcare. Signal detection was performed in the chemiluminescent 
scanning mode of Image reader LAS 3000 (FUJIFILM Science Lab), and signal quantitation 
was performed using ImageGauge version 3 (FUJIFILM Science Lab).  
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Results 
Workflow for quantitative proteome analysis using iTRAQ-label and label-free 
methods.  
Two independent workflows for iTRAQ-based and label-free approaches using lysates of 
non-infected A549 or HAdV-B3/HAdV-C5-infected A549 cells were applied (Fig. 1A). Cell 
lysates were harvested after 24 h p.i. and proteins were precipitated by TCA, followed by 
trypsin digestion. For the iTRAQ-label approach, the tryptic peptides were labeled with 
iTRAQ-8plex reagents, separated by SCX chromatography following reverse-phase 
chromatography and spotted onto MALDI plates. The mass spectrometric analyses were 
performed on the MALDI-TOF/TOF instrument. Protein quantitation based on iTRAQ data 
was performed with PP and Sc+ softwares. For the label-free approach, protein digests were 
analyzed with LC-MS/MS without pre-fractionation. Next, PL, PF2 and PF3 were used for 
protein quantitation of the label-free samples.  
An overview of the subsequently performed data comparisons is shown in Fig. 1B. We first 
compared the biological replicates within either iTRAQ-label or label-free quantitations. Next, 
we compared the iTRAQ-label data set with the two different quantitation softwares PP vs 
Sc+. Likewise, we compared the label-free data set with the two different softwares PL vs 
PF2. Finally, we addressed the correlation between iTRAQ-label and label-free methods by 
comparing four sets of PP vs PL, PP vs PF2, Sc+ vs PL, and Sc+ vs PF2.   
 
Reproducibility of iTRAQ-based protein quantitation analyzed by ProteinPilot or 
ScaffoldQ+ quantitation software.  
First we used the two commonly applied commercial softwares PP and Sc+ for analysis of 
the data acquired by the iTRAQ-labeling procedure. As a result, 1,538 proteins were 
quantified for HAdV-B3-infected and non-infected control cells, and 1,548 proteins for HAdV-
C5-infected and non-infected cells, among 1,802 identified proteins with confidence over 
95% (PP score 1.3) and protein FDR of 1.89% (Fig. 2). We then checked the reproducibility 
of two biological replicates for each condition. The squared Pearson correlation analysis 
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revealed a R2 of 0.55 for HAdV-B3-infected cells, and a R2 of 0.76 for HAdV-C5-infected cells 
(Fig. 3A and STable 1).  
Similarly, we also observed reproducibility between two biological replicates with Sc+ with a 
Pearson correlation R2 of 0.49 for HAdV-B3-infected cells and R2 of 0.69 for HAdV-C5-
infected cells with 1,340 and 1,343 quantified proteins in HAdV-B3- and HAdV-C5-infected 
cells, respectively, with 0% protein FDR (Fig. 3B and STable 1).  
 
Comparison of ProteinPilot and ScaffoldQ+ quantitations for iTRAQ-label analyses.  
Comparison of squared Pearson correlations between PP and Sc+ revealed reasonable 
good correlation, with a R2 of 0.7 for proteins of HAdV-B3-infected cells, and a R2 of 0.71 for 
proteins of HAdV-C5-infected cells (Fig. 3E and STable 1). This indicated that the 
quantitation of iTRAQ-labeling data was reliable, independent of the algorithm or search 
engine was used for quantitation. The deduced slope values of 0.8 and 0.84 for proteins of 
HAdV-B3- and HAdV-C5-infected cells, respectively, indicated that the expression changes 
quantified by Sc+ were slightly more significant than those quantified by PP. In addition, most 
of the proteins quantified by Sc+ were also found by using PP. For proteins of HAdV-B3-
infected cells, 1,263 proteins overlapped between PP and Sc+, whereas for proteins of 
HAdV-C5-infected cells, 1,267 proteins overlapped between PP and Sc+. The ratios for most 
of the quantified proteins were similar between PP and Sc+ (STable 1). In 827 (65.5%) out of 
1,263 proteins of HAdV-B3-infectecd cells, the ratios were found in the range of ±20% 
variations based on log 2 ratio between PP and Sc+, while for HAdV-C5-infected cells, 819 
(64.6%) out of 1,267 proteins were found in this range. 
Of note, the viral proteins were only detected in virus-infected samples, but not in non-
infected cells. The up-regulated proteins thus consisted of viral and cellular proteins in both, 
PP and Sc+ analyses. When using PP, 37 proteins were found to be up-regulated with 
threshold of 0.6 (log2 ratio) in HAdV-B3-infected cells, and 51 proteins were down-regulated 
in these cells (STable 2). Likewise, for HAdV-C5-infected cells, 33 proteins were up-
regulated and 20 proteins were down-regulated. Within Sc+, 31 proteins were found up-
regulated and 50 proteins were down-regulated in HAdV-B3-infected cells, while 23 proteins 
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were up-regulated and 25 proteins were down-regulated in HAdV-C5-infected cells. All 
together, for proteins of HAdV-B3-infected cells, 74 proteins were found up- or down-
regulated with both, the PP and the Sc+ program, whereas for proteins from HAdV-C5-
infected cells, 40 proteins were determined to be significantly changed by both analysis 
programs. 
12 and five viral proteins were detected in HAdV-B3-infected cells by use of PP and Sc+, 
respectively. For HAdV-C5-infected cells, 18 and nine viral proteins were detected by use of 
PP and Sc+, respectively. This is likely due to result from a different scoring algorithm in the 
PP software.  
For one protein of the 1,263 quantified proteins of HAdV-B3-infected cells, and two proteins 
of the 1,267 quantified proteins of HAdV-C5-infected cells, the quantitation using PP and Sc+ 
gave rise to ambiguous results (STable 2). These included eukaryotic translation initiation 
factor 3 subunit F (EIF3F, O00303) in HAdV-B3-infected cells, which revealed a change of -
1.12 log2 ratio with PP and a change of -0.6 log2 ratio with Sc+. The different quantitation 
values for this protein were due to the filtering parameters of PP and Sc+. In the Sc+, both 
ion precursors and their MS/MS fragmentations were used for protein quantitation while in 
the PP only one ion precursor and its MS/MS fragmentation was applied. These two ion 
precursors had different quantitative values; thus results were different depending whether 
one or two ions were used for quantitation. In case of sterol-4-alpha-carboxylate 3-
dehydrogenase, decarboxylating (NSDHL, Q15738), it was quantified by 1.1 of log2 ratio 
change in PP, and no significant change in Sc+ in HAdV-C5-infected cells. The different 
quantitation results also derived from a different number of ion precursors were applied for 
quantitation. Two different precursors were used for PP quantitation whereas one precursor 
ion was taken into account for Sc+ quantitation. In this case, one precursor ion showed 
differently in expression level while the other one had no different expression. The one 
without significant difference was used for Sc+ quantitation. For the case of DNA polymerase 
epsilon subunit 4, it was up-regulated by 0.85 of log2 ratio with PP while it was down-
regulated by -0.90 of log2 ratio with Sc+ in HAdV-C5-infected cells (STable 2). Unlike the 
other two previous cases described above, both two precursor ions were applied for both PP 
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and Sc+ quantitation but two precursor ions had low intensity of reporter ions which created 
a bias in the PP quantitation. This bias caused the different results.  
 
Reproducibility of label-free quantitation analyzed by Progenesis LC-MS, ProgenesisF-
T2PQ or ProgenesisF-T3PQ quantitation software.  
Three analysis platforms were used to quantify the data acquired by the label-free procedure. 
With PL quantification based on Mascot search, we were able to quantify 661 proteins in 
HAdV-B3-infected cells and 660 proteins in HAdV-C5-infected cells, with a squared Pearson 
correlation R2 of 0.50 for proteins of HAdV-B3-infected cells, and R2 value of 0.80 for proteins 
of HAdV-C5-infected cells (Fig. 3C and STable 1). 48 proteins were found up-regulated in 
HAdV-B3-infected cells, including sixteen viral proteins, whereas 39 proteins were down-
regulated in these cells (STable 2). For HAdV-C5-infected cells, 59 proteins were found to be 
up-regulated, including seventeen viral proteins, and five proteins were down-regulated.  
In parallel to the analysis by PL, the label-free data were also quantified by using our own 
high flyer strategy PF2 and PF3. As a result, 439 proteins for both HAdV-B3- and HAdV-C5-
infected cells were quantified based on the PF2 feature (Table 1). Correlations amounted to 
R2 of 0.62 for proteins of HAdV-B3-infected cells, and R2 of 0.86 for HAdV-C5-infected cells 
(Fig. 3D and STable 1). Details of proteins with significant changes exceeding the threshold 
of +/- 0.6 (log2 ratio) are shown in STable 2. Using PF2, 42 proteins were found to be up-
regulated in HAdV-B3-infected cells, including sixteen viral proteins, and 37 proteins were 
down-regulated. In HAdV-C5-infected cells, 54 proteins were determined to be up-regulated, 
including seventeen viral proteins, and seven proteins were found to be down-regulated. 
Among the significantly de-regulated cellular proteins, 17 proteins were commonly found in 
both, HAdV-B3- and HAdV-C5-infected cells. Most of the commonly regulated proteins had 
the same trend of either up- or down-regulation.  
Using PF3, we quantified 347 proteins in both, HAdV-B3- and HAdV-C5-infected cells 
(STable 1). Comparison of the data obtained with PF2 vs PF3 revealed a squared Pearson 
correlation R2 of 0.97 for proteins from HAdV-B3-infected cells and R2 of 0.99 for proteins of 
HAdV-C5-infected cells (SFig. 1 and STable 1). Since the obtained correlation was high and 
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since PF2 had higher sensitivity than PF3, all subsequent comparisons within label-free and 
iTRAQ-8plex approaches were performed using PF2. 
 
Comparison of Progenesis LC-MS and ProgenesisF-T2PQ quantitations for label-free 
analyses methods.  
When we compared the squared Pearson correlation between PL and PF2 data, the 
resulting correlation R2 amounted to 0.93 for proteins of HAdV-B3-infected cells, and 0.96 for 
proteins of HAdV-C5-infected cells for 439 common quantified proteins (Fig. 3F and 
STable 1). 78 proteins, including sixteen viral proteins, were significantly up- or down-
regulated in HAdV-B3-infected cells. All of those proteins revealed parallel trends. 57 
proteins were significantly up- or down-regulated in HAdV-C5-infected cells, including 16 viral 
proteins. These results indicated a high reproducibility of biological replicates when analyzing 
label-free quantitation with the two PL and PF2 software. In summary, the differential 
expression patterns of cellular proteins found in HAdV-B3/HAdV-C5-infected cells compared 
to non-infected cells were well correlated between the two software. This suggests that the 
observed difference in expression pattern correlated to the different serotypes used, and did 
not result from using different analysis software or algorithms.  
 
Comparison of quantitative proteomics with iTRAQ-label and label-free quantitation.  
Next we performed a systematic comparison of the data obtained by iTRAQ-labeling and by 
label-free quantitation. Since both, iTRAQ-labeling as well as label-free quantitation, were 
previously analyzed by two different softwares, this resulted in four pair to pair comparisons.  
The comparison of PP (iTRAQ-label) and PL (label-free) revealed a correlation R2 of 0.48 for 
proteins of HAdV-B3-infected cells, and R2 of 0.73 for proteins of HAdV-C5-infected cells 
within 564 and 569 common quantified proteins in HAdV-B3- and HAdV-C5-infected cells, 
respectively (Fig. 4A). Among the proteins quantified by HAdV-B3-infected cells, 23 proteins, 
including twelve viral proteins were significantly up- or down-regulated in both, iTRAQ-8plex 
(by PP) and label-free (by PL) (STable 2). For the proteins of HAdV-C5-infected cells, this 
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comparison resulted in eighteen significantly up- or down-regulated proteins with both 
methods.  All of them had the same trend of regulation, but the fold-change in the label-free 
approach was in general higher compared to the iTRAQ-labeling approach, illustrated by 
slope values of 1.06 for proteins of HAdV-B3-infected cells and 1.20 for proteins of HAdV-
C5-infected cells. This is seen for instance for the viral proteins of HAdV-B3 and HAdV-C5 
(STable 2).  
Most of the cellular proteins with significant expression changes revealed the same trend for 
both analysis programs, except two proteins, including P62633 (cellular nucleic acid-binding 
protein, CNBP), which was down-regulated with iTRAQ-label (by -0.74 of log2 ratio) but up-
regulated with label-free (by 1.01 of log2 ratio) in HAdV-B3-infected cells. In contrast, 
P68036 (ubiquitin-conjugating enzyme E2 L3, UBE2L3) was up-regulated with iTRAQ-label 
(by 0.88 of log2 ratio), while down-regulated with label-free (by -1.34 of log2 ratio) in HAdV-
B3 infected cells. In these cases, precursor ion resulted in low intensities and only one 
precursor ion was taken into quantitation. Thus, it is difficult to judge which quantitation 
method was more reliable in these cases. 
The squared Pearson correlation of the comparison of PP (iTRAQ-label) and PF2 (label-free) 
gave rise to higher R2 values compared to the pair of PP and PL. Thus we obtained a R2 of 
0.69 for HAdV-B3 including 406 proteins, and a R2 of 0.78 for HAdV-C5 including 410 
proteins (Fig. 4B and STable 1). For proteins of HAdV-B3-infected cells, 22 proteins were 
significantly changed in both iTRAQ-8plex (PP) and label-free (PF2) (STable 2). For proteins 
of HAdV-C5-infected cells, 18 proteins showed significant changes. However, not all proteins 
could be directly compared, since certain proteins with significant expression changes were 
only quantified with the iTRAQ-label, but not with the label-free-method. The number of 
proteins quantified by using the iTRAQ-8plex method is higher than in the label-free method. 
This is due to the pre-fractionation of complex peptide mixtures prior to LC-MS/MS in the 
iTRAQ-label workflow, while no pre-fractionation was applied in the label-free approach. 
Similarly to what was found in the PP vs PL comparison, fold-changes of protein expression 
levels were more pronounced for the data derived by PF2 compared to PP, illustrated by 
slope values of 1.22 and 1.35 for proteins of HAdV-B3- and HAdV-C5-infected cells, 
respectively. 
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For the comparison of Sc+ vs PL, the squared Pearson correlation R2 was 0.37 for 532 
proteins identified in HAdV-B3-infected cells, and 0.60 for 535 proteins identified in HAdV-
C5-infected cells (Fig. 4C, STable 1). For proteins of HAdV-B3-infected cells, 20 proteins 
were significantly changed in both iTRAQ-8plex (Sc+) and label-free (PL) (STable 2). For 
proteins of HAdV-C5-infected cells, nine proteins showed a significant change. The slope 
values of PL vs Sc+ were 1.11 for proteins of HAdV-B3-infected cells and 1.28 in case of 
proteins from HAdV-C5-infected cells, indicating again that dynamic changes were more 
pronounced in the label-free approach compared to the iTRAQ-labeling method.  
Similar to the squared Pearson correlation of Sc+ vs PL comparison, the R2 Pearson 
correlation of Sc+ vs PF2 was 0.54 for 394 identified proteins in HAdV-B3-infected cells, and 
0.71 for 396 proteins identified in HAdV-C5-infected cells (Fig. 4D, STable 1). For proteins of 
HAdV-B3-infected cells, thirteen proteins were significantly changed in both iTRAQ-8plex 
(Sc+) and label-free (PF2) (STable 2). For proteins of HAdV-C5-infected cells, nine proteins 
were found to be significantly regulated. For most of the commonly quantified proteins by 
Sc+ and PF2, significant changes were only seen in the label-free approach analyzed with 
PF2 (STable 2). The slope values of PF2 vs Sc+ amounted to 1.30 for proteins of HAdV-B3-
infected cells, and 1.59 for proteins of HAdV-C5-infected cells. All these results showed that 
quantification of proteins with label-free methods were more sensitive to changes in protein 
abundance than the iTRAQ-labeling method. 
 
Western blot quantitation for galectin-1 and transferrin receptor in HAdV-B3-infected 
cells.  
We followed up on two proteins which were found to be down-regulated by both iTRAQ-label 
and label-free approaches and performed Western quantitation of galectin-1 (LGALS1, 
P0938) and transferrin receptor (TFRC, P02786). For both proteins, down-regulation was 
more pronounced for HAdV-B3-infected cells than for HAdV-C5-infected cells, and was 
characterized by higher fold-changes with the label-free approach than with the iTRAQ-
labeling approach (STable 2). LGALS1 revealed log2 ratios of -2.81 to -2.73 for PL and 
Progenesis-T3PQ analysis, respectively, and -1.57 to -1.50 for PP and Sc+ analysis, 
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respectively. TFRC revealed log2 ratios of -1.28 to -1.27 for PL and PF2 analysis, 
respectively, and -0.65 to -0.61 for Sc+ and PP analysis, respectively. For the Western blot 
analysis, we prepared biological replicates of HAdV-B3-infected A549 cell lysates collected 
24 h p.i. and compared protein expression levels to those of non-infected cell lysates. 
Signals of LGALS1 and TFRC were compared with "-tubulin as a reference (Fig. 5A). 
Quantitation of the Western signals revealed a log2 -3.93 down-regulation for LGALS1 
(Fig. 5B) and a log2 -4.66 down-regulation for TFRC (Fig. 5C). Thus, the obtained fold 
changes in expression levels were closer to the values obtained with the label-free approach 
than with the iTRAQ-labeling approach. This is in agreement with the notion of 
underestimating signals in the iTRAQ-label quantitation method.  
114 
 Discussion and conclusions 
Technical issues of quantitative proteome analysis. 
The biological replicates for HAdV-B3- and HAdV-C5-infected cells showed fairly good 
correlations, in both iTRAQ-label, and label-free quantitation, irrespective of the particular 
quantitation software or strategy was used. With the same dataset obtained from iTRAQ-
label, PP searches resulted in 1,538 quantified proteins in HAdV-B3-infected cells and 1,548 
proteins in HAdV-C5-infected cells with $ 95% protein confidence (1.89% FDR) while Sc+ 
using the Mascot search engine showed 1,340 and 1,343 quantified proteins in HAdV-B3- 
and HAdV-C5-infected cells, respectively, on peptide level of an ion score $ 30 (resulting in 
0% FDR). Among these, 1,263 proteins in HAdV-B3-infected cells and 1,267 proteins in 
HAdV-C5-infected cells were commonly quantified by both the Sc+ and PP and the 
intersection could therefore be used to correlate the quantitative answers. In the label-free 
method, PL quantified 661 proteins in HAdV-B3-infected cells and 660 proteins in HAdV-C5-
infected cells while PF2 quantified 439 proteins in both HAdV-B3 and HAdV-C5-infected 
cells. The reduction to 439 proteins is explained by the fact that the PF2 method by definition 
requires at least two peptides per protein. All proteins, which were quantified by PF2, were 
also quantified by PL. In this study, the peptide complexity in the iTRAQ-label approach was 
reduced with a pre-fractionation step by using SCX-HPLC prior to LC-MS/MS, while pre-
fractionation of peptides in the label-free method was not considered prior LC-MS/MS. 
Therefore, the number of proteins quantified by the label-free method was much smaller than 
in the fractionated iTRAQ-label samples. Here, we wanted to compare and to correlate the 
different ratios of common proteins being quantified by both iTRAQ-based and label-free 
approaches.  
An important issue is whether the ratio in iTRAQ-label is comparable to that of label-free 
quantitation. As already noticed in the result section with sets of iTRAQ-label and label-free 
comparisons for HAdV-B3- and HAdV-C5-infected cells vs non-infected cells, the change of 
differentially expressed proteins generally resulted in the same direction with either up or 
down-regulation for both iTRAQ-label and the label-free quantitation. This indicates that 
ratiometric analyses by both iTRAQ-label and label-free quantitation are reliable. However, 
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the fold changes of both viral and cellular proteins tend to be larger dynamic range in the 
label-free method compared to the iTRAQ-label. Western blotting of the two significantly 
changed proteins LGALS1 and TFRC further suggested that the ratios quantified by the 
label-free method was closer to the Western blot analyses than the iTRAQ-label data. These 
results further support the previous notion by others that iTRAQ-label tends to underestimate 
the actual ratio  in  large-scale analysis of complex proteome samples 16, 17.   
 
Advantages and drawbacks of quantitative proteomics using iTRAQ and label-free 
methods.  
The findings that the label-free method provided a high dynamic order and was closer to the 
data from Western blotting than the iTRAQ-label approach is important for studies that aim to 
provide high accuracies of protein ratios for different samples. The finding of underestimation 
of iTRAQ-label is in agreement with previous observations 16, 17. There are a number of 
reasons, how iTRAQ-labeling could cause underestimation of the actual fold change; (i), 
technical reasons include that some additional precursors with similar masses but of 
completely different peptides are also selected for CID (for these additional peptides one can 
assume that the ratio of the reporters are close to one, since for most of the proteins the ratio 
should not undergo dramatic changes). This will shift the ratio towards one, which results in 
an underestimation of the quantitation of the peptide of interest that is identified in the CID 
spectrum. The label-free method does not have this drawback if the LCMS signals are 
properly aligned, they should correspond to only single peptides; (ii), identification and 
quantification are based on MS/MS data while other methods rely on both full MS and 
subsequent fragmentation of precursor ions; (iii), iTRAQ reagents can pose problems for 
many types of mass spectrometers due to the mass cut-off and due to contamination with 
impurities. Despite recent improvements of iTRAQ reporter intensity in iTRAQ-8plex 
compared to iTRAQ-4plex and algorithms in PP software to correct for background signals, 
the issue of underestimated ratios remains problematic. This is illustrated by the fact that this 
study used the iTRAQ-label combined with background correction mode in PP version 3. 
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Both the iTRAQ-8plex as well as label-free quantitation offers benefits and disadvantages 
(pros and cons). An advantage of the iTRAQ-8plex over the lable-free method is the ability to 
run to 8 samples within a single LC-MS/MS experiment, while label-free quantitation requires 
individual LC-MS/MS experiments, which consumes more machine time. On the other hand, 
which samples are compared with what other samples have to be determined upfront. This 
limits multiplexing in labeling approaches as for label-free approaches (if a successful 
aligning can be achieved) this can even be done at later stages. 
The former difficulty in handling of pre-fractionation steps of complex peptides prior to LC-
MS/MS in data analysis nowadays can be overcome by recent software development such 
as a new release of PL software package. Taking advantage of pre-fractionation prior to LC-
MS/MS or target proteomics represents a breakthrough for label-free quantitation because it 
adapts reliable quantitation, sensitivity and costs as well as time effectiveness. One crucial 
technical issue with label-free quantitation that remains to be considered is reproducibility. 
This includes maintaining the same retention times for multi-runs on the same LC column 
and running the same MS instrument. Thus, for deeply fractionated samples in multiple 
dimensions, the labeling approach probably is still preferred. 
 
Biological impact of the quantitative proteomics experiments.  
Both the iTRAQ-label and label-free methods allowed us to identify a number of significantly 
regulated proteins in HAdV-B3- or HAdV-C5-infected cells. For instance, ferritin light chain 
(FTL, P02792) was up-regulated 1.6 to 1.65 of log2-fold in HAdV-B3 and 2.13 to 2.45 of 
log2-fold in HAdV-C5, when using PP and Sc+, respectively (STable 2). FTL plays an 
important role for iron homeostasis and delivery of iron to cells. Another example is ITGB5 or 
#5 integrin( P18084), which was down-regulated by -0.6 to -0.75 of log2-fold in both HAdV-B3 
and HAdV-C5 infected cells. ITGB5 belongs to the heterodimeric integrin protein family, and 
"v#5 integrin functions as a receptor for fibronectin 36 and vitronectin 37. Both, "v#3 and "v#5 
integrins have been shown to function as internalization receptors during HAdV-C5 infection 
and HAdV-B3 infections 38-43. #v&3 has recently been shown to be recruited from the 
basolateral to the apical side of polarized cells upon cytokine stimulation to facilitate apical 
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invasion by HAdV-C5 or C2 44. In addition, high expression of ITGB5 was required for 
efficient HAdV-medicated gene transfer in the human airway cells 45.  
Another example, LGALS1 was significantly down-regulated in HAdV-B3-infected cells (-2.81 
of log2 ratio) although less significantly changed in HAdV-C5-infected cells. The down-
regulation was shown by both the iTRAQ-label and label-free quantitation (STable 2). The 
LGALS1 belongs to the lectin protein family, which functions in both extracellular and 
intracellular signaling 46. LGALS1 interacts with the extracellular parts of cell surface and 
matrix glycoproteins, as well as with cytoplasmic and nuclear proteins to trigger multiple 
signaling pathways. Consequently, LGALS1 contributes to modulation of the immune and 
inflammatory responses 47. In addition, LGALS1 has been shown to be involved in infection 
of several viruses such as Nipah virus 48 and human immunodeficiency virus (HIV) 49. In the 
case of Nipah virus, LGALS1 inhibits virus attachment and host cell fusion by binding N-
linked oligosaccharides from the virion envelope or capsid glycoproteins, promoting their 
crosslinking and oligomerization. In contrast, LGALS1 was found to act as a host factor to 
promote HIV infection by stabilization of virus attachment anchors to host cells. The role for 
LGALS1 in HAdV infections remains unknown. Thus, our finding of LGALS1 down-regulation 
during HAdV infection may hint at an interesting role of LGALS1 during HAdV infections.  
Another protein, immune modifier peptide thymosin alpha 1 (P06454, STable2) 50, was found 
to be down-regulated in HAdV-B3-infected cells by both the iTRAQ-label and label-free 
approaches. Thymosin alpha 1 has been clinically tested in combination with other drugs to 
confer resistance to certain infectious agents such as hepatitis B virus 51. The regulation of 
thymosin alpha 1 upon HAdV infections may represent an interesting topic for improvement 
of gene therapy efforts.   
Interestingly, we observed a number of proteins that showed different regulation patterns 
between HAdV-B3- and HAdV-C5-infected cells. They could relate to differences in the 
infectious pathways or more complex features of the infections. For instance, heterogeneous 
nuclear ribonucleoprotein H3 (HNRNPH3, P31942), which is involved in splicing and 
participates in early heat shock-induced splicing arrest 52, was down-regulated in HAdV-B3- 
(-0.85 of log2 ratio) and up-regulated in HAdV-C5-infected cells (0.62 of log2 ratio). Another 
example, thioredoxin domain-containing protein 17 (TXNDC17, Q9BRA2), which modulates 
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TNF-alpha signaling and NF-kappa-B activation 53, was down-regulated in HAdV-B3- (-1.25 
of log2 ratio) and up-regulated in HAdV-C5-infected cells (0.7 of log2 ratio). It has been 
shown previously that HAdV-2C E3-19 K protein activated transcription factor NF-kappa-B 54. 
Thus, the deregulation of TXNDC17 may be involved in a HAdV serotype-specific antiviral 
response.  
Overall, our findings provide new insights into advantages and disadvantages of iTRAQ-label 
and label-free quantitation and support the earlier notions of underestimating the actual fold 
changes by the iTRAQ-label approach. The obtained quantitative data of up- and down-
regulated cellular proteins can now be followed up to further increase our understanding of 
HAdV-host cell interactions.  
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Legends to figures  
Fig. 1. Workflow for comparisons of iTRAQ-label and label-free quantitations. (A), 
experimental procedures for the iTRAQ-label and label-free methods. A549 cells were 
infected with HAdV-B3 and HAdV-C5 using an MOI of 200. The cells were harvested at 24 h 
p.i.. Resulting cell lysates were used for either iTRAQ-label or label-free quantitation. For 
iTRAQ-label quantitation, tryptic peptides were separated by SCX-HPLC prior to LC-MS/MS 
by MALDI-TOF/TOF instrument. The PP and Sc+ were used for analyses of protein 
quantitation. For the label-free quantitation, tryptic peptides were injected directly to LC-
MS/MS (LTQ-FT-ICR) without pre-fractionation. The data generated by label-free approach 
was quantified by using PL and PF2 and PF3. (B), comparative analyses performed for 
reproducibility of biological replicates, quantification of iTRAQ-label/label-free with different 
software, and quantitation between iTRAQ-label vs label-free methods. 
Fig. 2. Number of quantified proteins in HAdV-B3 and HAdV-C5-infected cells using iTRAQ-
label and label-free methods and their pair-wise comparisons. PP and Sc+ softwares were 
used to analyze iTRAQ data, while PL, PF2 and PF3 software was applied for label-free 
quantitations.       
Fig. 3. Reproducibility of two independent biological replicates using either iTRAQ-label or 
label-free method and comparison within the iTRAQ-label or non-label with different 
quantitation software. Different expression of proteins in HAdV-B3-infected cells (red) and 
HAdV-C5-infected cells (black) is shown based on log2 ratio. Scatter plot for quantified 
proteins was analyzed by PP (A), Sc+ (B), PL (C), and by PF2 (D), comparison of PP vs Sc+ 
(E) and PL vs PF2 (F). 
Fig. 4. Comparisons of iTRAQ-label-based vs label-free quantitation. All four comparisons 
are given by log2 ratios with HAdV-B3-infected cells (red) and HAdV-C5-infected cells 
(black). Scatter plot analysis for quantified proteins was performed by PP vs PL (A), PP vs 
PF2 (B), Sc+ vs PL (C), and Sc+ vs PF2 (D). 
Fig. 5.  Western blot analysis of LGALS1 and TFRC and comparison of different quantitation 
methods. (A), lysates of HAdV-B3-infected A549 cells were immuno-stained for LGALS1 and 
TFRC. Tubulin (Tub) was used as loading control to normalize LGALS1 and TRFC signals. 
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Comparison of quantitative assesment by Western blot analysis, label-free method and 
iTRAQ-quantitation for LGALS1 (B), and TRFC (C). 
 
Legends to supplemental figures and tables 
SFig. 1. Comparison of PF2 and PF3 for label-free quantitations with samples obtained from 
HAdV-B3-infected cells (red), and HAdV-C5 infected cells (black), based on log2 ratios. 
STable 1. List of pairwise comparisons for commonly quantified proteins given by log2 ratios. 
(*) indicates values corresponding to (*) given by the software.  
STable 2. List of significantly up- or down-regulated viral and cellular proteins quantified by 
iTRAQ-label and/or by label-free methods. Proteins with significant (Sig) fold change higher 
than 0.6 (log2 ratio) are shown in bold. Viral proteins encoded by HAdV-B3 and HAdV-C5 
are shown in red and blue, respectively; cellular proteins appear in black  
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Abstract 
miRNAs function as key posttranscriptional regulators of gene expression not only in a range 
of eukaryotic species, but are also believed to potentially play a critical role in the life cycle of 
many viruses, in particular double-stranded DNA viruses. For human adenovirus (HAdV), a 
single miRNA (mivaRNAI-138) derived from the 3’-end of HAdV-C5 VA-RNAI has recently 
been described to target the splicing and translation regulator TIA-1, and additional genes 
that are important for cell growth, transcription, RNA metabolism and DNA repair. To uncover 
vsRNAs encoded by HAdV B species type 3 (HAdV-B3), we combined bioinformatic tools 
and experimental validation and evaluated putative novel vsRNAs for this important serotype. 
From the 75 vsRNA candidates predicted by three different programs, 25 were confirmed by 
stem-loop RT-PCR and 12 by microarray analysis in HAdV-B3 infected cells. Among these 
detectable putative vsRNAs, four were commonly detected by both methods. However, none 
of these were further confirmed when small RNA products were analyzed by deep 
sequencing, which gave rise to 32 small RNA sequence reads over a threshold of 20 counts. 
The deep sequencing vsRNAs candidates derived from VA-RNAI and VA-RNAII revealed 
high correlation with additionally performed microarray analysis of the tilled VA-RNA region. 
Five of these putative vsRNAs were further corroborated by Northern blot analysis and by 
stem-loop RT PCR with argonaute 2 immunoprecipitated RNA. To search for the potential 
cellular targets of the putative vsRNAs, we compiled cellular target prediction data obtained 
by TargetScan and miRanda analyses with results from a transcriptome analysis of HAdV-
B3-infected cells, acquired in a separate study. To search for potential target sequences 
within the HAdV-B3 genome or the according annotated transcripts, we utilized the miRanda 
prediction tool. Both tools revealed a large number of potential targets, which need to be 
further evaluated. In summary, we hope that elucidation of vsRNA pathways in HAdVs 
eventually will lead to a better design of HAdV vectors for gene therapy, with higher efficacy 
and lower toxicity than the ones currently used.  
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Introduction 
Viral miRNAs encoded by viruses.  
MicroRNAs (miRNAs) are small non-coding RNAs of 18–24 nucleotides in length. The 
miRNA lin-4 and its target mRNA, lin-14 were discovered by Ambros, Ruvkun and colleagues 
in Caenorhabiditis elegans 1,2. Subsequently, an increasing number of miRNAs were 
identified in the major metazoan species such as human 3,4 and viruses 5. Up to now, 235 
experimentally characterized virus-derived small RNAs (vsRNAs) are registered in the 
miRNA database miRbase 16 (http://microrna.sanger.ac.uk/). The vsRNAs are processed via 
their host miRNA biogenesis pathway, which is initiated with its transcription by RNA 
polymerase II or III in the nucleus to form large pri-miRNA transcripts. Next, they are 
processed by the microprocessor Drosha-DGCR8 (Pasha) into pre-miRNAs of 70-110 
nucleotides (nt), which are translocated into the cytoplasm by Exportin 5. Subsequently, the 
pre-miRNAs are recruited by Dicer to generate single-strand mature miRNAs of 18-24 nt, 
which are incorporated into the miRNA-associated multiprotein RNA-induced silencing 
complex (miRISC). miRNAs bind to the 3’ untranslated regions (3’UTRs) of the target 
mRNAs, which results in their sequence-specific cleavage, translational repression or 
deadenylation, resulting in post-transcriptional gene silencing 6-8. More recently, it has 
become evident that miRNAs are involved in many biological processes such as 
developmental timing, differentiation and cell death 9, cancer 10,11, diabetes 12 cardiovascular 
diseases 13,14 and virus infections 15,16. A promising result in miRNA related therapeutics 
against chronic hepatitis C virus infection was recently provided in primates by targeting miR-
122 with locked nucleic acid (LNA) 17. 
It is not surprising that viruses also encode their own endogenous vsRNAs, given their 
omnipresence in multicellular organisms. Pfeffer et al. identified the first virus-encoded 
miRNAs expressed in B cells latently infected with the $ herpes virus family member Epstein 
Barr virus (EBV) 5. Since then, twenty-five EBV pre-miRNAs have been reported in B cells 
and nasopharyngeal carcinomas 18-20. In influenza A, each 5’-end of the eight viral RNA 
genomic segments was found to encode a vsRNA 21. In various influenza A virus subtypes 
across multiple host species vsRNAs were detectable during replication and were found 
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associate with the RNA-dependent RNA polymerase. Depletion of these vsRNAs resulted in 
a dramatic loss of vsRNAs in a segment-specific manner 21, suggesting that vsRNAs regulate 
the switch from transcription to replication. In herpes simplex virus 1 (HSV), vsRNAs 
contribute to maintaining the latent infection state 22. Hsv1-miR-H6 derived from a latency-
associated transcript targets the transcription factor ICP4, which is required for expression of 
most of the HSV-1 genes during productive infection, thereby establishing viral latency 22,23. 
In a comprehensive study on vsRNAs in Hepatitis C, Polio, Dengue, Vesicular Stomatitis, 
and West Nile virus, expression of vimiRNAs was found to vary considerably during infection, 
from very low abundance to high abundance compared to abundant host miRNAs 24. In 
addition to the appearance of vsRNAs during infection, the authors also noticed a number of 
specific changes in host miRNA profiles. This likely resulted from the limited processing 
capacity of the mRISC with argonaute proteins as major components, leading to deregulation 
of host gene expression profiles 24.  
 
In silico predictions for virus-derived small RNAs. 
Along with the emergence of miRNAs as key posttranscriptional regulators of gene 
expression, the scientific community needed to obtain improved tools to recognize those 
minute sequences hidden in the maze of the genomes. Consequently, bioinformatic 
programs were developed aiming at the systematic identification of miRNAs 25,26. The 
principle of these computational approaches relies on two major features including sequence 
conservation within different species and formation of stem–loop structure by pre-miRNAs. 
However, the prediction approaches are more challenging in the case of viruses, as vsRNAs 
are rarely evolutionarily conserved. Thus, to address this issue, Li et al. developed an in 
silico tool specifically applied for predicting vsRNAs 27. The Vir-Mir db tool developed by Grad 
et al. makes use of the Srnaloop program in order to predict the putative secondary structure 
from given sequences 28. Unlike the Vir-Mir db tool, the BayesMiRNAfind program is based 
on a “machine-learning” approach with a Naïve Bayes classifier, which calculates the 
probability that a given sequence belongs to a certain Naïve Bayes class, by fulfilling defined 
criteria from known miRNA in various species 29. Alternatively, Yousef et al. recently 
developed the Bayes-SVM-MiRNA tool (unpublished), which uses a two-machines learning 
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approach, the Naïve Bayes and the Support-Vector-Machines (SVM), allowing the 
identification of both novel and conservative sequences. 
 
Roles of vsRNAs in controlling viral and cellular gene expression. 
Current evidence indicates that viruses use their own vsRNAs to manipulate both cellular 
and viral gene expression 30 or to regulate cellular miRNAs 24,31,32. An example of how a 
vsRNA controls its own viral gene expression was elucidated in SV40, where the sv40-miR-
S1 was found to down-regulate the early SV40 T antigen at the late stage of infection. This is 
advantageous for the virus because it limits susceptibility of infected cells to cytotoxic T cells 
33. Another example for a vsRNA targeting viral gene expression is the EBV miR-BART2, 
which targets viral DNA polymerase (BALF5). miR-BART2 is expressed during latent 
infection leading to BALF5 mRNA cleaveage 34. Transition to lytic replication is accompanied 
by miR-BART2 expression reduction, suggesting that miR-BART2 may regulate the latent-
lytic switch. Another EBV-encoded gene LMP1, which is involved in inducing cell growth and 
transformation, is targeted by three EBV miRNAs, including miR-BART1-5p, miRBART16, 
and miR-BART17-5p. Overexpression of these vsRNAs during virus latency causes inhibition 
of viral growth 35. 
On the other hand, vsRNAs target cellular genes involved in cell proliferation, survival and 
antiviral defense pathways 30. An example was found in the #-herpesvirus family member 
Human cytomegalovirus (HMCV) which expresses an immunoevasion miRNA that targets 
the mRNA encoding major histocompatibility complex class I polypeptide-related sequence B 
(MICB) 36. MICB is a ligand for a cell-surface receptor of natural killer (NK) cells. The MICB–
receptor interaction is a key regulator of NK-cell activity and hence of NK-cell killing of virus-
infected cells. Cellular Bcl2-associated factor (BCLAF1), a protein involved in apoptosis, was 
identified as a target of $ herpes virus family member Kaposi’s sarcoma-associated 
herpesvirus (KSHV) miR-K5 and several other KSHV miRNAs in both B cells and endothelial 
cells 37. Antagonism of these small interfering RNAs resulted in decreased virus production, 
suggesting that BCLAF1 impairs lytic viral replication and that modulation of BCLAF1 by 
KSHV miRNAs might promote the reversibility of latent infection. 
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vsRNAs encoded by human adenoviruses. 
Human adenoviruses (HAdVs) express highly abundant VA-RNAI and VA-RNAI, which are 
composed of 160-176 nt that reveal dsRNAs hairpin structures. The major structural features 
of these regulatory RNAs including the terminal stem, apical stem-loop and central domain 
are conserved in all HAdVs except the location of the loop 38. VA-RNAI and VA-RNAII were 
found to be transported by Exportin 5 to the cytoplasm, where they accumulate in the late 
phase of virus infection 39. Removal of both VA-RNAI and VA-RNAII resulted in a dramatic 
decrease in viral replication capacity 40. It has been suggested that VA-RNAI may serve two 
functions during HAdV propagation. Thus, it appears to antagonize the cellular defense 
pathways against both long and short dsRNA by binding the two key enzymes in the 
respective pathways, dsRNA-activated protein synthesis inhibitor (DAI) of the IFN pathway 
and Dicer of the RNA silencing pathway 41. DAI is a kinase, which is activated by viral 
replication, leading to phosphorylation of eukaryotic initiation factor 2, which prevents 
initiation of translation 42.  
VA-RNAI was found to be processed into 22 nt RNAs, but seems to be a poor Dicer 
substrate, as only 1% of VA-RNAI molecules was processed 43. 80% of the RISC 
complexes were loaded with VA-RNAII, although VA-RNAI is the more abundantly expressed 
RNA 44. More recently, targets of the viral miRNA mivaRNAI-138 derived from 3’-end of 
HAdV-C5 VA-RNAI were found to include the splicing and translation regulator TIA-1 was 
down-regulated in infected cells or in transfected cells expressing mivaRNAI-138 45. In 
addition, transfection of a plasmid expressing both VA-RNAs caused down-regulation of 
another 33 genes, while transfection of VA-RNAI alone resulted in down-regulation of 30 
genes, and transfection of mivaRNAI-138 in down-regulation of 26 genes. These finding 
strongly suggest that endogenous miRNAs play important roles in the infectious life cycle in 
HAdV.  
 
Human adenovirus and their applications in gene therapy.   
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HAdVs have served as a model system to study various aspects of molecular and cellular 
biology, including DNA replication, gene and cell cycle regulation, RNA splicing, and viral 
entry and transformation 46. HAdVs have also become the most widely used and most 
extensively studied viruses for gene delivery/therapy purposes such as targeting genetic 
diseases, for cancer treatment and vaccination 47,48. HAdVs are non-enveloped icosahedral 
particles composed of 20 facets and 12 vertices with a diameter of 70 to 100 nm 49,50. The 
particles are composed of an outer protein capsid and an inner, linear dsDNA-associated 
core. A total of 55 different human HAdV serotypes have been identified, which are classified 
into species A-G 51,52.  
In general, HAdVs cause mild infection of the upper respiratory tract, gastrointestinal tract, 
and the eye 53,54. Infections with HAdV-B3 are a major cause of acute febrile and severe 
respiratory illness, and most symptomatic HAdV infections affect children or military recruits 
55. HAdV-B3 encodes 46 ORFs 56, and binds to complement activation membrane cofactor 
protein CD46 and desmoglein 2 as an attachment receptor 57-60. Since the tropism of species 
B viruses is broader than that of the C species, and includes cancer cells, dendritic cells and 
hematopoietic stem cells, vectors based on B species gain interest for gene therapy and 
vaccination approaches 61.  
Here we investigated whether HAdV-B3 encodes vmirRNAs and what viral and cellular 
mRNAs are targeted. We used bioinformatic tools to predict vsRNAs, followed by 
experimental verification using deep sequencing, stem-loop RT-PCR, miRNA microarray, 
Northern blot analysis and RISC-immunoprecipitation. In silico predicted targets of these 
vsRNAs were compared to transcriptome analysis of HAdV-B3-infected human A549 lung 
cells. Elucidation of vsRNAs encoded by HAdV-B3 will provide new insights in virus-host 
interactions and regulations and possibly lead to improve clinical HAdV vectors. 
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Materials and Methods 
Cell culture, virus infection and RNA sample preparation.  
A549 human lung adenocarcinoma epithelial cells were cultured in the Dulbecco’s modified 
Eagle medium (Sigma) supplemented with 8% of fetal bovine serum (Invitrogen). HAdV-B3 
was purified by double cesium-chloride gradient as previously described 56. Infections with 
HAdV-B3 were performed with a multiplicity of infection (MOI) of 200 in A549 cells. Total 
RNAs from non-infected cells (Ctrl) and infected cells at 3, 12, 24, 36 and 48 hours (h) post 
infection (p.i.) were extracted using the mirVana kit (Ambion). Quality of total RNAs was 
monitored by determining the 260/230-nm absorption ratio (NanoDrop) and integrity of total 
RNAs was checked by using the Agilent 2100 bioanalyzer system of the Small RNA Chip Kit. 
For Northern blot analyses, total RNAs extracted with the mirVana kit were further isolated 
using YM-100 microspin columns (Millipore). 
 
miRNA microarray analysis.  
All together, 3,917 probes were spotted on the array, including 75 x 5 probes for the 
predicted mature sequences of the vsRNAs, 864 x 3 probes for cellular miRNAs listed at 
human miRbase 12 at the time, and 22 x 3 for VA-RNAI and 20 x 3 probes for VA-RNAII 
tilling using the Array Designer software (Premier Biosoft) including 24 nt in length and 16 nt 
overlap between two adjacent probes. In addition, we included positive probes like tRNAs 
and snoRNAs, negative probes like random sequences and sequences from other species, 
degradation probes for actin and heat shock protein, and probes serving as internal controls 
for normalization purposes and for correction of variations from array to array. Each 
oligonucleotide sequence was randomly spotted on the array, using five and three replicates 
for predicted vsRNAs and VA-RNAI/VA-RNAII tilling, respectively. Total RNAs isolated from 
A549 cells infected at a MOI 200 were first transcribed into cDNAs and labeled by using dual 
colors of Cy3 and Cy5 in which Ctrl was labeled with Cy3, and 24- or 48 h-HAdV-B3-infected 
samples were labeled with Cy5, and vice versa to avoid possible dye effects. Spotting of 
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arrays based on custom design, labeling, scanning and quality control was all carried out by 
LC Sciences services.  
For cellular gene expression profiling, the same total RNA samples used for miRNA 
microarray were analyzed including additional time points of 3 and 12 h. The cDNA 
microarray used for the Agilent platform (4x44K format) contained the complete human gene 
probes used by Agilent, plus in addition viral genes of HAdV-B3. Total RNAs were first 
transcribed into cDNAs and labeled by Cy3/Cy5 (Agilent). Each condition contained at least 
biological triplicates. Statistical analysis was performed with two-tailed Student’s t-test.   
 
Stem-loop RT-PCR analysis.  
Stem-loop RT-PCRs were carried as described by Chen et al. 62, with slight modifications for 
the RT-PCR cycle program. All oligonucleotide sequences used in this study including stem-
loop, universal reverse and forward primers are shown in STable 2. The cDNA reactions 
consisted of 50 nM stem-loop primer, 0.25 mM dNTPs each, 10 mM DTT, 4 units/µl RNAout 
inhibitor (Invitrogen), 1x first-strand buffer, 50 units/µl SuperScript III RT (Invitrogen) and 10-
50 ng/µl of total RNAs as a final concentration. In case of RT minus (negative control), the 
SuperScript III was omitted. The cDNA reaction was allowed to proceed for 30 minutes (min) 
at 16°C. The following 60 PCR cycles included 30°C for 30 sec, 42°C for 30 seconds (sec) 
and 50°C for 1 sec. The SuperScript III was inactivated at 85°C for 5 min. The real-time RT-
PCR reaction was composed of 1-2 µl cDNA, 1x SYBR (Applied Biosystems), 0.5 µM 
universal reverse primer and 0.5 µM forward primer with total volume of 10 µl. The thermo 
cycles included four stages; 50°C for 2 min (stage 1, 1 cycle), 95°C for 5 min (stage 2, 1 
cycle), 95°C for 15 sec, and 60°C for 1 min (stage 3, 45 cycles), 95°C for 15 sec and 60°C 
for 15 sec and 95°C for 15 sec (stage 4, 1 cycle) to dissociate products. The kinetics of the 
PCR product amplification was measured by incorporation of the intercalating SYBR Green 
dye 63 using an Applied Biosystems 7900 instrument. Quantitation for stem-loop RT-PCR 
data was performed according to Vandesompele et al. 64 using two internal controls, which 
included tRNA and snoRNA U8 for normalization. 
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Northern blot analysis.  
Antisense oligonucleotide probes (STable 2) were prepared as follows. 1 µl antisense (22 nt) 
oligonucleotide (20 µM), 2.5 µl Gamma-32P-ATP (10,000Ci/ul), 2 µl 10X T4 PNK buffer A 
(Fermentas), 0.4 µl T4 PNK (10 U/!l) and DEPC-water were filled up to 20 µl, followed by 
incubation at 37°C for 1 h. PNK was inactivated by addition of 20 µl 50 mM ETDA and 
heating to 95°C for 2 min. The labeling reactions were cleaned up using microspin G25 
columns (GE Healthcare). For labeling of the Ambion Decade™ Marker (Ambion), the 
labeling reaction was followed according to the manufacture’s instructions.  
Total RNAs or enrichment of miRNAs were separated on 15% Urea-PAGEs in TBE buffer. 
Quality of RNA separation was visualized by ethidium bromide staining. In addition, intensity 
of tRNAs in the ethidium bromide stain was used to normalize for a loading control. RNAs 
from urea-page were transferred in TBE buffer to GeneScreen plus membranes 
(NEF1017001PK, PerkinElmer), applying 200 mA/gel for 1 h on a SemiDry Transfer device 
(Bio-Rad). Membranes were dried at room temperature before exposure to UV crosslinking 
(Stratagene, auto-crosslink, 1200 J, 90 sec). Subsequently, the membranes were baked for 
1 h at 80°C. The membranes were prehybridized at 55°C in 6X SSC, 5X Denhardt’s, 0.2% 
SDS for at least 1 h. Hybridization with the labeled probe solution was performed overnight at 
42°C for at least 16 h, followed by an increase of hybridization temperature to 45°C for at 
least 4 h. Membranes were washed 3 times at room temperature with pre-warmed wash 
buffer (6X SSC and 0.2% SDS) for 5 min each, followed by a wash at 42°C for 10 min. 
Membranes were exposed to phosphoimager screens and signals were scanned with 
Phosphoimager FLA-7000 (FUJIFILM Science Lab). Quantitations for Northern blot signals 
were processed by ImageGauge version 4 (FUJIFILM Science Lab). 
 
Argonaute 2 immunoprecipitation of RNA. 
Argonaute 2 immunoprecipitation (Ago2-IP) experiments were performed as described by 
Rudel et al. 65, with slight modifications. Lysates of non-infected (Ctrl) or HAdV-B3-infected 
A549 cells harvested at 48 h p.i. were immunoprecipitated with a rat anti-human Ago2 
monoclonal antibody or a control rat anti-human ICAM antibody using protein G sepharose 
141 
beads (GE Healthcare). The beads were washed, followed by RNA extraction using Trizol. 
Eluted RNAs were further characterized by stem-loop RT-PCR or Northern blot analysis. 
 
Deep sequencing procedures and data analysis.  
Total RNAs derived from non-infected control and HAdV-B3-infected A549 cells using an 
MOI of 200 were isolated 24 h p.i.. Generation of small RNA libraries for SOLiD™ 
sequencing was performed using the SOLiD™ small RNA expression kit (Applied 
Biosystems), following the manufacture’s instructions. In brief, enriched RNA samples were 
ligated to either adapter mix A or adapter mix B at 16°C for at least 8 h. Ligation products 
were reverse transcribed into cDNAs at 42°C for 30 min following RNase H treatment at 
37°C for 30 min. The PCR master mix was added to amplify the cDNA libraries, followed by 
size-fractionation on PAGE.  Sequencing of small RNAs was performed using SOliDTM v3 
(Applied Biosystems). Sequence reads were analyzed with SOLiD™ System Small RNA 
Analysis Tool using a SGE unix computer cluster. All reads were first filtered by mapping 
them against the P2 adaptor sequence and human repeats. The remaining reads were 
mapped against the precursor sequences of known human miRNAs present in the Sanger 
miRBase version 12. The further remaining reads were mapped to the human genome 
(UCSC Genome Database Hg18) and the HAdV-B3 genome database (NCBI).  
 
In silico prediction for vsRNAs and for vsRNA targets in cellular and viral genes.  
Three different bioinformatics tools were applied to predict vsRNAs in HAdV-B3. These 
included BayesMiRNAfind 66, Bayes-SVM-MiRNA 66 and Vir-Mir db 27. For the cellular miRNA 
target predictions, we employed either TargetScan 5.1 67,68 (http://www.targetscan.org/) or 
miRanda v1.0b 69. In TargetScan, nucleotides 2-8 at the 5’-end of the seed sequences of 
vsRNAs are used for searching the 3’UTR human sequences. In miRanda, default setting 
parameters including -2.0 for open gap penalty, -8.0 for gap extend, 80.0 for score threshold, 
-14.0 kcal/mol for energy threshold and 2.0 for scaling parameter were applied for the search 
of 3’UTR human sequences. To search for potential vsRNA binding sites within the HAdV-B3 
142 
genome and their transcripts (NCBI accession number: DQ086466), we utilized miRanda 
v1.0b with the same setting parameter mentioned above.  
143 
Results  
In silico prediction of vsRNAs encoded by HAdV-B3.  
We applied three in silico tools including BayesMiRNAfind 66, Bayes-SVM-MiRNA 66 and Vir-
Mir db 27 to predict potential vsRNAs encoded by HAdV-B3. All together, 40 precursor 
vsRNAs were predicted, which gave rise to 75 mature vsRNAs (STable 1). Since precursor 
vsRNAs predicted by BayesMiRNAfind and Bayes-SVM-MiRNA tools give rise to a single 
mature vsRNA, and Vir-Mir db-predicted precursor vsRNAs give rise to two mature vsRNAs, 
this number breaks down to one (Bayes-1) and four (NBayes-2-5) mature vsRNA candidates 
predicted by BayesMiRNAfind and Bayes-SVM-MiRNA, respectively, and 70 mature vsRNA 
candidates predicted by Vir-Mir db. All five mature vsRNA candidates predicted by 
BayesMiRNAfind and Bayes-SVM-MiRNA were encoded on the plus strand, whereas vsRNA 
candidates predicted by Vir-Mir were distributed along the virus genome with 32 and 38 
encoded on the plus and minus strand, respectively. Of note, no vsRNA candidates were 
predicted from the two VA-RNA regions encompassing nt 10,417-10,840. This is due to a 
upper size limit of 110 nt used as selection criteria for miRNA precursors by all three in silico 
miRNA prediction tools applied here, thus excluding VA-RNAs as potential miRNA 
precursors. 
 
Experimental validation of predicted vsRNAs by stem-loop RT-PCR and miRNA 
microarray analysis.  
In order to experimentally evaluate the predicted vsRNAs, we first performed stem-loop RT-
PCR. To cover the sequential phases of HAdV-B3 infection, human lung A549 cells were 
infected with a MOI of 200, and total RNA samples were harvested 24 and 48 h p.i.. 
Quantitative stem-loop RT-PCR reactions were performed for all 75 predicted vsRNAs 
candidates, including in addition RT-PCR reactions for the four known human miRNAs miR-
103, miR-24-1*, miR-181a* and miR-208 as controls (Fig. 1A). The human miR-103, miR-24-
1*, and miR-181a* gave rise to similar expression levels in Ctrl and HAdV-B3-infected cells, 
at either 24 or 48 h p.i., suggesting that virus infection did not greatly affect expression levels 
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of these cellular miRNAs. Since hsa-miR-208 is a heart tissue-specific miRNA 70, no 
expression was detected in lung adenocarcinoma cells (data not shown). From the 75 
predicted vsRNAs, 25 revealed significant expression level differences in HAdV-B3-infected 
cells compared to Ctrl. Seven predicted vsRNAs resulted in high expression levels with over 
100-fold differences at both 24 and 48 h p.i compared to Ctrl. These included, VirMir-4871*: 
24,967-24,992, VirMir-4824*: 16,091-16,116, VirMir-4822: 15,598-15,623, VirMir-4805*: 
13,016-13,041, VirMir-4800*: 12,462-12,487, VirMir-4799*: 10,205-10,230 and VirMir-4792: 
9,544-9,569. Among these, VirMir-4792: 9,544-9,569 showed a remarkable high expression 
with an over 10,000- and 3,600-fold difference at 24 and 48 h, respectively. We noticed that 
all seven vsRNA candidates revealing high expression differences were derived from the 
VirMir-db prediction tool, while one of the four candidates predicted by Bayes-SVM-MiRNA 
(NBayes-2: 1,703-1,723) revealed 133- and 84-fold enhancement at 24 and 48 h p.i., 
respectively.  
As a next, we validated the predicted vsRNAs by miRNA microarray analysis. All together, 
3,917 probes were spotted on the array, including probes for the 75 predicted vsRNAs, 
cellular miRNAs, tilling probes for VA-RNAI (see below), and additional control probes (see 
Materials and Methods). Data describing changes of cellular miRNAs expression levels will 
be reported separately (Hung V. Trinh, manuscript in preparation). The vsRNA screen by 
microarray analysis revealed 11 vsRNA candidates with significantly increased expression 
levels in samples derived from 24 and at 48 h p.i., when compared to Ctrl (Fig. 1B). When 
compared to the results obtained from the stem-loop RT-PCR, four predicted vsRNA 
candidates were commonly detected by both methods and included VirMir-4796: 13,746-
13,771, 4799*: 10,205-10,230, VirMir-4792: 9,544-9,569, and VirMir-4824: 16,056-16,081. 
We noticed that fold-changes in the miRNA microarray analysis were not as high as detected 
by stem-loop RT-PCR, although the same total RNA samples were used for both assays.  
Since Aparicio et al. recently reported a HAdV-C5 vsRNA in, which was derived from the 3’-
end of VA-RNAI region 45, we also included a careful analysis of both VA-RNA regions 
contained in HAdV-B3. For this, probes resulting from tilling the VA-RNAI and VA-RNAIl 
regions were included in the miRNA microarray analysis (Fig. 2). At both time points of 24 
and 48 h p.i., we observed high signal intensities in HAdV-B3 infected cells, when compared 
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to non-infected control cells. In general, signals derived from the 5’- and 3’-end of both VA-
RNA regions revealed higher intensities than signals derived from the intermediate sequence 
of the two regions. The signals derived from the VA-RNAI region were about equal at both 
time points, but were much higher compared to signals derived from the VA-RNAII region. In 
contrast, signals for the 5’- and 3’-ends of the VA-RNAII region revealed higher expression at 
48 than at of 24 h (Fig. 2B). This suggests that under the described conditions here, small 
RNA products derived from VA-RNAI reached maximum expression levels already at 24 h 
p.i., whereas processing of VA-RNAII products might be kinetically delayed. For signals 
derived from the VA-RNAI region, five probes from the 5’- and 3’-end reached fold-induction 
levels > 500, including probes 10,425-10,488, 10,433-10,456, 10,441-10,464, 10,561-
10,584, and 10,577-10,600. Another ten probes gave rise to signals between 100 and 500, 
whereas the residual seven probes gave rise to signals in the range of 6 to 100. For signals 
derived from the VA-RNAII region, only the two 5’- and 3’-end probes 10,665-10,688 and 
10,817-10,840 revealed fold inductions > 10. Another two probes were around 5-fold 
induction, and the residual probes revealed signals close to 1. Thus, the finding of a dynamic 
expression of sequential probes distributed in particular over the VA-RNAI, suggests that 
multiple small RNA products were generated from the VA-RNAI region, and possibly from the 
VA-RNAII region.    
 
Identification of HAdV-B3-encoded vsRNA candidates by deep sequencing.  
Since deep sequencing is now commonly used to characterize vsRNAs, we used this 
method to determine HAdV-B3vsRNAs. Total RNAs derived from non-infected control and 
HAdV-B3-infected A549 cells at 24 h p.i. were isolated and used for analysis. We obtained 
26,090,995 sequence reads for the Ctrl sample and 26,257,331 sequence reads for HAdV-
B3-infected cells. The deduced sequence reads were aligned to plus and minus strand of the 
HAdV-B3 genome (Fig. 3A). The top 32 highest RNA intensity sequence reads for small 
RNAs in the range of 19-24 nt were further broken down (Fig. 3B). Among these, a single 
read was obtained from the minus strand genome, whereas the residual 31 reads all aligned 
to the plus strand genome sequence. As expected, we obtained very high count numbers in 
the VA-RNAI and RNAII regions located at 10,417–10,840, which is in agreement with our 
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data obtained by miRNA microarray analysis (Fig. 2A, B). Four clusters of sequence reads 
corresponding to the 5’- and 3’ ends each of the VA-RNAI and II regions highly correlated to 
the probes with the highest fold induction in miRNA microarray analyses. These included at 
the 5’- end of the VA-RNAI region four overlapping reads from 10,418-10,460, which coincide 
with the three microarray probes 10,425-10,488, 10,433-10,456, and 10,441-10,464. At the 
3’- end of the VA-RNAI region, three overlapping reads from 10,563-10,594 coincide with two 
microarray probes 10,561-10,584 and 10,577-10,600. Likewise, at the 5’- end of the VA-
RNAII region, two overlapping reads from 10,662-10,688 corresponded to microarray probe 
10,665-10,688, and at the 3’- end of the VA-RNAII region, a single read from 10,818-10,839 
overlapped with microarray probe 10,817-10,840.  
In addition to these four clusters of high sequence reads, we found an accumulation of four 
reads in the range of 77 to 182 counts within the genome sequence from 5,893 to 6,209 of 
the plus strand, consisting of reads 5,905-5,924; 5,915-5,935; 5,936-5,956; and 6,187-6,209 
(Fig. 3B). Sequence read 6,187-6,209 coincided with the sequence of the hypothetical 11.5-
kDa gene 56, whereas the rest of the reads correlated to sequences within the non-coding 
genome. Other reads >100 included a cluster of two reads within the genome sequence from 
18,231-18,264 in the pVI gene, and a isolated read sequence 9,664-9,687 in the non-coding 
region. 
 
Experimental validations of vsRNAs by Northern blot analysis and stem-loop RT-PCR 
with argonaute 2-precipitated RNA.  
Two additional methods were performed to further evaluate the in silico predicted or deep 
sequencing-derived vsRNA candidates of HAdV-B3. These included Northern blot analysis 
using size-fractionated RNAs and stem loop RT-PCR with argonaute 2 (Ago2)-precipitated 
RNA 65. A549 cells were infected with HAdV-B3 and the kinetics of small RNA appearance 
was analyzed by Northern blotting using RNA samples harvested at the five time points 3, 
12, 24, 36 and 48 h (Fig. 4B-E). The five hybridization probes derived from deep sequencing 
included sequence read 6,187-6,209 (hypothetical 11.5-kDa gene), 10,430-10,452 and 
10,474-10,496 (5’-end of VA-RNAI) and 10,563-10,584 and 10,573-10,594 (3’-end of VA-
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RNAI). Quantitative evaluation of the Northern blots is shown in Fig. 4F. All five Northern 
probes gave rise to signals of about 17-27 nt in size for RNAs isolated from HAdV-B3-
infected cells, but not for RNAs of non-infected cells. In all blots with VA-RNAI-derived 
probes, larger size precursors in the range of 150 to 200 nt could be observed, 
corresponding to the sizes of 170 and 172 nt for HAdV-B3 VA-RNAI and II, respectively 56. In 
the Northern blot with the 6,187-6,209 sequence probe, a prominent precursor of about 90 nt 
was visible. For most probes, no significant expression was detected at the earliest time 
point of 3 h, but expression became visible at 12 h. Peak expression for all four probes 
derived from the VA-RNAI sequence were found either at 24 or 36 h p.i., followed by a 
decrease of expression at 48 h. In contrast, peak expression for the 6,187-6,209 sequence 
probe was reached at 12 h p.i.. Fold-induction of signals were higher for the small RNA 
hybridizing probes derived from the 5’- and 3’- ends of the VA-RNAI region and were in the 
range of 31.88- to 91.2-fold, whereas RNAs hybridizing to probe 6,187-6,209 and the probe 
derived from the intermediate sequence of the VA-RNAI region revealed signals of 3.69- and 
7.79-fold induction over background, respectively. In case of the sequence read 10,563-
10,584-probe derived from VA-RNAI, two small RNA bands were apparent, one at ' 26 nt 
and another at ' 17 nt (Fig. 4D).  
miRNAs and vsRNAs are generated by the same cellular biogenesis pathway. Thus, 
precipitation of Ago2-associated RISC combined with characterization of comprised vsRNAs 
adds considerable specificity to vsRNA evaluation. For this, A549 were infected with HAdV-
B3 and cell lysates were prepared 48 h p.i., followed by RNA immunoprecipitation. PCR was 
set-up for all five vsRNA candidates previously evaluated by Northern blot analysis, and two 
cellular miRNAs including hsa-mir-181 and hsa-mir-24. As a result, we detected expression 
enhancement in the range of 5.6- to 316.68-fold in HAdV-B3 infected cells compared to non-
infected cells (Fig. 5), while no overt changes in the expression levels of hsa-mir-181 and 
hsa-mir-24 was observed. A comparison to the five vsRNAs used in Northern blot 
quantitation (Fig. 4) revealed that the deduced fold-inductions were in general higher for RT-
PCR/Ago2-IP-method. This difference in sensitivity is likely due to differences in the dynamic 
range of the two methods. Despite the considerable signal enhancements found for four of 
the five vsRNAs tested, miRNA signals were not in general increased, since expression of 
the cellular hsa-mir-181 and hsa-mir-24 were only minimally enhanced. Furthermore, no RT-
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PCR signals were obtained when control pull-downs were made including a nonspecific 
antibody (data not shown). In summary, we confirmed the presence of five vsRNAs by multi-
detection methods including deep sequencing, Northern blot and Ago2-IP. 
In order to visualize the location of the 16 by deep sequncing-derived putative vsRNAs 
contained in the VA-RNAI and VA-RNAII regions, we used the mfold software tool to 
generate secondary structure models for both RNAs 71. The same mfold software had been 
used previously to predict VA-RNA structures of various HAdV serotypes, but not for HAdV-
B3 38. Alignment of the 12 putative vsRNAs of VA-RNAI is shown in Fig. 6A, and alignment of 
four vsRNAs of VA-RNAII is shown in Fig. 6B.  
 
In silico prediction of vsRNAs cellular and viral targets.  
We next addressed the question which cellular or viral genes could be potentially targeted by 
the discovered vsRNA candidates. By applying TargetScan 67,68, or miRanda 69, we first 
searched the 3’UTRs of human transcripts for binding sites to the vsRNA seed sequences 
encompassing 2-8 nt. The five vsRNA candidates included for the analysis were the same 
also tested for Northern blot analysis. The obtained in silico target data from either 
TargetScan or miRanda were then compiled with our quantitative transcriptome data which 
we acquired in a separate study, including a detailed expression analysis of HAdV-B3-
infected A549 cells at four time points of 3, 12, 24 and 48 h (Hung V. Trinh, unpublished 
data). The transcriptome-filtered (with log2 ratio % -0.6 and p-value % 0.05) TargetScan and 
miRanda data sets are shown in STable 3, and STable 5, respectively, whereas STable 4 
lists the complete cellular target sites determined by miRanda. Applying stringent exclusion 
criteria, 16 cellular vsRNA targets were predicted by TargetScan, with four of them showing 
relative consistent and significant down-regulation for most time points. These included the 
KLF3, CIT, ETV1, and KCNMA1 genes. The miRanda tool predicted 44 cellular mRNA 
targets (STable 5), with a single target (ubiquitin-conjugating enzyme E2) and a related 
target (kelch-like 3 and kelch-like 2) commonly predicted by both tools. One gene (EDN2) 
with binding sites for all five putative vsRNA revealed significant reduction for all time 
courses, whereas most other genes revealed significant downregulation for the three time 
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points 12, 24 and 48 h. Most of these targets contained multiple binding sites for several of 
the five vsRNA tested.  
In order to find out whether the potential HAdV-B3 vsRNA candidates target viral gene 
expression in an autoregulatory fashion, we applied the miRanda target prediction tool to 
either the complete viral genome in both plus and minus strands (STable 6), or to the 
annotated coding sequences (STable 7). As a result, multiple binding sites were found in 
different regions of the viral genomes or viral transcripts. Particularly, we observed that 
basically all viral transcripts contained multiple binding sites for the vsRNAs tested. It thus 
seems mandatory to apply additional filtering parameters like binding energy and perfect 
alignment of seed sequences to reduce the number of false positive targets.  
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Discussion 
In silico vsRNA prediction and deep sequencing analysis  
In silico prediction of cellular miRNAs and vsRNAs relies on inherent structural constraints 
such as hairpin structure contained in most miRNAs. All three in silico prediction tools 
applied here for determination of HAdV-B3 vsRNAs are based on this premise. However, the 
number of predicted vsRNAs candidates varied considerably depending on which in silico 
tool was used. Whereas the BayesMiRNAfind program predicted a single mature vsRNA, 
Bayes-SVM-MiRNA predicted four, and Vir-Mir db even 70 mature vsRNAs, which were 
distributed all over the viral genome in both plus and minus strand. None of the vsRNA 
predicted by the three different tools showed complete sequence overlap, but partial overlap 
of sequences was found for some predicted mature vsRNAs including VirMir-4728*: 1,687-
1,712 (VirMir-db) and NBayes-2: 1,703-1,723 (Bayes-SVM-MiRNA) with 10 nt, and NBayes-
4: 3,337-3,357 (Bayes-SVM-MiRNA) Bayes-1: 3,649-3,669 (BayesMiRNAfind). Validations 
for all 75 predicted vsRNAs revealed experimental detection of 25 vsRNAs by stem-loop RT-
PCR, and 12 vsRNAs by miRNA microarray analysis. Four of these vsRNAs candidates were 
commonly detected by both methods. This numerical difference between the two methods 
may on one side be due to limited sensitivity of the microarray high throughput method, and 
on the other side it could turn up from erroneous amplifications by the stem-loop RT-PCR 
method resulting from degraded mRNAs 62.  
As previously report, the Bayes miRNAfind tool revealed very high accuracy of 91.3% in EBV 
(21 predicted out of 23 known vsRNAs), 90.91% accuracy in HCMV (10 predicted out of 11 
known vsRNAs), 69.23% accuracy in KSHV (9 predicted out of 11 known vsRNAs) and 
100% accuracy in herpes simplex virus (2 predicted out of 2 vsRNAs) 72. In addition, by 
utilizing Bayes miRNAfind, Jaber et al. could identify the mature svRNA sequence in Bovine 
Herpesvirus 1 73. In contrast to the Bayes miRNAfind tool, the VirMir-db tool which is based 
on SVM algorithm revealed a higher false positive prediction rate, as for example, an 
implausible high 579 vsRNA precursors were predicted in mouse CMV using VirMir-db 74. To 
improve reliability of the VirMir-db bioinformatic tool, Buck et al. introduced an additional 
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ranking of top SVM score. Experimental validation in this system revealed four confirmed 
vsRNAs among the top ten predicted precursors 74.  
Despite that particularly in DNA viruses in silico prediction methods contributed considerably 
to identify novel vsRNAs, ,the recent development and application of mass parallel (deep) 
sequencing increasingly displaced in silico predictions. Since deep sequencing not only 
provides more precise sequence information of mature vsRNAs but at the same time also 
allows to quantify vsRNA abundance, this method has become the standard for vsRNAs 
determination. For examples, deep sequencing has been used to identify vsRNAs in 
Hepatitis C, Polio, Dengue, Vesicular Stomatitis, West Nile, Epstein Bar, and Influenza A 
virus 21,24,75.  
In this study, deep sequencing revealed multiple small RNA sequence reads encoded by 
HAdV-B3. The top 32 highest RNA intensity sequence reads consisted of 16 encoded in the 
VA-RNAI and II regions, and another 16 encoded in other viral genes or in non-coding 
sequences. The vsRNAs derived from VA-RNAI appeared in remarkable high quantities, in 
particular those from the 5’-arm and 3’-arm ends of VA-RNAI. In agreement with HAdV-C5, 
3’-end of VA-RNAI also encoded a vsRNA mivaRNAI-138 45. The VA-RNAI: 10,573-10,594 in 
HAdV-B3 and mivaRNAI-138 derived from the same location in VA-RNAI but the seed 
sequence. Expression of these vsRNAs candidates also correlated well with microarray data 
obtained from tilling the VA-RNAI and VA-RNAII region. Northern blot analysis with time 
courses of infections starting from 3 to 48 h p.i. revealed beginning of expression at the 3 h 
time point, which then remained high up to the late time phase, suggesting these vsRNAs 
might be required for the late phase of virus infection. None of the 32 top sequence reads 
determined by deep sequencing overlapped with the in silico prediction. This is in part 
explained by the constitution of viral genome sequence. VA-RNAI and VA-RNAII give rise to 
transcripts of 170 and 172 nt, respectively. Since the in silico miRNA prediction tools set a 
length limit of 110 nt for miRNA precursors, VA-RNAI and VA-RNAII transcripts were filtered 
out.  
The 16 vsRNAs candidates derived from intronic or non-coding regions represent rather 
novel types of vsRNAs as the only so far reported HAdV vsRNA is encoded in the VA-RNA 
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region 45. Particularly, we found an intronic region coding for three to five potential vsRNAs, 
which could form a discrete cluster of miRNAs.  
 
HAdV-B3 encoded vsRNA candidates and their potential targets 
Cellular target prediction for a first set of five potential HAdV-B3 vsRNAs in combination with 
an in parallel performed transcriptome analysis of HAdV-B3- infected cells revealed 16 
significant hits for the TargetScan search, and 44 hits for the miRanda search (STable 3, 5). 
Although in general there was not a substantial overlap observed using these prediction 
tools, we noticed that proteins involveing in the ubiquitination pathway were commonly 
predicted by both these target tools. This included the E2 ubiquitin-conjugating enzymes 
UBE2L3 (predicted by TargetScan), and the related UEBE2J2 (predicted by miRanda) and 
the ubiquitin protein ligase E3 (UBR4) predicted by miRanda only. Of note, miRanda 
prediction for UBR4 included binding sites for all five vsRNA candidates (STable 4). 
Ubiquitination of proteins represents an important cellular mechanism for targeting proteins 
to degradation, and involves at least three classes of enzymes that include ubiquitin-
activating enzymes (E1s), ubiquitin-conjugating enzymes (E2s), and ubiquitin-protein ligases 
(E3s) 76. The recognized UBR4 is an E3 ubiquitin-protein ligase, which belongs to the E3s 
family. UBR4 (or p600) interacts with retinoblastoma protein in the nucleus and with calcium-
bound calmodulin in the cytoplasm. It recognizes and binds to proteins bearing specific N-
terminal residues, which leads to their ubiquitination and subsequent degradation 77. 
Together with clathrin, UBR4 is involved in membrane morphogenesis and cytoskeletal 
organization, which regulates integrin-mediated signaling via activation of focal adhesion 
kinase in response to cell-matrix interactions 78. In addition, it binds to protein E7 from human 
papilloma virus (HPV)-16, HPV-6B and HPV-11 78,79. The ubiquitin-conjugating enzyme 
UBE2J2 belongs to the E2s family, which was significantly downregulated in HAdV-B3 
infections upon 12, 24 and 48 h (STable 5). UEB2J2 was predicted by the miRanda tool to 
contain multiple binding sites for all five vsRNAs. It has been reported that various viruses 
modulate the ubiquitination system to enable replication, egress and immune evasion 80,81. 
For HAdV-C2, Balakirev et al. showed that virus infection was accompanied by an increased 
ubiquitin-cleaving (deubiquitinating) activity in host cells 82. This activity was excerted by the 
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viral L3 23K proteinase, which was found to associate with ubiquitin aldehyde. The viral 
protease is a necessary protein for the processing of viral precursor proteins during virion 
maturation. Therefore, our finding that vsRNAs target enzymes of the ubiquitination pathway 
may open new insights of virus-host modulation via this important pathway.   
Another possible vsRNA-targeted protein was endothelin 2 (EDN2), which was 
downregulated at all time points of HAdV-B3 infection (STable 5). EDN2 encodes a member 
of the endothelin protein family of secretory vasoconstrictive peptides 83, which acts as a 
ligand for the endothelin receptors to initiate intracellular signaling events involving a wide 
range of biological processes such as hypertension and ovulation 84. A further target was 
microtubule-actin crosslinking factor 1 (MACF1), which belongs to the plakin family of 
cytoskeletal linker proteins 85,86. MACF1 functions by forming bridges between different 
cytoskeletal elements through specialized modular domains including actin and microtuble 
binding domains. It appears to stabilize actin at sites where microtubules and microfilaments 
meet, suggesting to function in microtubule dynamics and to facilitate actin-microtubule 
interactions. Of note, HAdVs also utilize microtubles for their transport 87, and downregulation 
of microtubles triggered by vsRNAs may reduce the virus transport and spreading, which 
could help viruses to maintain latent infections.  
We also noticed that DNA cross-link repair 1B transcript (DCLRE1B), which is involved in 
repair of interstrand cross-links 88, was significantly downregulated during virus infections 
(STable 5). Its 5'-3' exonuclease plays a central role in telomere maintenance and protection 
during S-phase 89. DCLRE1B participates in the protection of telomeres against non-
homologous end-joining (NHEJ)-mediated repair, thereby ensuring that telomeres do not 
fuse 90-92. Together with TERF2, DCLRE1B is required to protect telomeres from replicative 
damage during replication by controlling the amount of DNA topoisomerases during fork 
passage and to prevent aberrant telomere topology 93.  
 
Experiments for further characterization of vsRNA candidates 
We so far obtained good evidence for the presence of at least five vsRNAs encoded by 
HAdV-B3. Cellular and eventual viral targets for these vsRNAs remain to be characterized. 
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This will include functional analyses such as loss-of-function and gain-of-function 
approaches. The strategy for loss-of-function of vsRNAs is based on miRNA inhibitors such 
as antagomirs 94, or knock down with “Locked Nucleic Acid probes” 95. Quantitative 
transcriptomics will be used to analyze gene expression in virus-infected cells pre-treated 
with such inhibitors. Data obtained from such experiments will be compared with in silico 
target predictions. Gain-of-function approaches for vsRNAs will be done by cloning target 
sequences downstream of luciferase and evaluate co-expression effects with miRNA-
expressing plasmids. Alternatively, targets of vsRNAs candidates can be studied by Ago2-IP 
in combination with deep sequencing, similar as it has been recently done in human (-
herpesviruses 96.  
It has been shown that vsRNAs can also bind to 5’UTRs 97 or encoding sequences of cellular 
genes 98, possibilities that we have not investigated in this study, but could be taken up in a 
follow-up investigation.  
Final efforts will be dedicated to identify virus-host interaction networks involving vsRNA 
regulations, with the ultimate goal to uncover novel aspects of the HAdV-B3 infection 
process. Important question that need to be addressed will include identification of the 
vsRNAs targets, whether these are involved in entry, endocytosis, trafficking, replication or 
egress of the virus, and to what extent triggering of signaling pathways are involved. Possible 
implications of the anticipated results may include discovery of new antiviral mechanisms 
triggered by vsRNA, subversion of cellular miRNAs by the virus, development of HAdV-B3 
vectors with less immunoreactivity for gene therapy, and, more far fetched, mechanistic 
insights into the regulation of latent HAdV infections in human mucosal T cells.
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Legends to figures 
Fig. 1. Verification of in silico-predicted HAdV-B3 vsRNA candidates by stem-loop RT-PCR 
and miRNA microarray analysis. All 75 predicted vsRNAs and two known cellular miRNAs 
including hsa-miR-24 and hsa-miR-181a* were quantified using biological and technical 
replicates. (A) Detection of predicted vsRNAs was performed by stem-loop RT-PCR, which 
was set with threshold of over 2-fold changes for both HAdV-B3 infected-cells at 24 and 48 h 
p.i. vs non-infected cells. (*) refers to vsRNA derived from the opposing arm, (+) and (-) 
indicate location of predicted vsRNAs in plus or minus viral DNA strand. (B) Detection of 
predicted vsRNAs was performed by miRNA microarray, which was set with threshold over 
2-fold changes for both HAdV-B3 infected-cells at 24 and 48 h p.i. vs non-infected cells. 
Ratios were determined by normalizing the data obtained from infected cells to date from 
non-infected (Ctrl) samples. (x) indicates that no signal was detected in non-infected cells, 
but signal was obtained in the microarray analysis of HAdV-B3-infected samples. 
Fig. 2. Expression analysis of small RNAs derived from HAdV-B3 VA-RNAI and VA-RNAII 
regions by miRNA microarray. Total RNAs as in Fig. 1B were used for hybridization to VA-
RNAI and VA-RNAII tilling probes encompassing nucleotides 10,422-10,596 and 10,666-
10,837, respectively.  
Fig. 3. Identification of HAdV-B3 vsRNA candidates by deep sequencing. RNA samples of 
non-infected and HAdV-B3-infected A549 cells were isolated 24 h p.i. (A) Overview of the 
possible vsRNA (19-24 nt) sequence reads with > 10 counts plotted to HAdV-B3 genome of 
35,343 bp (NCBI accession no. DQ086466). The upper panel represents sequence counts in 
the HAdV-B3 (-) strand, while the lower panel indicates read counts of the (+) strand. (B), 
sequence reads of the top 32 sequence reads with assignment to their location in the HAdV-
B3 genome.  
Fig. 4. Characterization of HAdV-B3 vsRNA candidates by Northern blot analysis. (A-E) Total 
RNAs from non-infected and HAdV-B3-infected cells were isolated at 3, 12, 24, 36 and 48 h 
p.i. and size-fractionated on 7M Urea-PAGEs, followed by transfer to membranes. 32P-
labelled probes included hyp 11.5-kDa: 6,187-6,208 (A), VA-RNAI: 10,430-10,452 (B), VA-
RNAI: 10,475-10,496 (C), VA-RNAI: 10,563-10,584 (D), VA-RNAI: 10,563-10,584 (E). (F) 
161 
Quantification of %17-27 nt bands of Northern blots A-E. In case of VA-RNAI: 10,563-10,584, 
two different signals were recorded, one larger than 20 nt (++), and one smaller than 20 nt 
(+).  
Fig. 5. Quantification of five HAdV-B3 vsRNA candidates by stem-loop RT-PCR combined 
with argonaute 2 immunoprecipitation. RNA samples were isolated from non-infected or 
HAdV-B3-infected A549 cells 48 h p.i.. The five vsRNA candidates examined were the same 
as tested by Northern blotting in Fig. 4. The two cellular hsa-mir-181 and hsa-mir-24 were 
additionally included as controls.  
Fig. 6. Alignment of 16 vsRNAs candidates obtained from deep sequencing analysis to 
predicted secondary structure of VA-RNAI and VA-RNAI by mfold 
(http://mfold.rna.albany.edu/). vsRNA candidates verified by Northern blot analysis and 
Ago2-IP combined with stem-loop RT-PCR are shown in red. vsRNAs candidates obtained 
from deep sequencing, but not been confirmed by Northern blot analysis and Ago-IP, are 
shown in bold black.  
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Legends to supplemental tables 
STable 1. Precursor and mature sequences of predicted vsRNAs encoded by HAdV-B3. 
vsRNAs in silico predictions were performed using three bioinformatics tools including 
BayesMiRNAfind, Bayes-SVM-MiRNAs and Vir-Mir db. Indicated are size and location of 
predicted precursors as well as of mature vsRNAs within the HAdV-B3 genome. Each 
precursor miRNAs predicted by Vir-Mir db gives rise to two mature vsRNAs, while miRNA 
precursor derived from BayesMiRNAfind and Bayes-SVM-MiRNAs give rise to single mature 
vsRNAs.  
STable 2. List of oligonucleotide primers used for this study. These include forward and 
universal reverse primers used for stem-loop RT-PCR, and primers used as Northern blot 
probes.  
STable 3. Comparison of predicted cellular targets for five HAdV-B3 vsRNA candidates using 
TargetScan and transcriptome analysis of infected A549 cells. Transcriptome analysis was 
filtered by significant changes of gene expression (log2 ratio % -0.6 and p value % 0.05, 
indicated in bold) for at least one time point of virus infection (3, 12, 24, and 48 h) compared 
to non-infected cells.   
STable 4. Cellular target prediction for five HAdV-B3 vsRNA candidates using miRanda. 
Indicated are the individual binding sites with their locations in the 3’UTRs. Score represents 
ranking based on alignment. Energy describes optimal strand-strand interaction between 
miRNA and UTR and was calculated using the Vienna package 99. Align miRNA length 
indicates the sequence of vsRNAs used for the alignment, with start and stop nt. Target 
sequence represents the location of binding sequences at the 3’UTR.  
STable 5. Comparison of predicted cellular targets for five HAdV-B3 vsRNA candidates using 
miRanda and transcriptome analysis. Significantly downregulated genes (log2 ratio % -0.6) 
and their p value % 0.05 are indicated in bold. 
STable 6. Prediction of targets for five vsRNA candidates within the HAdV-B3 genome by 
miRanda. Target sequence represents the location of binding sequences on either plus or 
minus strand of the HAdV-B3 genome. 
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STable 7. Prediction of targets for five vsRNA candidates in HAdV-B3 annotated coding 
sequences (NCBI accession no. DQ086466) by miRanda. Target sequence represents the 
location of binding sequences on HAdV-B3 transcripts.  
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FIG. 1.  
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FIG. 2.  
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FIG. 3.  
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FIG. 4.  
 
 
168 
FIG. 5.  
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ABBREVIATIONS 
 
 
Name Description 
A549 human lung adenocarcinoma epithelial cells  
Ago2 argonaute 2 
APEX absolute proteomics expression  
ATF cyclic AMP-dependent transcription factor  
BALF5 Epstein-Barr virus DNA polymerase catalytic subunit 
C18 reverse phase C18 matrix 
CAR coxsackie virus B and adenovirus receptor  
CD46 cluster of differentiation 46, complement regulatory protein 
CID collision-induced dissociation 
c-MYB proto-oncogene protein  
COPI #-subunit of the coat protein I 
CRD carbohydrate-recognition domains  
DBP DNA binding protein  
DC dendritic cell 
DGCR8 DiGeorge syndrome critical region 8/Microprocessor complex subunit DGCR8 
DIGE difference gel electrophoresi 
DNA Deoxyribonucleic acid 
dNTP deoxynucleotide triphosphate 
DOC Deoxycholate 
Drosha Ribonuclease 3 
ds double-strand 
DSG2 desmoglein 2  
EBER Epstein-Barr virus non-coding ribonucleic acid 
EBV Epstein-Barr virus 
EGFR epidermal growth factor receptor 
ESI electrospray ionization  
ETD electron-transfer dissociation 
FACS fluorescence activated cell sorting 
FBS fetal bovine serum 
FCS fetal calf serum 
FDA Food and Drug Administration 
FDR false discovery rate 
FITC fluorescein isothiocyanate 
FK fiber knob 
FRAP fluorescence recovery after photobleaching 
gal-1 galectin-1 
gal-3 galectin-3 
GFP green fluorescent protein 
GON group-of-nine 
GOS group-of-six 
h hour 
H2B histone 2B 
HAdV human adenovirus 
HAdV-B11 human adenovirus species B serotype 11 
HAdV-B14 human adenovirus species B serotype 14 
HAdV-B16 human adenovirus species B serotype 16 
HAdV-B21   human adenovirus species B serotype 21 
HAdV-B3 human adenovirus species B serotype 3 
HAdV-B34  human adenovirus species B serotype 34 
HAdV-B35 human adenovirus species B serotype 35 
HAdV-B50  human adenovirus species B serotype 50 
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HAdV-B7 human adenovirus species B serotype 7 
HAdV-C2 human adenovirus species C serotype 2 
HAdV-C5 human adenovirus species C serotype 5 
HAdV-D37 human adenovirus species D serotype 37 
HAdV-D49 human adenovirus species D serotype 49 
HCMV human cytomegalovirus 
HCV hepatitis C virus 
HIV human immunodeficiency virus 
HSV herpes simplex virus 
IAA iodoacetamide 
ICAT isotope coded affinity tags 
IFN Interferon 
IP immunoprecipitation 
iTRAQ-8plex isobaric tag for relative and absolute quantitation - multiplex 8 plex 
KSHV Kaposi’s sarcoma-associated herpesvirus  
LC-MS/MS  liquid chromatography tandem mass spectrometry 
LMP-1 Epstein-Barr virus latent membrane protein 1 
LTQ-FT-ICR 
MS linear ion trap-Fourier-transform ion cyclotron resonance mass spectrometry 
M Mascot 
MALDI-
TOF/TOF Matrix-assisted laser desorption/ionization-time of light/time of light 
MCMV murine cytomegalovirus 
MDA-5 melanoma differentiation-associated protein 5 
MFI mean fluorescence intensity 
MHC major histocompatibility complex 
MICB major histocompatibility complex class I polypeptide-related sequence B 
miRNAs small miRNAs 
MLP major late promoter  
MMTS methyl methanethiosulfonate  
MOI  multiplicity of infection 
MV measles virus 
NK natural killer  
NP-40 Nonidet P40  
N-WASP  neuronal Wiskott-Aldrich Syndrome protein 
ORF open reading frame 
PL Progenesis LC-MS 
p.i. post infection 
PF2 
ProgenesisF-T2PQ (combined of export feature of Progenesis LC-MC and top 
2 peptide quantitation) 
PF3 
ProgenesisF-T3PQ (combined of export feature of Progenesis LC-MC and top 
3 peptide quantitation) 
PAMP pathogen-associated molecular pattern 
PBS phosphate-buffered saline 
pfu plaque forming unit 
PI4KA phosphatidylinositol 4-kinase  
PKA protein kinase RNA-activated  
PKR double-stranded RNA-activated protein kinase 
Pol DNA polymerase 
PP ProteinPilot 
PTM post translational modification 
PVDF polyvinylidene fluoride 
Q-TOF  hybrid quadrupole time of flight mass spectrometer  
RID receptor internalization and degradation  
RIG-1 retinoid-inducible gene 1 
RISC RNA-induced silencing complex 
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RNA Ribonucleic acid 
ROI   region of interest 
RRV rhesus monkey rhadinovirus 
RT-PCR real time - polymerase chain reaction 
RU resonance units 
S ScaffoldQ+ 
SCR short consensus repeats 
SCX-HPLC strong cationic exchange - high performance liquid chromatography 
SDS Sodium Dodecyl Sulfate  
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SILAC cell-culture enriched stable isotope labeled amino acids 
siRNA interference ribonucleic acid 
SPR surface plasmon resonance 
SPT using single-particle tracking 
SRM selected reaction monitoring 
ss single-strand  
TCA trichloroacetic acid  
TCEP Tris[2-carboxyethyl] phosphine 
TFA trifloroacetic acid  
TIA1 T-cell-restricted intracellular antigen-1 
TLR toll-like receptor  
TNF tumor necrosis factor  
TNPQ top N peptide quantitation 
TP binding protein 
TRF transferrin receptor/CD71 
Tub tubulin 
UTR untranslated region 
vmiRNAs viral small miRNAs 
vp virus particle 
WNV West Nile virus  
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